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Abstract
Gastric cancer is a common cause of cancer death in the UK. It most often 
presents in patients when the disease is advanced, and hence treatment options are 
limited. As such, studies on the pre-malignant stages of gastric cancer, and interest in 
the mechanisms of the carcinogenic process (reactive oxygen species, ROS) and the 
agents that may drive the carcinogenic pathway {Helicobacter pylori infection), are 
important, with a view to improving disease outcome. This series of experiments has 
firstly shown, using CBMN assay +/- kinetochore staining and interphase FISH, that 
ROS causes aneuploidy of chromosomes 4, 8, 20 and 17(p53) in a human cell line. 
Secondly, gastric cells have been collected using endoscopic cytology brush 
techniques, and prepared, such that interphase FISH could be performed. Again, 
aneuploidy of chromosomes 4, 8, 20 and 17(p53) were detected in normal gastric 
mucosa, gastritis and intestinal metaplasia. The level of aneuploidy detected increased 
as disease severity increased. Amplification of chromosome 4, amplification of 
chromosome 20 and deletion of chromosome 17(p53) were the more significant 
findings. The degree of chromosomal abnormalities detected increased further, in a 
stepwise manner, when gastric dysplasia and gastric adenocarinoma cells were 
studied. Hence, a role for these abnormalities may exist in the initiation of, and the 
progression to, gastric cancer. The presence of H. pylori was also determined in the 
gastric tissue studied using histological analysis and PCR technology. Detection rates 
were comparable. The more virulent strain of H. pylori, Cag A, was found to be 
associated with increased disease pathology and chromosomal abnormalities, yet 
numbers were small. The amplification of chromosome 4 in gastric tissue was again 
highlighted in association with H  pylori infection, hence it may reflect a role for 
chromosome 4 in the initiation of gastric cancer.
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Chapter 1 
General Introduction
1.1 Gastric cancer
1.1.1 Introduction to gastric cancer
Gastric cancer is often diagnosed at an advanced stage when symptoms such 
as weight loss, abdominal pain, vomiting and gastrointestinal bleeding finally alert 
patients to seek medical advice. Treatment regimens, such as surgery, chemotherapy 
and radiotherapy, are therefore limited by advanced local disease and metastatic 
spread. In fact, only 55-65% of gastric cancers are surgically respectable at diagnosis 
(Keighley 2003). Hence, the prognosis of gastric cancer is poor, helping to make 
gastric cancer a leading cause of cancer death worldwide (Parkin et al., 1999). 5 year 
survival rates for gastric cancer in Wales are currently estimated at 13%, with a 
median survival time of 4 months (www.wcisu. nhs. w ales). Other countries in Europe 
have similar 5 year survival rates, but rates can increase up to 28% in Spain and 
Austria (Keighley 2003). Japanese 5 year survival rates are significantly higher, up to 
95%, but reflect high disease prevalence and are associated with a surveillance 
programme to detect early gastric cancers. Early gastric cancers only account for 10% 
of the European gastric cancers diagnosed (Keighley 2003).
1.1.2 Incidence of gastric cancer
Gastric cancer is regarded as the second commonest cancer worldwide (Parkin 
et al., 1985) and there are 755,000 incident cases in the world each year (Sugimura 
and Sasako 1997). There is a significant geographical variation in the incidence of 
gastric cancer worldwide. In the UK, including Wales, it is the sixth most frequent
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cancer in men and the seventh in women (Cancer research Campaign 1995, 
www.wcisu.nhs.uk). In China, it is the commonest cancer diagnosed, and it has been 
estimated that 38% of all gastric cancers worldwide develop in China (Parkin et al., 
1999). In Japan, incidence rates are high at 78 per 100,000 in males, but in Northern 
Africa the rate falls to 2.6 per 100,000 in females, reflecting geographical and sex 
differences (Parkin et al., 1999). In Wales, incidence rates are estimated at 25.9 per
100.000 in males, and 10.6 per 100,000 in females, which is comparable to other 
European countries (www.wcisu.nhs.uk).
Gastric cancer is one of the main cause of deaths associated with cancers 
worldwide, accounting for 12.1% of cancer deaths in 1999, and responsible for
628.000 recorded deaths (Parkin et al., 1999, Grady 2001). In 2001 in Wales, 300 
deaths in men and 190 deaths in women were attributed to gastric cancer, with a 
mortality incidence ratio of 73% in men and 70% in women (www.wcisu.nhs.ukV
However, the incidence of gastric cancer has been declining on an annual 
basis, and in the USA the male incidence has decreased from 38 to 5.2 per 100, 000 
between 1930 and 1994, and in women from 28 to 2.3 per 100,000 (Landis et al.,
1998). In Wales, there has also been a significant decrease in the incidence of gastric 
cancer (1992-2003), 3.8% decline in men per annum, with a 3.1% decline noted in 
women (www.wcisu.nhs.uk).
1.1.3 Classification of gastric cancer
Gastric cancers can be classified by a number of methods. They can be 
subdivided according to anatomical site. Figure 1.1 illustrates the different areas of 
the stomach. What has been traditionally referred to as gastric cancer is in fact cancer 
of the distal stomach. These distal cancers are declining in incidence, with the
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incidence of the more proximal cancers increasing (Grady 2001). Proximal gastric 
cancers of the cardia are often difficult to distinguish from oesophageal 
adenocarcinomas, as presentation is usually at an advanced stage of the disease, hence 
the term gastro-oesophageal cancer is used. The incidence of Barretts metaplasia has 
increased in developed countries and hence the incidence of Barretts associated 
adenocarcinoma of the oesophagus has also increased (Blot et al., 1991, Clark et a l , 
1994, Kabat et al., 1993). The decline in the incidence of distal gastric cancer may 
reflect the improvements in lifestyle and the socio-economic climate, which have 
been evident over the last few decades, particularly in developed countries. Later in 
this chapter the contribution a number of environmental factors make to gastric cancer 
incidence, is discussed further.
Gastric tumours can also be classified according to cell of origin and 
histological patterns. 90% of malignant gastric tumours are adenocarcinomas, with 
lymphomas, carcinoid tumours and leiomyosarcomas making up the residual tumour 
types (Luk et al., 1998). The Lauren classification of adenocarcinomas is universally 
accepted, dividing cancers into intestinal and diffuse tumours (Lauren 1965, Grady 
2002). Intestinal tumours are composed of well-differentiated cells arranged in glands, 
unlike the diffuse tumour type in which cells show little glandular formation and cells 
infiltrate in sheets or in single file. There are not only histological differences between 
these two types of gastric adenocarcinomas, but also differences in the demographic 
characteristics of the individuals affected, and possibly even in their prognosis. There 
may be variations in their aetiologies also, and hence the genetic makeup of the 
tumours. This is discussed in more detail in Chapter 5 when specimens of each cancer 
types were studied.
3
1.1.4 Multistep pathway of gastric carcinogenesis
The pathway leading to gastric cancer from normal gastric tissue, and the 
sequence of genetic changes involved at each stage remains unclear. However, Correa 
has proposed a multistep pathway to intestinal cancer, including pre-cancerous stages 
and the possible environmental insults sustained, illustrated in Figure 1.2 (Correa 
1988).
Gastritis is an inflammation of the gastric tissue, and may be acute or chronic. 
Gastric atrophy is the loss of gastric glands due to ulceration or a prolonged 
inflammatory process. Cancer risk increases as gastric atrophy becomes more 
widespread and extends proximally into the corpus (Sipponen et al., 1998). Intestinal 
metaplasia represents a non-neoplastic change in cell phenotype usually due to a 
sustained adverse environment, and is caused by alteration of the stem cell lineage or 
epigenetic changes. It is not always recognisable macroscopically, but may be seen as 
a plaque or non-homogeneous area of the gastric mucosa (Walker 2003). Intestinal 
metaplasia is associated with an increased risk of cancer (Morson et al., 1980), 
however intestinal metaplasia is common and gastric cancer is not. Intestinal 
metaplasia may progress from small bowel metaplasia to colonic metaplasia, and can 
be divided into 3 types (1) complete -  (small intestine) -  containing goblet, Paneth, 
endocrine and brush bordered cells (enterocytes), (2) incomplete -  (goblet cell 
metaplasia) containing goblet and mucous cell, no enterocytes, plus sialomucins, (3) 
incomplete -  (colonic type) -  containing goblet and mucous cells, no enterocytes, plus 
sulphomucins (Correa 1988). Type 3 intestinal metaplasia, has been shown to contain 
the most genetic changes and therefore may harbour an increased risk of cancer 
(Dixon et al., 2001). Dysplasia is the term used to describe a histological abnormality 
in cells associated with progression to cancer (Morson et al. 1980). Dysplastic cells
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Figure 1.2 Correa hypothesis of gastric cancer aetiology. (Correa 1988)
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have enlarged hyperchromatic nuclei with coarse chromatin and irregular nucleoli. 
Apoptosis and karyorrhexis can be seen together with irregular crypt architecture. 
These features are associated with a failure of cells to mature as they migrate away 
from the stem cell compartment.
1.1.5 Aetiology of gastric cancer
The aetiology of gastric cancer is multifactorial. Host genetics and 
environmental agents have been implicated through epidemiological and laboratory 
studies.
Helicobacter pylori was declared a class 1 carcinogen in 1994 due to its 
association with gastric cancer (I ARC 1994) and, because of the large amount of 
experimental and epidemiological evidence, it is considered to be a major 
epidemiological factor in gastric carcinogenesis. This will be discussed in greater 
detail later in this chapter. Other bacteria have been implicated in gastric 
carcinogenesis, such as Helicobacter heilmannii and mycoplasma infection, but their 
correlation is weak (Stadtlander and Waterbro 1999). The importance of viral, fimgal 
and parasitic infection has also been investigated. Epstein-Barr viral infection, already 
recognised as a human carcinogen because of its relationship to other cancers 
(Hodgkins disease, sinonasal carcinoma) (I ARC 1997), is one of the infections which 
has been implicated in gastric cancer development (Stadlander and Waterbro 1999).
Dietary compounds have been linked to gastric cancer and its pre-malignant 
stages. A wealth of epidemiological and experimental studies have shown that certain 
foods can be protective against gastric carcinogenesis, and include fruit (especially 
when containing ascorbic acid) and vegetables. Other foods containing nitrosamines 
and salt, together with alcohol, are all agents associated with increased rates of gastric
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carcinogenesis (Chan et al., 1999, Correa 1988, Osaka et al., 1997, UK Subgroup of 
EPC-EURONUT-IM Study Group 1991, Sobala et a l, 1992, Neuget et al, 1996). 
Epidemiological studies from 20-30 years ago have shown an association between 
excessive salt intake and gastric cancer (Joosens and Geboers 1981), as well as 
excessive salt intake and gastritis/intestinal metaplasia (Stemmermann et a l, 1977, 
Correa et al, 1975). Populations at high risk of gastric cancer, such as those in Asia, 
have been found to have disproportionately high levels of nitrosoamines in their diet 
(Wakabayashi et a l, 1987). You et al 2000 have noted, in a follow up study to 
identify people at risk of developing gastric cancer, that higher levels of dietary 
ascorbic acid decreased the risk of progression to cancer by up to 80%. Previous work 
by the same author has also shown a similar negative correlation with pre-malignant 
gastric disease i.e. chronic gastritis, intestinal metaplasia and dysplasia (You et al, 
1993). Studies have shown too, that a low intake of fruit and vegetables is associated 
with higher levels of p53 mutation in gastric cancers (Fedriga et a l, 2000). You et a l 
2000 have also documented a positive association with smoking (20 cigarettes per 
day) and pre-malignant gastric diseases. Smokers have further been suggested to have 
a moderately increased risk of gastric cancer (I ARC 1985).
Both socio-economic factors and geographic differences influence the 
incidence rates of gastric cancer (Chan et a l, 1999, Correa 1988). Stadlander and 
Waterbro have reviewed a large number of epidemiological studies, and surmise that 
there is a geographical variation in the gastric cancer incidence amongst and within 
countries. The highest incidence rates of gastric cancer exist in Asian countries, with 
significant disease also occurring in European countries, Latin America and the USA 
(Stadlander and Waterbro 1999). Parkin et a l 1999 have also noted that the incidence 
of gastric cancer in the Far East was far higher than that in the Western populations,
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with 38% of all stomach cancers occurring in China. An association has also been 
shown for higher levels of p53 mutation in gastric cancers and lower social class 
(Fedriga et al., 2000).
Family history is associated with increased risk of gastric cancer (Chan et al., 
1999, Correa 1988, La Vecchoa et al., 1992, Zaghieri et al., 1990, Graham and 
Lilenfeld 1958), and with an increased risk of pre-cancerous abnormalities (Cameiro 
et al., 1993). Nomura demonstrated a 2-3x increased risk of gastric cancer in relatives 
of patients with gastric cancer (Nomura 1982). El -Omar et al have shown that 
relatives of patients with gastric cancer have increased prevalence of pre-cancerous 
gastric abnormalities, although only predominantly in patients with Helicobacter 
pylori infection (El-Omar et al., 2000). Brenner et al. have also noted that increased 
levels of H. pylori exist in children of gastric cancer patients (Brenner et al., 2000). 
Thus, family clustering of gastric cancer may not only be due to shared genes but 
might be due to environmental factors such as shared H. pylori infection.
We know that age is important in the progression to gastric cancer (Chan et 
al., 1999, Correa 1988). As the population ages so the incidence of intestinal type 
gastric cancer increases (Sipponen et al., 1998). Younger people commonly exhibit 
inflammation and gastritis with intestinal metaplasia, whereas the older population 
show gastric atrophy and colonic type intestinal metaplasia, hence increasing the risk 
of developing gastric cancer (Asaka et al, 1997, Tahara et al., 1994, Lengauer et al,
1999).
Sex differences also exist in intestinal type gastric cancer. The male incidence 
increases after the 3rd decade, but the female incidence only starts to increase after the 
6th decade (Sipponen et al., 1998). Possibly a protective effect is exerted by female 
hormones present until the menopause. No difference in gender is seen in the pre-
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malignant stages of gastric cancer, or in the incidence of Helicobacter pylori 
infection. Blood group A has also been shown to be positively associated with gastric 
cancer (Nomura 1982), although the mechanisms behind this are not well understood.
There is significant overlap between all these aetiological agents, and 
determining the effect of individual risk factors on gastric carcinogenesis has proven 
difficult. Of clinical importance is the theory that the prevention of gastric cancer in a 
large number of populations should be possible by addressing the different 
aetiological factors discussed, although this is obviously more complicated in 
practice.
1.1.6 Familial gastric cancers
The majority of gastric cancers described above arise as a result of a number 
of sporadic genetic events arising in gastric epithelial cells in people with no inherited 
predisposition to gastric cancer. The accumulation of a number of genetic 
abnormalities in tumour suppressor genes and oncogenes underlies the multistep 
pathway of gastric cells to gastric adenocarcinoma (Correa 1998). Abnormalities are 
often the result of a failure in the normal mechanisms present in the cell to conserve 
DNA fidelity. Clonal selection of the abnormalities favouring tumourigenesis then 
occurs to further promote cancer development.
A small number of gastric cancers are however familial. Inherited 
predisposition syndromes include hereditary non-polyposis colon cancer syndrome 
(HNPCC). HNPCC is caused by a germline mutation of a mismatch repair gene, and 
this allows errors in DNA replication to persist. These are characterised by frameshift 
mutations in microsatellite repeats i.e. microsatellite instability. This genomic 
instability predisposes to mutational inactivation of tumour suppressor genes
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containing microsatellites in their coding regions (Grady 2001). Up to 79% of the 
associated gastric cancers in HNPCC are of the intestinal type, and they occur in 11% 
of HNPCC families with MLH1 or MSH2 germline mutations (Aarnio et al., 1997, 
Vasen et al., 1996). Other syndromes that have increased risks of gastric cancer 
include hereditary diffuse gastric cancer (HDGC). HDGC has been attributed to a 
germline mutation of CDH1, the gene for E-cadherin whose role includes intercellular 
adhesion (Bevan and Houlston 1999, Guilford et al., 1998). HDGC is also associated 
with breast and colon cancer ( Keller et al., 1999). Li-Fraumeni syndrome includes 
predisposition to soft tissue sarcomas, leukaemia, brain tumours, breast cancer and 
gastric cancer, and is caused by p53 germline mutations (Grady 2001). Peutz-Jeuger 
syndrome, characterised by gastrointestinal hamartomatous polyps, is associated with 
ovarian tumours, pancreatic cancers, melanoma and gastric cancer (Grady 2001) and 
has germline mutations of a serine threonine kinase (STK 11) (Hemminke et al.,
1998). In Japan, familial adenomatous polyposis (FAP) families, have had reported 
associations with gastric cancer (Bevan and Houston 1999). These families have 
abnormalities of the tumour suppressor gene APC.
1.1.7 p53 and gastric cancer
P53 is a well known tumour suppressor gene located on chromosome 17 
(17pl3.1). It acts as a transcription factor, maintaining cell stability through its control 
of cell cycle progression and apoptosis in response to DNA damage (Grady 2001).
The ability of p53 to activate transcription in genes containing p53 binding sites 
appears to be required for this response (Sud et al., 2001). Loss of p53 function is 
most commonly induced through point mutation (Bates and Vousden 1996), and there
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are over 15,000 different types of p53 mutations described in cancers (www.iarc.frf  It 
is the most frequently mutated gene in human cancers (Levine et al., 1991) and is 
mutated in up to 60% of all human tumours (Tamura et al., 1991, Sipponen et al., 
1998, Levine et al., 1991, Vogelstein and Kinzer 1992). It is commonly found to be 
abnormal in 30-58% of intestinal and diffuse gastric tumours (Grady 2001). Mutations 
of p53 have been found in advanced gastric cancer (Romiti et al., 1998, Brito et al, 
1994, Joypaul et al., 1993), whereas other authors have found it to be present in early 
gastric cancer (Uchino et al., 1993, Tohodo et al., 1993, Morgan et al, 2003). Uchino 
et al., found that abnormalities of p53 were present in 25% of early gastric cancers 
and 42% of the advanced stage (Uchino et al, 1993). There is quite a large variation 
in the frequency rate of p53 mutation quoted in the literature, and this may occur due 
to the different methods of mutation detection and the different methods of tissue 
preparation. Sud et al., noted a p53 mutation rate of 31% in the tumours they studied. 
This is similar to other studies -  33-38% (Tamura 1991, Uchino et al., 1993), but 
some studies quote higher figures of 65% (Imazeki et al., 1991). Loss of 
heterozygosity (deletion of one copy of gene) of p53 can be seen in 60% of gastric 
tumours and this is most often accompanied by mutation of the other copy of p53 (30- 
50%), therefore causing complete inactivation (Sano et al., 1991, Sud et al., 2001).
The presence of p53 mutations in gastric cancer has been associated with a 
worse prognosis than those cancers without p53 abnormalities, 5 year survival rates of 
24% compared to 56% respectively have been reported (Martin et al, 1992). 
Association between p53 abnormalities and metastatic spread has also been noted 
(Monig et al., 1997).
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Abnormalities of p53 have been found in pre-malignant gastric cancer tissue 
and this is discussed in greater detail in Chapter 4.
1.1.8 Aneuploidy and gastric cancer
It is widely accepted that gastric cancer results from genetic alterations, and 
studies have shown that genetic instability can lead to accumulation of somatic 
mutations and chromosomal instability (Grady 2001, Kabayashi et al, 2000). There is 
now a hypothesis that levels of aneuploidy are related to tumour instability (Lengauer 
et al., Nardone et al., 1999). Aneuploidy is the term used to describe numerical 
aberrations in chromosomes, producing cells with chromosome number greater or 
smaller than the diploid complement.
Cytogenetic studies can be used to identify a broad range of chromosome 
aberrations, both structural and numerical. As the techniques to look at chromosome 
patterns improve, so the information available regarding the aberrations in cancer 
increases. Numerical and structural chromosomal abnormalities have been found in 
gastric cancer tissue and gastric cancer cell lines, with high levels of chromosome 
rearrangement demonstrated (Bertoni et al., 1998). Genomic ploidy measurements 
can be made with flow cytometry, and Giemsa banding (G banding) can look at 
changes in the whole karyotype. The development of Comparative Genomic 
Hybridisation (CGH) and in situ hybridisation has allowed better resolution of the 
chromosomal aberrations present in tumour cells (Sen 2000). CGH has shown an 
increase in DNA content (up to 4 fold) in 86% of gastric cancer tissue studied, with 
the majority of chromosomes being involved (Kokkola et al., 1998, Han et al., 1998, 
Kitayama et al., 2000). G banding has also shown altered karyotypes in gastric 
cancers (Panini et al., 1995).
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The developments in Fluorescence in Situ Hybridisation (FISH) and the 
increasing number of centromeric probes and gene specific probes now available, 
allow the accurate characterisation of numerical and structural genetic changes. 
Difficulties in performing these techniques on solid tissue are slowly being overcome, 
and techniques to produce a monolayer of cells have now been developed, as shown 
later in this thesis. FISH studies in gastric cancer have shown that certain 
chromosomes and regions of chromosomes are affected more commonly than others, 
although different studies implicate chromosomes with differing frequencies. Table
1.1 illustrates the results of a number of cytogenetic studies on gastric cancer cells. A 
more detailed table is presented in Chapter 4. Aneuploidy of varying degrees has been 
documented in all stages of gastric cancer (Beuzen et al., 2000). Chromosome 3 
involvement is seen commonly, not only in studies of gastric cancer but also of solid 
tumours elsewhere in the body (Pathak 1992). Sex chromosomes are lost in gastric 
cancers in up to 70% of cases, but sex chromosome loss can be seen in normal 
individuals as they age, and therefore may not be relevant to carcinogenesis (Yadav et 
al, 1996, Beuzen et al 2000, Nowinski et al., 1990). The list of cytogenetic studies 
given is obviously not exhaustive but illustrates the problems arising when correlating 
study results. What is obvious is the variation in the results shown, although some 
overlap is seen between studies. A large proportion of the studies on gastric cancer 
genetics feature Japanese patients, as gastric cancer is the most prevalent cancer in 
East Asia (Chun et al., 2000). As already has been explained, host genetics and socio­
economic features play a part in the aetiology of cancer, hence comparing the results 
of these studies to those of a Western population may not be straightforward. It is 
also important to remember that these studies are usually of advanced tumours and 
that sample numbers are often small. This, together with the knowledge that gastric
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Table 1.1: The results of a number of cytogenetic studies looking at chromosomal
aberrations in gastric cancer.
Author Sample size Cancer Type
Panini 1995 11
(Greece)
Kokkola 22 
1998(Finland)
Koo 2000 37
(South Korea)
Yadav 1996 4
(USA/Japan)
Fringes 20 
2000(Germany)
Beuzen 2000 60 
(France)
Okada 2000 5
(Japan)
Bertoni 1996 2 
(Italy)
Han 1996 18
(South Korea)
10/11 intestinal 
(3 metastatic)
intestinal
50% intestinal 
(22/37 metastatic)
1 metastatic
intestinal/diffuse
cardia, antrum 
& oesophageal
diffuse
(80% metastatic) 
metastatic
diffuse
Chromosome
3
gain-20q
loss-18q
gain-8q
loss-17p
3,7, 11, X
gains-1
7, 8, 11, 17, Y 
(40-65%allcancers)
loss-18q 
gain-7, 20
6,
karyotype rearrangement
widespread numerical 
rearrangement
Table 1.1 (cont’d): The results of a number of cytogenetic studies looking at
chromosomal aberrations in gastric cancer.
Author Sample size Cancer Type
Chun 2000 6 advanced
(South Korea)
Igashari 2000 39 
(Japan)
Kitiyama 24
2000(Japan)
Sud 2001 9
(UK)
Wu 2001 53
(Taiwan)
Sugai 1999 99
(Japan)
17 intestinal 
9 diffuse
65% advanced 
55% intestinal 
45% diffuse
65 intestinal 
34 diffuse
Chromosome
loss-17p
lp lost in advanced
1,2-  early 
1, 2, 4, 20 - later
loss - 22q
gains -  8q 
loss -  16q 
aneuploidy in 73%
cancer cells are inherently unstable, makes the characterisation of a simple step-wise 
genetic pathway to gastric cancer difficult.
Opinions vary as to whether intestinal and diffuse gastric cancers have 
different chromosomal abnormalities, and hence different genetic pathways (Kokkola 
et al, 1998, Pathak 1992, Nowinski et al., 1990, Hoshi et al, 1999 Yasui W et al., 
2000, Sugai et al, 1999). As different phenotypic pathways are said to exist for each 
cancer, and as patient characteristics vary, then it would be plausible to believe those 
who favour two distinct genetic aetiologies. It is also not clear as to whether site of 
tumour influences chromosomal changes (Beuzen et al., 2000, Nowinski et al., 1990). 
However, there is agreement that advanced cancers have more extensive genetic 
change than early cancers (Kitayama et al., 2000, Koo et al., 2000, Kim et al., 2000, 
Lee et al, 1999, Igarashi et al, 2000, Brito et a l , 1994, Fonesca et al., 1994). For 
example, a Japanese study of intestinal type cancers has found aneuploidy in 55.6% of 
early cancers, compared to 86.4% of advanced cancers (Sugai et al, 1999). 
Chromosomal instability has certainly been identified as an indicator of aggressive 
tumour behaviour (Yadav et al., 1996).
A number of researchers have also looked at pre-malignant states and found 
that some of the genetic changes present in the most advanced gastric cancers are 
present in these early stages too (Tahara 1995), indicative of important driving 
changes in carcinogenesis. This is discussed in more detail in Chapter 4, where the 
results of a cytogenetic analysis study on pre-malignant gastric tissue is described.
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1.2 Aneuploidv
1.2.1 Aneuploidv and cancer
A number of genetic changes have been identified in cancers. These include 
point mutations in genes, gene expression alterations, chromosomal translocations 
causing structural rearrangement of genes, and finally, numerical changes in part or 
whole chromosomes. In 1936, abnormal amounts of DNA were first recognised in 
human cancers (Caspersson 1936), and almost 100 years ago it was thought that 
chromosomal imbalance was the cause of human cancers (Boveri 1914). Today, 
aneuploidy is commonly seen involving one or more chromosomes in human cancers 
(Sen 2000), and it is the most prevalent genetic abnormality seen in solid tumours 
(Heim and Mitelman 1995). The association of aneuploidy and cancer is therefore 
undisputed, but the mechanism for aneuploidy induction and indeed carcinogenesis in 
most tissues is still unresolved.
The identification of aneuploidy early in cancer development, has suggested 
that altered DNA content, and its underlying cause may play an important role in the 
development and progression of cancer (Barret et al., 1999, DeAngelis et al., 1999). 
DNA aneuploidy has been associated with poor prognosis in a number of cancers 
(Ross et al., 1996, Macgennis et al., 1997). There is also a hypothesis that tumour 
instability is related to chromosome aneuploidy (Lengauer et al., 1999, Nardonne et 
al, 1999). In vitro studies show that aneuploidy is required for neoplastic 
transformation, and its development is necessary for cell immortilisation. Aneuploidy 
in cells has been shown to be induced by chemical carcinogens and oncogenic viruses 
(Namba et al., 1996, Li et al., 1997).
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The association of aneuploidy and GI cancer is strong. Aneuploidy in 
colorectal cancers, oesophageal adenocarcinomas and gastric adenocarcinoma is 
common. Tumours with aneuploidy have been shown to behave more aggressively, 
suggesting a clinical use to establish risk and prognosis of disease. For example, DNA 
aneuploidy has been shown to be a possible indicator of disease progression in 
ulcerative colitis to colonic cancer (Lindberg et al., 1999). Similar observations as to 
the importance of aneuploidy in progression to cancer have been noted in Barretts 
disease of the oesophagus (Teodori et al., 1998, Doak et al., 2003). In gastric cancer, 
higher levels of aneuploidy have been associated with advanced tumours (Sugai et al.,
1999), and metastatic spread of gastric cancer (Sasaki et al., 1999). The association of 
gastric cancer and aneuploidy has been discussed in detail earlier in this chapter.
1.2.2 Mechanisms of aneuploidv development
The development of aneuploidy is possible through three broad mechanisms. 
Firstly, it could arise from the sporadic missegregation of chromosomes leading to 
stable cells with a relatively homogenous DNA content. Secondly, the development of 
polyploidisation leads to aneuploidy, which can be caused by multiple rounds of 
replication, mitotic failure (spindle failure, cytokinesis failure), or methods such as 
cell fusion. This again would result in tumour cells with stable chromosome number.
A third mechanism, and the most likely to occur in cancers, involves the acquisition 
of a permanent defect in the ability to segregate chromosomes. This leads to persistent 
changes in chromosome numbers within tumour cells, therefore producing a 
heterogeneous cell population undergoing constant change (Pilan and Doxsey 1999). 
This is seen in a number of different human cancers (Lenguaer et al., 1997) and could 
explain the variety of karyotypes in tumours. Persistent missegregation of
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chromosomes could cause, accelerate or contribute to tumourigenesis, by facilitating 
the accumulation of chromosomes housing genes which have the ability to potentiate 
growth, and also by losing chromosomes with growth restraining genes. Hence, cells 
possessing a growth advantage are selected. This is also an important consideration in 
the treatment of cancers, as chemoresistant cancer cells would need to possess similar 
characteristics.
Figure 1.3 illustrates the different components in mitosis where defects can 
lead to chromosome missegregation and hence aneuploidy (Pihan and Doxsey 1999). 
Centrosomes, or spindle poles, are microtubular barrels surrounded by a protein 
matrix. Their function is to organise the microtubular structures of interphase cells 
and the mitotic spindle during cell division. They have a role in the nucleation, 
severing, movement and anchoring of microtubules, and also provide a support for 
mitotic regulatory activities. Abnormalities of centrosome function (extra copies, 
aberrant size and shape, acentriolar) can cause aberrant spindle formation and result in 
chromosome missegregation and high rates of aneuploidy, and this has been 
demonstrated in many tumours, including GI tumours (Pihan et al., 1998, Lenguaer et 
al., 1997). The identification of a family of serine/threonine protein kinases, Aurora 
kinases, with a role in the regulation of cell division has proved interesting (Carmena 
and Eamshaw 2003). There are 3 main types of Aurora kinases, A, B and C. Aurora A 
kinases are linked to centrosome separation and spindle assembly through 
microtubular function (Carmensa and Eamshaw 2003). One such centrosome 
associated kinase, STK15/BTAK/aurora2, has been found to be amplified and 
overexpressed in human cancers (Zhou et el., 1998). This has led to the suggestion 
that this kinase is involved in abnormal centrosome function and hence, chromosome
16
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missegregation. In vitro experiments have correlated this kinase activity with both 
aneuploidy and tumourigenesis (Giet et al., 1999).
Microtubule spindle proteins provide the structural framework for mitosis, and 
the tracks for chromosomes during their separation. Hence, defects in these structures 
could upset chromosome segregation. Experiments have shown that chemicals 
affecting microtubular function result in aneuploidy (Oshimura and Barret 1986). 
Changes in the expression of tubulin, the subunit of microtubules, and mutation in the 
tubulin genes, lead to chromosomal missegregation (Burke et al., 1989, Huffaker et 
a l , 1988).
Motor proteins provide the force for chromosome separation, condensation 
and segregation, and also the elongation and positioning of the spindle. Disruption of 
any number of these microtubular motor proteins could lead to chromosome 
missegregation and hence, aneuploidy (Pihan and Doxsey 1999).
Kinetochores are proteins found around the chromosome centromeres. These 
proteins allow spindle attachment and also anchor motor proteins to allow 
chromosome movement. They also possess checkpoint proteins that ensure compete 
chromosome separation prior to separation into daughter cells. The disruption of these 
proteins could result in aneuploidy. In fact, centromeres lacking kinetochore proteins 
have been shown in cancer cells (Vig and Stemes 1991).
Abnormalities in chromosome condensation can lead to fragmentation and 
missegregation during mitosis. Abnormalities of topoisomerases, whose usual 
function is to help avoid chromomosomal entanglement, have been demonstrated in 
tumour cells (Hashimoto et al., 1995).
Cohesion of sister chromatids is needed during mitosis. Mutations in several 
yeast genes have shown that early and late separation of these chromatids results in
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non-disjunction of chromosomes, and hence aneuploidy ((Miyazaki and Orr-Weaver 
1994). Similar events have been shown in cancer (Gebhart 1989). The overexpression 
of a protein called securin, which is known to inhibit chromatid separation, has been 
found in human cancer cells (Zou et al., 1999).
The disruption of cytokinesis, the process of cell separation into two daughter 
cells, also has potential to be implicated in carcinogenesis. It has been observed in 
cancer cells and implicated in polyploidisation (Shackney et al., 1989).
The regulation of mitosis involves a number of pathways including regulatory 
circuits, mitotic checkpoints and apoptotic checkpoints. Entry into and exit from 
mitosis is controlled by a number of regulatory pathways, and abnormalities seen in 
some of these proteins have been shown in cancer cells with polyploidisation 
(Yamamoto et al., 1998). Mitotic checkpoints exist throughout mitosis, and proteins 
thought to be important in avoiding chromosome missegregation include the Mad and 
Bub proteins. Defects of these checkpoint proteins have been demonstrated in cancers 
with chromosomal instability (Cahill et al., 1998). The apoptotic checkpoint ensures 
that any cells do not survive if they have an aberrant chromosome number. Cancer 
cells have been shown to possess increased amounts of a protein called survivin, an 
inhibitor of apoptosis, and hence this may represent a mechanism whereby cells with 
aberrant chromosome copy number survive (Ambosisni et al., 1997).
1.3 Helicobacter pylori
1.3.1 Introduction to Helicobacter pylori
Helicobacter pylori is a member of a large family of Gram negative bacilli 
known for many decades to inhabit the human host. In 1983, Warren and Marshall
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described this spiral bacterium, which is similar to Campylobacter, in the mucosa of 
patients with chronic gastritis (Warren and Marshall 1983). See figure 1.4. Since then 
its presence has been implicated in the aetiology of many diseases. Peptic ulcer 
disease, mucosa associated lymphoma (MALTomas) and gastric cancer, have been 
causally linked to H. pylori infection (Cover and Blaser 1995). In the case of other 
diseases such as non-ulcer dyspepsia, oesophageal disease (gastrooesophageal reflux 
disease/GORD, Barretts oesophagus) and atherosclerotic disease, the link is less clear. 
The presence of H. pylori has been suggested as being protective against GORD, 
Barretts disease and hence adenocarcinoma of the oesophagus. Asymptomatic 
carriage of the infection is also common (Blaser 1998), with only an estimated 20% of 
infected individuals developing clinical disease (Kuipers et al., 1995, Uemura et al., 
2001). Co factors both in the host and the environment may help to explain why not all 
cases of H. pylori infection result in disease, and why different diseases are seen 
(Graham 2000, Sipponen et al., 1998, Blaser 1998).
1.3.2 Incidence of H. pylori infection
The prevalence of H. pylori infection worldwide has been estimated at 50% 
(Marshall 1994, Nepomnayshy and Burkitt 2000), but different rates occur depending 
upon geographic location. A review by O’Connor and Sebastian 2003, suggested 20% 
of people under 40 years of age in a developed country would carry H. pylori 
infection, increasing to 50% in those over 60 years, whereas in developing countries 
80% of the population by age 20 would already be infected. This geographical 
variation would partly reflect the differences in the socio-economic conditions of the 
different populations. The bacterium is transmitted via the faecal oral route, and as 
such, high rates of infectivity in developing nations may reflect large family units and
19
Figure 1.4 Helicobacter pylori
poor hygiene practices. Obviously the use of antibiotics will also partly be responsible 
for the lower prevalence rate in developed countries. The number of positive H. pylori 
serological tests increases with low socio-economic class (Logan and Walker 2001).
A decline in the incidence of H  pylori has indeed been noted over time. A 
Scandinavian study noted H. pylori antibody levels in their population fell between 
1973 and 1994 from 56% to 31% respectively (Kosunen et al., 1997). In fact, in 
developed countries the increased infection rates seen with age, may represent the 
childhood acquisition of the infection at a time when prevalence rates of H. pylori 
were higher (Logan and Walker 2001, O’Connor and Sebastian 2003).
Infection in early childhood is the usual scenario. In developed countries 
primary infection in adults is rare, as is re-infection after eradication in adults, 
although this is not always the case in developing nations (Logan and Walker 2001, 
O’Connor and Sebastian 2003).
1.3.3 Mechanism of action of H. pylori
Helicobacter pylori organisms are located in the mucus lining of the stomach. 
They affect the gastric tissue by inducing gastric inflammation, disrupting the gastric 
mucosal barrier and altering gastric acid metabolism (Dunn et al, 1997).
Cellular hyperproliferation is seen in the infected gastric tissue and this is 
linked with increased apoptosis (Nardonne et al., 1999, Moss et al., 1995). 
Inflammation is associated with increased cytokine release, such as interleukin 6 and 
8 (Graham 2000, Sipponen et al., 1998, Blaser 1998, Kuniyasu et al., 2000), and 
indeed there are increased numbers of inflammatory cells in the gastric mucosa of H. 
pylori infected individuals (Correa and Shiao, 1994). These inflammatory leucocytes 
release Reactive Oxygen Species (ROS), such as superoxide and H2O2, as a defence
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mechanism against the bacterial infection. Reactive oxygen species are discussed in 
more detail later in this introduction. Infection is known to be a risk factor for many 
types of cancer as it increases the ROS levels as a result of the inflammatory immune 
response (Ames et al., 1993). Increased levels of ROS in the gastric mucosa, and 
therefore the levels of oxidative DNA damage, are known to be highest in the gastritis 
stage of gastric cancer and are associated with the greatest inflammatory response 
(Morgan et al., 2003, Mamett, 2000). H. pylori has been shown capable of inducing 
ROS production both directly (Bagchi et al., 1996, Obst et al., 2000), and indirectly 
through activation of polymorphonuclear leukocytes (Obst et al., 2000, Farinatti et al.,
1998). ROS levels have been shown to correlate with H. pylori presence in the gastric 
mucosa (Baik et al., 1996) and, in fact the level of ROS has been shown to be 
proportional to the bacterial load (Dunn et al., 1997). H pylori is linked causally to 
gastric cancer and we know that the production of ROS is one way the bacterium 
exerts its effect on gastric cells (Chan et al., 1999, Correa, 1988, Asaka et al., 1997, 
Wagner et al., 2000). Studies have shown abnormalities at the cytogenetic level and 
the molecular level in pre-malignant gastric tissue infected with Helicobacter pylori 
(Nardonne et al., 1999).
1.3.4 H. pylori and gastric disease
H. pylori is capable of inducing a number of phenotypic changes in the gastric 
mucosa of infected individuals. Superficial gastritis, chronic gastritis, atrophic 
gastritis and intestinal metaplasia have all been demonstrated (Graham 2000,
Sipponen et al. 1997, Kuniyasu et al, 2000). All these histological changes can be 
found in the pre-malignant stages of gastric carcinogenesis (Correa 1988). H. pylori 
infection has been causally associated with Maltomas, peptic ulcer disease and gastric
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cancer. H. pylori has been found in 70% of gastric antrum samples of patients with 
chronic active gastritis/gastric ulcer, and in 90% of patients with duodenal ulceration 
(Pakodi et al., 2000), although American studies suggest lower rates of infection 
(Nepomnayshy and Birkett 2000).
15% of infected individuals will develop peptic ulcer or gastric cancer as a 
consequence of longterm infection. The site of infection seems to be important in 
determining the type of disease. (See Figure 1.2.) Infection of the corpus, and then 
acute pangastritis, can lead to mild gastritis with no upset in gastric acid secretion and 
hence the patient will remain asymptomatic. However, chronic infection can lead to 
loss of acid secreting cells, hypochlorhydria, bacterial overgrowth and, hence an 
increased risk of gastric ulcer and gastric cancer (Logan and Walker, 2001, Faraji and 
Frank 2002). An association has been suggested with repeated infection as ageing 
occurs, and also with poor nutrition. A similar effect of pangastritis is seen in 
autoimmune gastritis (pernicious anaemia), whereby hypochlorhydria develops with 
bacterial overgrowth and conversion of nitrates to nitrosamines, giving an increased 
risk of gastric cancer in the order of 1.5-3 fold (Faraji and Frank 2002).
Predominantly antral H. pylori infection, leads to antral gastritis with an intact acid 
secreting corpus, and hence results in an increased parietal cell mass and increased 
acid secretion due to the disruption of the regulatory feedback pathway by gastrin 
produced in the antrum. This process results in a high acid load developing in the 
duodenum and leads to duodenal pyloric metaplasia. These islands of pyloric 
metaplasia are colonised by H  pylori, and duodenitis and ulceration occurs (Logan 
and Walker 2001, Faraji and Frank 2002). In summary, H. pylori infection of the 
antrum results in hyperacidity and duodenal ulcer formation, whereas corpal infection 
is associated with hypoacidity and gastric ulcer and gastric cancer formation.
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Chronic H. pylori infection can occur when the host immune response 
generated by the bacteria is not sufficient to clear the infection. Concurrent infection 
with different strains is possible and produces a polyclonal infection, hence allowing 
DNA exchange and the development of more virulent strains (Logan and Walker 
2001).
Environmental factors and host factors determine how strong the association is 
between H. pylori and gastric disease (Graham 2000). HLA status affects the severity 
of disease associated with H. pylori infection (Azuma et al., 1998), as do the different 
polymorphisms known to exist in interleukin production (El Omar et al, 2000). 
Hence, the risk of gastric cancer risk in individuals with H. pylori infection is 
probably also affected by host factors.
1.3.5 Association of H. pylori with gastric cancer
In 1994, the International Agency for Research on Cancer (IARC) declared the 
bacterium Helicobacter pylori a class one human carcinogen, capable of inducing 
changes leading to gastric cancer (IARC 1994). H. pylori is linked causally to gastric 
cancer and we know that the production of ROS is one way the bacterium exerts its 
effect on gastric cells (Chan et al., 1999, Correa, 1988, Asaka et al., 1997, Wagner et 
al., 2000). O’Connor and Sebastian 2003 suggested that H. pylori may account for 
60% of all gastric cancers worldwide. There is now a large body of evidence linking
H. pylori to gastric cancer with epidemiological studies showing a 2.7-12 fold 
increased risk of gastric cancer in those people infected with H. pylori (Cover and 
Blaser 1995). The EuroGast Study Group found that incidence rates of H. pylori 
infection, as determined by the presence of antibodies, was significantly higher in 
patients with gastric cancer than in controls (EuroGast 1993), and estimated a 6 fold
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increased cancer risk associated with H  pylori infection. A UK study found infection 
rates of 69% in gastric cancers as compared to 47% in controls (Forman et al., 1991). 
Asaka et al. determined an odds ratio of 2.6 when comparing H. pylori antibodies in 
controls to gastric cancer patients (Asaka et al., 1997). Rugge et al. determined an 
odds ratio of H. pylori infection and gastric cancer of 2.9, and they found an 
association with both diffuse and intestinal gastric cancer (Rugge et al., 1999). A 
Chinese study suggested that H. pylori infection increased the risk of gastric 
dysplasia, as well as gastric cancer (You et al., 2000). A meta analysis of 42 
epidemiological studies found an overall increased risk of gastric cancer in H. pylori 
infected people of two fold (Eslick et al., 1999).
Animal models have demonstrated a whole spectrum of gastric disease is 
associated with Hpylori infection, the endpoint being gastric carcinoma (Honda et al,
1998).
1.3.6 H. pylori virulence factors
A number of virulence factors have been described in H. pylori and can be 
divided into colonisation factors and disease associated factors (McGee and Mobley
1999). Colonisation factors, present in all strains of H. pylori, enable the bacteria to 
invade the host, and proliferate unharmed in the gastric environment. Well-recognised 
examples include, urease activity to neutralize acidity and reduce inflammation, and 
the presence of flagella to enhance motility. Disease associated factors are expressed 
only in certain strains of H. pylori, and cause increased virulence. The two major 
virulence factors are the vacuolating cytotoxin (VacA) and the cytotoxin associated 
protein (CagA) (Cellin and Donelli 2000). The importance of CagA positive H. pylori 
infection is discussed in greater detail in Chapter 6.
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1.3.7 Diagnosis of H  pylori
There are a number of invasive and non-invasive tests to determine H. pylori 
infection in patients. Chapter 6 outlines the different methods available, commenting 
upon their clinical usefulness and their relative sensitivities.
1.3.8 Eradication of H. pylori
The treatment of H. pylori is best approached by adopting a ‘test and treat’ or 
more correctly a ‘diagnose, treat and confirm eradication’ strategy (Graham 2000). A 
combination treatment of an acid suppressor i.e. a proton pump inhibitor (or ranitidine 
bismuth) and 2 antibiotics (amoxicillin/clarithromycin, metronidazole/clarithromycin 
or amoxicillin/metronidazole) is a popular and effective therapy, quoting eradication 
rates of 90% (Unge 1998). Quadruple therapy has also proven to be an effective 
treatment using a proton pump inhibitor, tetracycline, metronidazole and bismuth and 
is often used if triple therapy fails (Graham 2000, O’Connor and Sebastian 2003). 
Successful eradication of H. pylori leads to peptic ulcer healing and a decrease in 
ulcer recurrence. It also has symptom benefit in those patients with non-ulcer 
dyspepsia. It can cause complete resolution of most low grade MALT lymphomas.
In the pre-malignant stages of gastric cancer, eradication of H. pylori has been 
shown to reverse certain genetic abnormalities, with the degree of genetic change 
returning to that of the non-infected tissue after bacterial eradication (Blaser 1998, 
Nardonne et al., 1999, Walker 2002). The degree of cell proliferation visible in H  
pylori associated chronic gastritis, has been shown to be less after successful 
eradication, as has the degree of gastric atrophy. There was also noted to be an 
improvement in the genomic instability of the cells after H. pylori eradication, 
specifically the DNA content and mutations of bcl-2, p53 and the c-myc genes
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(Nardone et al., 1999). Furthermore, the level of ROS has been shown to drop after 
eradication of H  pylori (Drake et al., 1995). A Japanese study has gone one step 
further and suggested that in a series of patients with early gastric cancer the 
successful eradication of H. pylori was associated with a reduced risk of cancer 
recurrence (Uemura et al., 1997). Treatment of people with relatives known to have 
gastric cancer is also now a consideration (O’Connor and Sebastian 2003).
Widespread antibiotic usage and the ability of the bacteria to mutate, has been 
blamed for the increasing resistance seen in developed countries (Baser 1998). Patient 
compliance is now improved with the introduction of the pre-packed medication 
regimen, ‘Heliclear’, which is now commercially available. There is geographic 
variation in the success rate of H. pylori eradication, and anitibiotic resistance has 
been shown to vary between different populations (Owen 2002). Previous studies 
have proved that eradication rates fall as bacterial resistance increases (Van der 
Wouden et al., 1999). Resistance to amoxicillin or tetracycline is rare (Owen 2002), 
however resistance to metronidazole has been reported in 10-70% of cases (Canton et 
al., 2001). This possibly reflects the popularity of metronidazole as a drug to combat 
non- H. pylori infections. As the fiill eradication of H. pylori is not always achieved 
the resistant strains of H  pylori are commonly selected for, and hence they increase in 
frequency. In a European study, resistance to both clarithromycin and metronidazole 
was found in 86% of H. pylori isolates resulting in failure to eradicate the infection 
(Heep et al., 2000). Another study suggested rates of combined antibiotic resistance in
H. pylori infection of 72% (Owen 2002).
Vaccinations against H. pylori infection are being considered as some success 
has been shown with animal vaccinations against Hfelis, a bacterium similar to H. 
pylori (Czinn et al., 1993). Difficulties with human vaccination studies exist however.
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The identification of a single oral vaccination able to provide full protection, as well 
as producing good rates of eradication and complete disease resolution, together with 
a minimal side-effect profile, has not yet been developed. Also, determining the 
subset of the population who would benefit from the vaccination is still very much in 
question (Czinn and Nedrud 1999). Developing nations may benefit most from 
vaccination as prevalence rates are high, but as reinfection rates exist vaccination 
without addressing socioeconoimc factors would be unlikely to be successful.
1.4 Oxidative DNA damage and Reactive Oxygen Species
The induction of oxidative DNA damage is an important mechanism in 
carcinogenesis. Indeed it has been postulated that up to 50% of all human cancers 
result from oxidative DNA damage (Beckman and Ames, 1997). Importantly for this 
thesis, oxidative damage has been proposed as a potential causative agent in gastric 
cancer (Correa and Shiao, 1994, Stadtlander et al., 1999). Oxidative DNA damage 
results mainly from the leakage of Reactive Oxygen Species (ROS) within cells. ROS 
are produced by a number of sources both environmental and cellular. Environmental 
sources, include UV light and man-made pollutants, whereas cellular sources include 
byproducts of mitochondrial metabolism and neutrophil activation (Gracey et al.,
1999). During the normal metabolism of aerobic organisms, mitochondria are 
responsible for oxidative phosphorylation. Unfortunately, the 1-2% of oxygen that is 
released from mitochondria as ROS (Yakes and Van Houten, 1997) is the price to pay 
for the 12 additional adenosine triphosphate (ATP) molecules produced per Acetyl 
Coenzyme A combusted during aerobic respiration (Marnett, 2000). ROS are low 
molecular weight compounds and are released from the mitochondria as superoxide
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radicals, hydrogen peroxide and hydroxyl radicals (Friedberg et al., 1995, Gracey et 
a l , 1999).
These ROS are considered to be complete carcinogens in that they can both 
damage DNA (mutagenic) and stimulate cell division (mitogenic) (Perwez Hussain et 
al., 1994), this combination being most effective at inducing cancer development after 
longterm exposure. ROS can interact directly with DNA, or exert their effect on DNA 
via cellular components such as proteins and lipids (Mamett, 2000). ROS damage 
DNA by modifying the base structure of DNA and by introducing strand breaks.
These strand breaks can also be introduced during DNA repair processes (involving 
DNA glycosylases of the base excision repair pathway) (Wang et al., 1998). DNA 
strand breaks, when occurring on opposite DNA strands in the same proximity, can 
lead to double stranded chromosomal breaks resulting in fragmentation of 
chromosomes. It has been estimated that approximately 1000 oxidative damage 
events occur in the DNA of each cell per day (Wang et al., 1998), with more DNA 
damage occurring in the mitochondrial DNA resulting in higher mutational rates in 
mitochondrial DNA compared to genomic DNA (Richter et al., 1988). ROS induced 
DNA damage, which escapes the DNA repair systems designed to deal with them, can 
cause cells to become genetically unstable and develop into tumours.
1.5 Aims/Hypothesis
Gastric cancer was chosen to study, as it is a common cancer resulting in 
significant mortality and morbidity. As has been discussed already in this 
introduction, Correa has proposed a multistep pathway of gastric carcinogenesis 
(Correa 1988), and gastric tissue with malignant potential, gastritis 
(active/chronic/atrophic) and intestinal metaplasia, has been identified. In this thesis
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tissues with malignant potential have been studied, and have been collectively termed 
pre-malignant tissue. Numerous studies outlined in this chapter have shown 
chromosomal abnormalities in gastric cancer, and experiments in this thesis have 
attempted to determine if specific chromosomal abnormalities (aneuploidy of 
chromosome 20, 8, 4, 17( p53)) are important in gastric carcinogenesis, and in 
particular play a role in the initiation of gastric cancer.
Evidence has been reviewed in this introduction to ascertain the cause of 
gastric cancer, and Helicobacter pylori has proved to be an important aetiological 
agent, therefore its relationship to chromosomal abnormalities was also investigated.
Oxidative damage has been described as a mechanism for carcinogenesis, and 
is also present in gastric tissue infected with Helicobacter pylori. An attempt has been 
made in this thesis to determine its role in the stages of gastric carcinogenesis.
Hence the aims of the work described in this thesis were three fold.
(1) To determine the type of chromosomal damage induced by
oxidative damage in a human cell line.
(2) To investigate the level of aneuploidy existing in pre-
malignant and malignant gastric tissue.
(3) To correlate the degree of aneuploidy in gastric tissue with
Helicobacter pylori infection, and also make a comparison 
with the chromosomal abnormalities shown to be induced 
by oxidative damage.
The hypothesis to be tested was that Helicobacter pylori infection induces 
oxidative damage in gastric tissue, leading to aneuploidy, and that this is important in 
the initiation and progression to gastric cancer.
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The first series of experiments, outlined in Chapter 3, looked at the effect of 
ROS exposure in a human cell line. Different cytogenetic methods were used to 
identify chromosomal damage, CBMN assay, CBMN assay + kinetochore staining 
and interphase FISH, using CEN probes (4,8,20) and LSI probes (p53).
Chapter 4 investigated gastric cells at different stages of disease -  normal 
gastric mucosa, gastritis and intestinal metaplasia. Interphase FISH was used to assess 
chromosomal damage (CEN 4,8,20 and LSI p53). A correlation was made with 
patient characteristics, histological diagnosis and H  pylori infection.
The third interphase FISH study, Chapter 5, was performed on surgical 
resections to assess the chromosomal abnormalities in malignant gastric disease, and 
make a comparison with the pre-malignant tissue already studied.
Finally in Chapter 6, a PCR study was undertaken to determine the level of H. 
pylori infection in the pre-malignant tissue already assessed in the Chapter 4. A 
comparison of the detection rates of H  pylori infection, using PCR and histological 
analysis, was made. The determination of the more virulent strain of H. pylori, Cag A, 
was also made using PCR, and an attempt to correlate disease severity and the level of 
chromosomal abnormalities was also made.
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Chapter 2. 
Materials and Methods
This chapter outlines the process involved in patient recruitment and data 
collection in those patients studied in the endoscopic study described in Chapter 4, 
and in the assessment of surgical resections in Chapter 5. The methods of cell 
collection from endoscopic samples and resection samples is described, as is the 
method of interphase FISH used to determine cytogenetic abnormalities. The 
statistical analysis used to assess the results for the interphase FISH is explained, as 
well as the process whereby the histological diagnosis of gastric biopsies was made.
2.1 Patient enrolment into the study
The patients who were invited to participate in this study were all attending 
Neath Port Talbot Hospital. The hospital is situated in a mixed rural and urban area of 
West Wales, and serves a socially deprived population of approximately 140,000. 
Prior to the start of this study Ethical Approval was obtained from the Local Research 
Ethics Committee, November 2001. The study was performed from January 2002 to 
September 2002. Patients enrolled in this study were identified during routine 
endoscopy lists at Neath Port Talbot Hospital. Only those people attending my 
endoscopy list were invited to participate, as I was the only endoscopist able to collect 
and transfer the samples to the university for analysis. Time only allowed a maximum 
of two people to be enrolled in the study at each list. Exclusions to the study were 
made when it was felt consent could not be adequately given (<18 years, unable to 
give informed consent). In an effort to achieve informed consent patient information 
leaflets (appendix 1.1) were sent out to all patients together with their appointment
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details, and a discussion of the leaflet was made before consent was taken (appendix
1.2). Patients were not asked to consent if factors were present that were thought to 
modify the gastric environment (currently taking proton pump inhibitors and non 
steroidal anti-inflammatory drugs, recent H  pylori eradication and a history of 
previous upper GI surgery). Information was collected on sex, age, ethnicity, family 
history, diet, smoking, alcohol and drug intake, prior to the endoscopy and 
documented on Patient Case Record Forms, see appendix 1.3. The information from 
the patient was the only source of information collected, and no other records were 
reviewed.
2.2 Endoscopic cytology brushings.
At the end of an upper GI endoscopy examination, cytology brushes (Diagmed 
Ltd) were used to collect cells from the gastric and oesophageal mucosa. Figure 2.1 
shows a cytology brush at the tip of an endoscope. The endoscopic procedure was 
only prolonged by 2-3 minutes to collect the brush and biopsy samples needed.
Gastric brushes were taken at the same site of the gastric biopsy. If an area of the 
stomach was macroscopically normal the brush/biopsy was taken form the gastric 
antrum, otherwise the abnormal area was sampled. Oesophageal brushes were taken 
from macroscopically normal distal oesophagus. This methodology has been 
described for oesophageal samples (Doak et al., 2003). Brushes/biopsies were not 
taken from patients on anticoagulation therapy, those with obvious bleeding lesions at 
endoscopy and those who showed any adverse signs during the procedure, therefore 
these patients were not entered into the study. No patient reported any immediate 
complications following any endoscopic procedure performed in the study.
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Figure 2.1 Cytology brush protruding through tip of endoscope
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Initially gastric cell collection on the cytology brushes was found to be poor. 
This improved after care was taken to adjust the angle of the brush to maintain better 
contact with the gastric mucosa, as the stomach is less tubular than the oesophagus. 
Also yield was noted to be poor if bile, residual food or blood was present in the 
stomach, therefore 20ml sterile water washes were used prior to brushing. Brushes 
were also taken prior to biopsy, as biopsy resulted in small amounts of local bleeding.
Brushes were stored in 10ml of 90% methanol, on ice, in the Endoscopy Unit 
for transportation to the University for laboratory analysis. Vigorous shaking of the 
brushes to dislodge the cells from the bristles immediately after storage in the vials 
was found to improve cell yield. These brushes were stored successfully for up to a 
week. Initially in the study, brushes were transported from the Endoscopy Unit in 
ETN buffer (0.1M EDTA, 0.01M Tris-HCl, 0.02M NaCl, pH 7) on ice, as described 
for oesophageal brushes (Doak et al., 2003), but in spite of harvesting these cells 
within 4 hours, cell yield was unreliable and the media was therefore changed to 90% 
methanol.
2.3 Cytology brushes from surgical resections of gastric cancer
Patients in the Neath Port Talbot locality requiring gastrectomy for gastric 
cancer are referred to Morriston Hospital for surgery. Surgical resection specimens 
from 10 patients undergoing gastrectomy for gastric cancer at Morriston Hospital 
Swansea, (Consultant Surgeon Mr T Brown), were identified by Dr AP Griffiths, 
Consultant Pathologist. Multiple brushings (Diagmed Ltd) from the surgical resection 
specimens were taken, together with biopsies at the same sites, hence allowing 
histological diagnosis. The cytology brushes were stored in 90% methanol within 30 
minutes of resection. Samples were collected between July 2002 and April 2003.
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2.4 Interphase cell preparations.
The cell suspension was washed x3 by centrifugation/resuspension in ETN 
buffer (Doak et ah, 2003). If the cell pellet produced was noted to be small the third 
wash was omitted. The resultant cell pellet was resuspended in 0.5ml ETN buffer and 
a cytodot was produced on a glass slide using Cytospin 4 (ThermoShandon, Cheshire, 
UK). Larger pellets were resuspended in 1ml ETN buffer. The cytodot was examined 
with a light microscope, and cell suspensions were diluted accordingly to ensure that 
an adequate number of cells evenly spaced apart were present for interphase FISH to 
be successful. Oesophageal cells were easily visualised, but the gastric cells 
frequently had no clear cytoplasm/cell membrane, appearing partially digested. This 
improved when the brushes were stored in 90% methanol giving a better yield of 
cells. The poor yield in ETN was most likely due to persisting activity of endogenous 
enzymes present in the gastric secretions. Cell preparations on slides were fixed in 
90% methanol at -20° C for 10 minutes and left to air dry. An average of 2-5 slides 
were produced per sample. Figure 2.2 shows examples of cells easily visualised on 
light microscopy, and cells obscured by debris.
Interphase cell preparations were incubated at 37° C for 10 minutes and then 
treated with 300 pi /ml HC1 pepsin, pH 2.7-3 (Sigma, Dorset, UK) at 37°C, to remove 
cytoplasmic proteins, hence improving probe penetration. Oesophageal cells were 
treated for 7 minutes as described by Doak et al., but over this period of time 
overdigestion of gastric cells resulted in loss of nuclei. Again, this suggested that 
partial gastric cell digestion after the collection phase at endoscopy had already 
occurred, therefore the pepsin digestion time was reduced to 5 minutes and the yield 
improved. Slides were washed in PBS (5 minutes) and PBS/MgCE (5 minutes) at
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Easily visualised cells after preparation onto slide, using light microscoi
Figure 2.2.
room temperature to arrest the enzymatic action of pepsin. They were then dehydrated 
in increasing concentrations of ethanol prior to FISH.
Figure 2.3 shows examples of cells after pepsin digestion.
2.5 Interphase FISH.
Centromeric enumeration probes (CEN) for chromosomes 4, 8 and 20, and a 
locus specific identifier probe (LSI) for p53 (Vysis, Surrey, UK) were used. Two 
probes were used simultaneously, 20 and 4, p53 and 8. FISH was performed 
according to slightly modified manufacturers instructions. 5pi of probe mixture was 
added to each cytodot (3.5pl hybridisation buffer, 0.5pl of each probe and 0.5pi of 
water). The sample and probe were co-denatured on a 75°C hotplate for 2 minutes and 
incubated in the dark at 37°C for 30 minutes (CEN) or 16 hours (LSI). Slides were 
washed for 2 minutes at 73°C with 0.4xSSC/0.3% Nonidet P-40, and for 30 seconds at 
room temperature in 2xSSC/0.1% Nonidet P-40, and allowed to air dry in the dark. To 
counter stain the nuclei lOpl Dapi n  (Vysis, Surrey, UK) was added to each slide. A 
30 minutes hybridisation step using a combination of CEN 20 and CEN 4 probes 
worked well, as did a 16 hour hybridisation step with LSI p53 and CEN 8 (using LSI 
hybridisation buffer). When CEN probe 4 was left to hybridise longer than 30 minutes 
the probe was seen to adhere to other sites in the nucleus, as it is able to bind weakly 
to chromosome 9 (Vysis, Surrey,UK).
FISH probes could be washed off the slide as described by Doak et aL, 2003, 
therefore slides could be reused. However, this was only the case if the Dapi n  stain 
was removed immediately.
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Figure 2.3. Cells after pepsin digestion.
2.6 Signal visualisation and scoring.
An Olympus BX50 microsope and Powergene 4.3 software (Applied Imaging, 
Newcastle Upon Tyne, UK) was used to score each slide. Slides with <100 cells were 
excluded and an average of 223 cells per slide was scored (range 100-452). Nuclei 
were only included if they had at least one signal from each probe to avoid inclusion 
of results where hybridisation was inadequate. Nuclei that were smeared or 
overlapping were also excluded.
CEN probes highlight the centromere of the chromosome and were used to 
determine whole chromosome changes i.e. aneuploidy. A loss of a CEN signal was 
said to be a deletion of that chromosome, and more than 2 signals was determined an 
amplification. The LSI probe for p53 was a marker of that gene locus, and again a loss 
of a signal represented deletion, whereas a gain represented amplification.
Slides were coded before scoring, with no knowledge of the histological 
details of the tissue sample.
2.7 Statistical analysis of chromosomal abnormalities
Fisher’s exact analysis was used to compare the chromosomal changes 
between the differing histological diagnoses. Statistical significance was achieved if 
the calculated p values were less than 0.05, documented as p<0.05 (actual values have 
not been given).
2.8 Reproducibiltv of interphase FISH
The reproducibility of this technique has been assessed in Chapter 4, section
4.3.4.
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2.9 Histological diagnosis of tissue biopsies
The histological diagnoses of both the endoscopic biopsies taken at Neath Port 
Talbot Hospital, and the surgical resection biopsies taken at Morriston Hospital, were 
determined at the Pathology Department Morriston Hospital, Dr AP Griffiths, 
Consultant Pathologist.
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Chapter 3.
Identification of chromosomal abnormalities induced by a model Reactive
Oxygen Species (ROS) in a cultured human cell line, using Fluorescence In Situ 
Hybridisation (FISH).
This chapter describes experiments to assess the chromosomal abnormalities 
seen in a human cell line exposed to a model ROS. Different cytogenetic methods 
were used, CBMN assay, CBMN assay + kinetochore staining and interphase FISH. 
Chromosomal damage was demonstrated by the production of micronuclei in the cell 
line exposed to oxidative damage. Kinetochore staining suggested that aneuploidy 
was the main type of chromosomal abnormality caused. Interphase FISH showed that 
aneuploidy of chromosome 20, 4, 8 and 17(p53) was seen in the cells exposed to 
ROS. Amplification of chromosome 4, deletion of p53 and aneuploidy of 
chromosome 20 were the most significant chromosomal abnormalities caused by 
oxidative damage.
3.1 Introduction.
3.1.1 Oxidative DNA damage
Oxidative damage is an important mechanism in carcinogenesis. It has been 
implicated in up to 50% of all human cancers (Beckman and Ames, 1997) and 
importantly, has been considered a potential causative agent in gastric cancer (Correa 
and Shiao, 1994, Stadtlander et al., 1999). Oxidative DNA damage results mainly 
from the leakage of Reactive Oxygen Species (ROS) within cells and an example of 
ROS is hydrogen peroxide (Friedberg et al., 1995, Gracey et al., 1999).
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Many agents are suspected of playing a role in the aetiology of gastric cancer 
and some are capable of producing Reactive Oxygen Species (ROS). A number of 
studies have demonstrated that H. pylori is able to exert oxidative damage on infected 
tissue, the evidence for which has been reviewed in the general introduction.
3.1.2 Hydrogen peroxide
In order to mimic the ROS inducing potential of H. pylori in vitro, the model 
ROS, hydrogen peroxide (H2O2), which is one of the forms of ROS actually produced 
in vivo and known to be capable of causing oxidative cell damage was used (Fenech 
et al., 1999, Jaruga and Dizdoroglu, 1996). It is a readily available ROS, accessible in 
liquid form, and in previous studies, it has been noted that human cells exposed to 
H2O2 show a dose dependent increase in chromosomal aberrations (Fenech et al., 
1999, Uemgaki and Fenech, 2000, Rueff et al., 1993). Similar chromosomal damage is 
seen when cells are exposed to activated neutrophils (Uemgaki and Fenech, 2000), 
hence H2O2 is likely to be involved in the inflammatory mediated release of ROS. In 
fact, H2O2 is likely to represent the diffusible form of ROS that is responsible for 
genomic DNA damage in vivo, as the other types of ROS formed in vivo are too 
reactive to be translocated through the cell to the nucleus (Mamett, 2000). H2O2 is 
considered to be an ideal model of ROS induced DNA damage due to its production 
of the hydroxyl radical, which is considered to be the ultimate ROS in terms of DNA 
damage induction (Henle and Linn, 1997, Dreher and Junod, 1996). H2O2 produces 
the hydroxyl radical by Fenton chemistry, involving transition metal cofactors. Iron 
(Fe2+) reduces H2O2, and the extremely reactive hydroxyl radical is formed (Gracey et 
al., 1999).
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The hydroxyl radical is capable of reacting with biomolecules including DNA 
(Gracey et al., 1999). H2O2 damages DNA at 11 different sites (Jaruga and 
Dizdoroglu, 1996). These DNA adducts have a half-life of 8-60 minutes in 
lymphoblastoid cells (Beckman and Ames, 1997), presumably as a consequence of 
their removal by efficient DNA repair pathways. H2O2 has been shown to be capable 
of inducing DNA strand breaks as measured by the Comet assay (Duthie et al., 1997) 
and chromosomal breakage in the Cytokinesis Block Micronucleus Assay (CBMN) 
(Fenech et al., 1997), hence showing a potential role for ROS in inducing 
chromosomal abnormalities. H2O2 is also a gene mutagen, as determined by its 
induction of mutations of the p53 tumour suppressor gene (Jenkins et al., 2001). The 
doses of H2O2 used in these above studies to damage DNA have ranged from lOOpM 
to 700pM.
3.1.3 The Micronucleus and FISH methodologies
The Cytokinesis-Block Micronucleus Assay (CBMN) assay is a non-specific 
method of estimating the degree of chromosomal damage, necrosis and apoptosis. 
Micronuclei are formed from chromosomal fragments, or whole chromosomes, that 
separate from the normal chromosomal segregation step during mitosis forming small 
DNA containing micronuclei in the cytoplasm (Fenech et al., 1999, Albertini et al.,
2000). Micronuclei can be formed as chromosome fragments because of direct DNA 
breakage, replication of damaged DNA or inhibition of DNA synthesis. Micronuclei 
can also be formed from whole chromosomes because of a failure of the normal 
chromosome segregation mechanism at mitosis, as discussed in the chapter 1. The 
micronucleus assay has been shown to be an effective way of measuring general 
chromosome damage in vitro and in vivo (Fenech et al., 1999). Figure 3.1 illustrates
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the basic principle behind the methodology. After treatment with the test agent, cells 
are allowed to divide in the presence of cytochalasin B. Cytochalasin B inhibits 
cytokinesis (cell separation after mitosis) as it inhibits the actin polymerisation needed 
to form the microfilament ring that constricts the cytoplasm between the daughter 
nuclei (Fenech 2000). Hence, the cytochalasin B step produces binucleate cells. It is 
important to score the micronuclei only in binucleate cells, as a comparison of 
micronuclei incidence between populations of dividing cells only becomes reliable if 
scoring is restricted to cells that complete one nuclear division after the DNA insult 
(Fenech and Morley, 1985). The CBMN assay was used here as an indicator of 
chromosomal damage in order to establish the optimum amount of hydrogen peroxide 
needed to produce chromosomal damage for subsequent FISH analysis.
The addition of anti-kinetochore antibodies to the CBMN assay allows us to 
distinguish whole chromosome presence in the micronuclei from chromosomal 
fragments (Fritzer et al., 1980, Vig and Sweamigin 1986). The detection of these 
antibodies to the kinetochore complex was first reported in 1980, in patients suffering 
from the autoimmune condition CREST, (calcinosis, Raynaud’s, oesophageal fibrosis, 
sclerosis, telangiectasia) (Fritzer at al., 1980). Kinetochore positive micronuclei 
indicate centromere presence, and therefore whole chromosome presence, in the 
micronuclei. Chemicals that produce mostly kinetochore positive micronuclei (>70%) 
are said to be aneugens, whereas those forming mostly negative micronuclei (>70%) 
are clastogenic compounds (Antoccia et al., 1991). Parry et al., in 2002, illustrated the 
importance of this amended CBMN assay to determine chemicals causing aneugenic 
chromosomal damage (Parry et al., 2002). However, it should be noted that only the 
chromosomes with active centromeres which bind to anti-kinetochore antibodies are
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detected, and that false negatives can occur if chemicals present target the kinetochore 
protein and stop the antibody binding (Dellarco et al., 1985).
The cell line used in these studies was the AHH-1 cell line (Genetest 
Corporation). AHH-1 is a human lymphoblastoid cell line, derived from a B 
lymphocytic cell line RPMI 1788, which expresses inducible aryl hydrocarbon 
hydroxylase (AHH). Experiments have shown that this cell line is sensitive to 
mutagens that require oxidative metabolism to exert their effect and, as such, it is a 
useful human cell line for studies on mixed-function oxygenases (Crespi and Thilly, 
1984, Freedman et al., 1979). It is a readily available human cell line, able to be 
grown in vitro with little cell death or contamination, and with a doubling time that 
allows the effect of chemical exposure to be assessed relatively easily (Crespi et al., 
1991, Doherty 1996). Analysis of the cell line has shown it to possess a stable 
karyotype, with 48 chromosomes due to an extra copy of chromosomes 3 and 9 
(Doherty 1996).
This study allowed the optimisation of FISH methodology using the chosen 
centromeric probes for chromosomes 4, 8 and 20, and the locus specific probe for the 
p53 gene (17pl3). Centromeric FISH probes can demonstrate whole chromosome 
changes in the cell and therefore detect chemicals producing an aneugenic effect 
(Parry et al, 2002). The chromosomes were chosen due to their implication in gastric 
cancer progression in previous publications, as illustrated in Table 1.1. Later in this 
thesis, the specific chromosomal alterations detected here are compared to 
chromosomal abnormalities found in pre-malignant and malignant gastric tissue 
(Chapters 4 and 5), with or without H. pylori infection, in order to compare the 
chromosome changes induced by a known ROS in vitro (H2O2) and a suspected ROS 
in vivo (H. pylori).
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3.1.4 Aims
This series of experiments was designed to illustrate the effects a model ROS 
(H2O2) has on the chromosome integrity of a human cell line as measured with 
Fluoresence In Situ Hybridisation (FISH) and the Cytokinesis-Block Micronucleus 
Assay (CBMN) assay. The aims of the work described in this chapter were three fold; 
initial investigations using the CBMN assay were confirmation studies to show that 
H2O2 causes chromosomal damage, as well as range finding studies for the 
clastogenicity / aneugenicity of H2O2 . Secondly, the data from this study was used to 
choose suitable doses for the study of specific chromosomal aberrations induced by 
H2O2 with the FISH methodology. Finally, this study aimed to optimise the use of 
FISH on the selected chromosomes prior to studying these chromosomes in gastric 
epithelial cells isolated from patients with pre-malignant and malignant gastric cancer.
3.2 Materials and Methods.
3.2.1 General cell culture.
All the glassware and pipettes used were sterilised in an autoclave (Prior Clave 
Ltd) at 121°C and 15psi for 30 minutes. The disposable, sterile, plastic tissue culture 
vessels, pipettes, centrifuge tubes and universal containers, were supplied by 
Invitrogen and Sterilin. All cell culture manipulation was carried out in aseptic 
conditions using a Cytomat Pharmaceutical Safety cabinet, class 2 (Medical Air 
Technology Ltd). LEEC MK11 proportional temperature controller incubators at 
37°C and 5% CO2 were used for all incubations.
AHH-1 cells (Genetest Corporation) were stored in DMSO in liquid nitrogen 
prior to use. After the cells were defrosted, using a waterbath at 37 °C, they were
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incubated at 37 °C with a 5% CO2 atmosphere, in a medium composed of RPMI (+ 
glutamine) with 10% horse serum (GIBCO, Invitrogen Corporation, UK). The best 
cell growth was achieved if cells were cultured in plastic flat bottomed flasks, and 
diluted with pre-warmed medium every 48 hours to obtain a cell concentration of 1.5 
- 2 x 105 cells per ml (Crespi et al., 1991,Genetest Corporation).
Freezing of the cell stock, and thawing, was carried out as detailed in Doherty
1996.
3.2.2 AHH-1 cell culture and dosing with Hydrogen Peroxide.
AHH-1 cells were suspended in serum free medium just prior to dosing with 
H2O2 . This was to eliminate any interactions between the hydrogen peroxide and the 
protein containing serum. In toxic fume hoods, the AHH-1 cells were dosed with 
differing concentrations of hydrogen peroxide (SigmaAldrich, Poole, UK) i.e. 0, 50 
and 100 pM, and incubated at 37 °C for thirty minutes. This dose range was chosen to 
reflect the lower concentrations used in previous studies of DNA damage induction 
(Uemgaki et al., 2000, Rueff et al., 1993, Jenkins et al., 2001, Fenech et al., 1999, 
Perwez Hussain et al., 1994, Duthie et al., 1997). Previous work in the University of 
Wales Swansea has shown that higher concentrations than 1 OOpM H2 O2 are cytotoxic 
to cells and therefore chromosomal events can be confused with general toxicity 
(Jenkins et al., 2001). Hence, in this study a sub-toxic dose range was chosen in an 
attempt to mimic chronic inflammation, as the actual doses of ROS in vivo are 
unknown. After exposure to H2O2 the cells were centrifuged using the Thermo 
Shandon Cytospin 3 (at 1200 rpm for 8 minutes) and re-suspended in full serum 
containing medium. The cells were then subjected to cytochalasin B treatment for 24 
hours to produce binucleate cells for the micronucleus study.
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3.2.3 Cytokinesis block micronucleus (CBMN) assay.
Cytochalasin B was added to the cells, giving a final concentration of 3pg/ml. 
They were then incubated at 37 °C with 5% C02 atmosphere for 24 hours. Cells were 
harvested using a Cytospin to produce a cytodot on a microscope slide. A 
haemocytometer was employed in order to produce slides with a cell solution 
concentration of 1 x 105 cells per ml. The cells were fixed onto the slides by 
immersion in a solution of 90% methanol for 10 minutes at -20 °C. The slides were 
then stained with Giemsa before scoring for micronucleated cells.
Kinetochore labelling was performed on the the binucleate cells produced, 
when AHH1 cells were dosed with 0 and lOOpM H2O2 . The frozen cells were 
rehydrated with PBS at room temperature for 2 minutes, and then placed in primulin 
(0.5 pg /ml) in deionised water for 30 seconds. A solution of anti-kinetochore antibody 
(antinuclear antibody centromere pattern from human serum in 0.1% sodium azide, 
MedicaEncinitas) diluted 1:1 with PBS was prepared and 50pl added to each cytodot. 
A plastic coverslip was used and the slides incubated in a humidified chamber for 45 
minutes at 37 °C. The slides were then immersed x3 in a solution of bovine serum 
albumin in PBS (lg per 100ml) for 3 minutes at room temperature, and then x3 in 
PBS at room temperature for 3 minutes. 50pl of FITC (1 pi of fluorescent anti human 
IgG, Sigma, + 99pl of PBS in a foil covered tube at 2-8°C) was added to the cytodot, 
covered with a plastic coverslip and incubated at 37° C for 45 minutes. Again the 
slides were washed in albumin/PBS for 3 minutes x2, and then PBS for 3 minutes x l . 
They were then air dried in the dark and stored at 4C. To view 20pl of Dapi 1 was 
added to each slide.
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3.2.4 Scoring micronucleated cells.
Micronuclei cells were coded and the number of micronuclei present in the 
binucleated cells scored using an Olympus BH2 microsocope at lOOx magnification. 
Binucleated cells with and without micronuclei were scored for each treatment group. 
Micronuclei were collectively scored whether present in the cells as single or multiple 
events.
Micronuclei (MN) were scored if they fulfilled the following criteria (Fenech
2000):
- MN morphologically identical to nuclei
MN diameter between 1/16 and 1/3 of mean diameter nuclei
- MN non-refractile therefore distinguishable from artefact
- MN not linked or connected to main nuclei
MN may touch but not overlap main nuclei, clear boundaries
- MN same staining intensity as main nuclei
Kinetochore staining was scored only in binucleate cells with micronuclei, by 
using the Olympus BX50 microsope and the Poweregene 4.3. Kinetochore probe was 
visualised as a green signal in the main nuclei +/- the micronuclei.
Figure 3.2 shows an example of a binucleate cell bearing a micronucleus and 
kinetochore staining.
3.2.5 FISH
After the analysis of the micronuclei induction by H2O2 , suitable doses were 
used to investigate specific chromosomal alterations induced by H2O2 . AHH-1 cells 
were dosed with hydrogen peroxide at 0, 50 and 100 pM, harvested onto slides and 
fixed with 90% methanol as above. FISH was then performed using centromeric
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probes for chromosomes 4, 8 and 20, and a locus specific probe for p53, see Chapter 
2. At least 400 cells were scored for each probe and slide.
The reproducibility of FISH as a technique will be discussed later in chapter 4. 
In this series of experiments however, a duplicate experiment was performed with 
AHH1 cells exposed to 50pM H2O2, and with AHH1 cells exposed to no H2O2 . FISH 
with CEN probe 20 was then performed.
3.2.6 Statistical analysis of the micronucleus test and FISH results.
For both the micronucleus test and for FISH analysis, p values of statistical 
significance (95% confidence intervals) were obtained using the Fisher’s exact 
analysis.
3.3 Results
3.3.1 Cytokinesis block micronucleus assay
Table 3.1 contains the average values of duplicate CBMN experiments, and 
Figure 3.3 illustrates the percentage of micronuclei formed when cells were dosed 
with differing concentrations of hydrogen peroxide (0, 50 and 100 pM).
The percentage of micronuclei is representative of the chromosomal damage 
produced by hydrogen peroxide. As the dose increased so chromosomal damage 
increased. Statistical significance for the percentage of micronuclei formed was 
reached when comparing control cells to those dosed with 100 pM H2O2 .
Kinetochore labelling results are illustrated on Table 3.1 for AHH1 cells dosed 
with 0 and lOOpM H2O2 . Chromosomal damage seen when cells were treated with
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hydrogen peroxide was mostly in the form of whole chromosome loss, therefore 
aneugenic.
These initial experiments have confirmed that hydrogen peroxide, at these 
concentrations, is capable of causing chromosomal abnormalities in human cells. The 
finding is in keeping with a range of studies using different techniques, as discussed 
in the introduction. Hence, the same concentrations of 0, 50 and lOOpM hydrogen 
peroxide were chosen to perform FISH analysis looking at targeted chromosomes.
3.3.2 FISH analysis of AHH-1 cells dosed with hydrogen peroxide.
All somatic cells should possess 2 copies of each chromosome (apart from sex 
chromosomes X and Y). Hence all cells should show 2 copies of each chromosome 
probe. If the cell has < 2 copies or > 2 copies then the normal chromosome 
complement has been altered. Changes in centromeric probes for chromosome 4, 8 
and 20 suggest whole chromosome change, aneuploidy. Aneuploidy can have severe 
consequences on the individual cell, for example an extra copy of a protooncogene 
can result, or a loss of a copy of a tumour suppressor gene. Figure 3.4 illustrates the 
percentage of cells with two signals of each probe, (centromeric probes 20, 8 and 4, 
and locus specific probe p53) at differing concentrations of hydrogen peroxide. The 
percentage of cells with a normal complement of chromosomes (i.e. two 
chromosomes) remained above 90% for all probes and all doses, hence reflecting the 
stability of this particular cell line. The p values shown were calculated using Fisher’s 
exact for control samples versus lOOpM hydrogen peroxide. All values were 
significant suggesting that hydrogen peroxide is capable of causing these specific 
chromosomal aberrations, as illustrated with the centromeric and locus specific probes
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used. The general trend was for the degree of chromosomal abnormality to increase as 
the dose of hydrogen peroxide increased.
Table 3.2 shows the raw data and Figures 3.5, 3.6, 3.7 and 3.8 show the 
percentage of cells with abnormal number (gain and loss) of each specific probe. 
Again using the Fisher’s exact test, p values were calculated. In the case of 
chromosome 20 (Figure 3.5), the trend was for chromosomal abnormalities of 20 to 
increase as dose of hydrogen peroxide increased. Significance was seen for both loss 
and gain of chromosome 20 when comparing control cells to cells exposed to lOOpM 
hydrogen peroxide. In the case of chromosome 4 (Figure 3.6), the trend was for 
chromosomal abnormalities to increase as dose of hydrogen peroxide increased. 
Significance was seen for gain of chromosome 4 only. Figure 3.7 shows the 
abnormalities of chromosome 8 as a function of the dose of hydrogen peroxide.
Again, the trend was for chromosomal damage to increase as dose of hydrogen 
peroxide increased, but significance was not reached for either loss or gain of 
chromosome 8.
As with the centromeric probes, the level of abnormalities seen with the p53 
probe increased as the hydrogen peroxide dose increased. From Figure 3.8, it is 
possible to see that significance was obtained with p53 loss.
The effect of 50pM hydrogen peroxide, and no hydrogen peroxide, on the 
AHH1 cell line was reassessed in a second experiment, using CEN probe 20. There 
was very little difference in the percentage of chromosome 20 abnormalities between 
the first and second experiments. Cells with no exposure to hydrogen peroxide 
showed chromosomal abnormalities in 1.7% and 1.4% of cells respectively, and in 
those cells exposed to hydrogen peroxide chromosomal abnormalities were present in 
5.6% and 5.5% of cells respectively.
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3.3.3 Examples of chromosome abnormalities induced by hydrogen peroxide
Figure 3.9 shows examples of some of the specific chromosomal events 
induced by exposure to hydrogen peroxide and detected by FISH.
3.5 Discussion
The aim of this chapter was to illustrate the chromosomal abnormalities 
induced in human cells by ROS in vitro, for comparison to the in vivo situation 
described in Chapter 4. Hydrogen peroxide is a model ROS in vitro, and is likely to 
mimic the DNA damage induced in vivo in inflammatory tissues, as it is actually 
produced during these processes and may represent the diffusible form of ROS in vivo 
(Mamett, 2000). A dose range was chosen in an attempt to mimic the in vivo state. 
Hydrogen peroxide has been shown to cause DNA damage, and differing cytogenetic 
techniques have shown chromosomal abnormalities when human cells are exposed to 
hydrogen peroxide (Duthie et al., 1997, Fenech et al., 1999, Jenkins et al., 2001, 
Uemegi and Fenech, 2000).
This chapter illustrates, using two separate techniques, that chromosomal 
abnormalities were seen in a cultured human cell line, AHH-1, when dosed with 
hydrogen peroxide, and that this chemical could cause aneuploidy.
CBMN assay (+/- kinetochore staining) and interphase FISH are both observer 
dependent. However, the fact that two different cytogenetic techniques were 
employed and the results were the same, strengthens the statement that an oxidative 
insult results in aneuploidy. The findings of aneuploidy in the chromosome 20, 8 4 
and 17(53) validates the choice of probes to assess gastric disease (+/- H. pylori 
infection).
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Figure 3.9. Examples of FISH in cells treated with model ROS
Normal complement 20 and 8 (2 signals)
Amplification o f chromosome 20 (red signal) -  3 copies
%
Deletion of chromosome 20 (red signal) -  1 copy
Firstly, the CBMN assay illustrated chromosomal damage in AHH-1 cells 
exposed to hydrogen peroxide. This was illustrated by the production of micronuclei. 
60% of the micronuclei were kinetochore positive, suggesting whole chromosome 
loss into the micronuclei. The effect was dose responsive, and the higher dose of 
1 OOpM hydrogen peroxide showed a statistically significant increase in the number of 
micronuclei produced. This dose was in line with the previous literature cited in the 
introduction to this chapter. Thus, human cells exposed to ROS in vitro undergo 
chromosomal damage. The type of chromosome damage induced by H2O2 shown here 
is mainly in the form of whole chromosome abnormality, consistent with an 
aneugenic effect.
Secondly, FISH was performed on AFIH-1 cells dosed with the same 
concentration of hydrogen peroxide as in the micronucleus assay. FISH can measure 
aneuploidy, where non-disjunction of chromosomes occurs, and also simultaneously 
allows us to target particular chromosomes to monitor the effect of ROS on specific 
chromosome number. The overall aim of this project was to look at the chromosomes 
implicated in gastric cancer progression. Hence the chromosomes chosen have all 
been found to be abnormal in gastric cancer, or in the development of another upper 
GI cancer, adenocarcinoma of the oesophagus i.e. chromosome 20, 8, 4 and 17 (p53), 
(see Chapter 1). When AHH-1 cells were exposed to hydrogen peroxide, 
abnormalities in each chromosome occurred. For each chromosome investigated, the 
number of cells with aberrant copy number increased as the dose of hydrogen 
peroxide increased. When the total chromosomal damage (loss and gain) of cells 
exposed to the higher concentration of hydrogen peroxide was compared to those with 
no exposure, statistical significance was achieved for each probe used, (p<0.05).
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Thus, human cells exposed to ROS in vitro undergo chromosomal damage, and 
specifically aneuploidy of chromosomes 20, 8 and 4 and 17(p53).
When results for individual probes were analysed more fully, statistical 
significance, (p<0.05), was achieved for loss and gain of chromosome 20, gain of 
chromosome 4 and loss of the p53 locus. It is possible to compare these changes to 
those in the literature. Doak et al 2003 showed an amplification of chromosome 4 in 
the progression of disease from Barrett’s metaplasia to adenocarcinoma. Hence, this 
mirrors the in vitro situation described here, where gain, and not loss, of chromosome 
4 is induced by ROS. Given that Barrett’s disease and H. pylori infection (and hence 
gastric cancer) are both inflammatory conditions, this result suggests that 
amplification of chromosome 4 is a non-random event, and may represent a 
significant event in disease progression. p53 is a tumour suppressor gene and as such 
its loss leads to genetic instability, including chromosomal instability and aneuploidy 
(Bouffler at al., 1995, Fukasawa et al., 1996). p53 loss has been implicated in 60% of 
human cancers, including gastric cancer (Levine et al., 1991, Sano et al., 1991, 
Sipponen et al., 1998, Vogelstein and Kinzer, 1992). Interestingly in the present 
study, p53 loss is preferentially induced by H2O2 , as opposed to p53 gain. From 
Figure 3.5 it is also seen that untreated cells have more p53 loss than gain, suggesting 
possible instability. In the case of chromosome 20, CGH and FISH studies have 
shown levels of chromosome 20 to be altered in gastric adenocarcinoma (Kokkala et 
al., 1998, Han et al., 1996, Koo et al., 2000, Kityama et al., 2000, Okada et al., 2000). 
The data given here shows both loss and gain of chromosome 20 induced by H2O2 , 
suggesting no specific role for chromosome 20, but possibly reflecting genetic 
instability.
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The in vitro experiments described here allow the determination of the types 
of chromosomal aberrations typical of ROS exposure in vitro. Chapters 4 and 5 have 
looked at the chromosomal damage seen in gastric tissue at all stages of disease i.e. 
normal gastric mucosa, gastritis, intestinal metaplasia, gastric dysplasia and gastric 
adenocarcinoma, using the same FISH probes for chromosome 20, 8 and 4 and p53. 
Thus, allowing the comparison of the type of chromosomal aberrations in the model 
ROS in vitro study, with those seen in the in vivo study of gastric tissue.
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Chapter 4
The detection of chromosomal abnormalities in gastric tissue, using Interphase
Fluorescence In Situ Hybridisation
In this series of in vivo experiments patients were enrolled at endoscopy and 
patient details collected. Gastric cells were obtained from the patients and a 
histological diagnosis determined as well as the degree of chromosomal abnormality, 
using interphase FISH. The level of aneuploidy in chromosomes 20, 8, 4 and 17(p53) 
was found to increase as the gastric pathology worsened (normal gastric mucosa > 
gastritis > intestinal metaplasia). Amplification of chromosome 4, deletion of p53 and 
amplification of chromosome 20 were the most significant events found in the 
premalignant stages of gastric carcinogenesis.
4.1 Introduction
4.1.1 Gastric cancer development
Gastric cancer is regarded to be the second commonest cancer worldwide 
(Parkin et al., 1985) and in the UK accounts for a significant proportion of national 
morbidity and mortality as it is the sixth most frequent cancer in men and the seventh 
in women (Cancer Research Campaign 1995). Presentation of gastric cancer is usually 
advanced and therefore prognosis is poor. Improving the outcome of cancers can 
often be achieved by identifying people at a high risk of developing cancer (Hussain 
and Harris 1996) and by early cancer detection (Matturri et al., 1998). The latter has 
been addressed in Japan, where the incidence of gastric cancer is one of the highest 
worldwide, and screening programmes have been developed to diagnose lesions early.
54
Identifying those people who will actually progress to gastric cancer has proved more 
difficult, as unfortunately the actual genetic events responsible for the initiation and 
progression to gastric cancer are still unknown (Koo et al., 2000, Sud et al, 2001).
The pathways leading to gastric cancer from normal gastric mucosal tissue and 
the sequence of genetic changes involved, remains unclear. However, Correa has 
formulated a multi-step pathway to gastric cancer, including pre-cancerous stages and 
the possible environmental insults sustained which is illustrated in the general 
introduction, Figure 1.2 (Correa 1998). This pathway is described in more detail in 
Chapter 1. In this chapter premalignant gastric tissue will be analysed to look for 
aneuploidy.
4.1.2 Cytogenetics of gastric cancer
It is widely accepted that gastric cancer results from genetic alterations, and 
studies have shown that genetic instability can lead to accumulation of somatic 
mutations and chromosomal instability (Grady 2001, Kabayashi et al., 2000). A 
stepwise pathway of genetic change in gastric carcinogenesis has not yet been 
identified, although some abnormalities in the karyotype have been found in gastric 
cancer cells and in some of the pre-cancerous stages outlined by Correa (Correa 
1988).
Aneuploidy of varying degrees has been documented in all stages of gastric 
cancer (Beuzen et al., 2000). Table 4.1 describes a number of cytogenetic studies and 
highlights the particular chromosomes that are found to be abnormal in gastric cancer. 
Chromosome 20 and 8 are frequently implicated (Kokkola et al., 1998, Koo et al., 
2000, Wu et al., 2001). A number of researchers have also looked at the pre­
malignant states of gastritis and intestinal metaplasia, and found that some of the
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Table 4.1: The results of a number of cytogenetic studies looking at chromosomal
aberrations in gastric cancer.
Author Sample size Cancer Type
Panini 1995 11 10/11 intestinal
(Greece) (3 metastatic)
Kokkola 22 
1998(Finland)
Koo 2000 37
(South Korea)
Yadav 1996 4
(USA/Japan)
Fringes 20 
2000(Germany)
Beuzen 2000 60 
(France)
Okada 2000 5
(Japan)
Bertoni 1996 2 
(Italy)
Han 1996 18
(South Korea)
intestinal
50% intestinal 
(22/37 metastatic)
1 metastatic
intestinal/diffuse
cardia, antrum 
& oesophageal
diffuse
(80% metastatic) 
metastatic
diffuse
Chromosome
3, 6, 13
gain-20q (55%) 
17q(41%), 8q(41%) 
loss-18q(41%), 4q(32%)
gain-8q, 2q, 7pq, 13q, 7q, 
gain - 18q, 20pq 
loss-17p
3, 7, 11, X
gains-l(63%), 17(59%)
7, 8, 11, 17, Y 
(40-65%allcancers)
loss-18q 
gain-7, 20
6,
karyotype rearrangement
widespread numerical 
rearrangement
Table 4.1 (cont’d): The results of a number of cytogenetic studies looking at
chromosomal aberrations in gastric cancer.
Author Sample size Cancer Type
Chun 2000 6 advanced
(South Korea)
Igashari2000 39 
(Japan)
Kitiyama 24
2000(Japan)
Sud 2001 9
(UK)
Wu 2001 53
(Taiwan)
Sugai1999 99
(Japan)
17 intestinal 
9 diffuse
65% advanced 
55% intestinal 
45% diffuse
65 intestinal 
34 diffuse
Chromosome
loss-17p(100%)
gain-7
lp lost in advanced
1 ,2 - early 
1, 2, 4, 20 - later
loss - 22q, 14q, 4q, 17p
gains- 8q,6q, llq , 13q,
7p7p, 17q, 20q 
loss -  l6^|, 19p, 5q, 3p, 4q, lp
aneuploidy in 73%
(bold =commonest)
genetic changes present in the most advanced gastric cancers are present in these early 
stages (Tahara 1995), indicative of important driving changes in carcinogenesis. DNA 
copy number has also been looked at in adenomas of the stomach and both DNA 
increases (amplifications) and losses (deletions) were found. The more severely 
dysplastic adenomas had higher chromosome copy number (in almost 50%), than 
those with moderate dysplasia (Panani et al., 1995). Studies have also looked at 
patients with chronic gastritis and found aneuploidy (Nardone et al., 1999).
Kobayashi et al. looked at intestinal metaplasia and early adenocarcinoma samples 
from the same patients and found that the same molecular changes of microsatellite 
instability were present in both, but to a higher degree in cancer. They also showed 
that the loss of heterozygosity was more prevalent in cancer, and suggested a place for 
chromosomal instability in the initiation of carcinogenesis (Kobayashi et al., 2000).
p53 is the most frequently mutated gene in human cancers and is mutated in 
up to 60% of all human tumours (Sippponen et al., 1998, Levine et al., 1991, 
Vogelstein and Kinzer 1992) and a significant proportion of intestinal and diffuse 
gastric tumours (Grady 2001). A number of studies support the findings of p53 
abnormalities in pre-malignant conditions (Dixon et al., 2001, Ochiaio et al., 1996, 
Shiao et al., 1994). Rugge et al found abnormalities of p53 in 61% carcinomas, 64% 
severe dysplasia, 27% moderate dysplasia and 19% mild dysplasia (Rugge et al., 
1992). Brito et al, also noted a stepwise elevation of p53 abnormalities from 
dysplasia to advanced gastric cancer (Brito et al., 1994). p53 abnormalities exist at all 
stages of carcinogenesis, i.e. even before dysplasia has developed (Correa and Shaio 
1992). p53 mutations have been detected in early stages of pre-malignant gastric 
tissue, both in gastritis (Stemmermann et al., 1994, Kodama et al., 1998, Morgan et 
al., 2003) and in intestinal metaplasia (Shaio et al., 1994, Ochai et al., 1996, Zheng et
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al., 1998). Tohodo et al noted p53 abnormalities to be present in 33% of gastric 
adenomas and atrophic gastritis (Tohodo et al., 1993). Interestingly, p53 loss often 
precedes and may cause chromosomal instability and hence produce aneuploidy 
(Bouffler et al., 1995, Fukasawa et al., 1996).
4.1.3 Helicobacter pylori and gastric cancer .
In 1994, the International Agency for Research on Cancer (IARC) classified 
the bacterium Helicobacter pylori a Class 1 human carcinogen, capable of inducing 
changes leading to gastric cancer (IARC 1994). Epidemiological studies have shown a 
2-12 fold increased risk of gastric cancer in those infected with H. pylori (Blaser 
1998, Forman 1998, Eurogast 1993, You et al., 2000, Rugge et al., 1999). As such, 
infection must be a significant risk factor for gastric cancer, although it should be 
stressed that the majority of people who acquire the infection do not develop cancer.
In the pathway outlined by Correa and illustrated in the general introduction 
H. pylori has been shown capable of inducing the tissue changes described in the pre- 
malignant stages (Graham 2000, Sipponen et al. 1997, Kuniyasu et al, 2000). 
Experimental work has also shown the release of Reactive Oxygen Species (ROS) in 
the presence of H. pylori, and this is known to lead to DNA damage (also discussed in 
the general introduction).
4.1.2 Aims
Chapter 3 has described the optimisation of the interphase FISH methods 
needed to determine chromosomal abnormalities, and also illustrated the specific 
abnormalities seen when cells were exposed to ROS in vitro. In this chapter the 
methods described in the in vitro study were modified to study the in vivo changes in
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gastric tissue. The chromosomes studied have been chosen as they are all suspected of 
being important in gastric carcinogenesis. Chromosomes 20 and 4, and the p53 
chromosome locus 17pl 3 have been found to be abnormal in gastric cancer. 
Chromosome 4 has been implicated in the progression of another upper GI cancer, 
adenocarcinoma of the oesophagus (Croft et al., 2002, Doak et al., 2003). The types 
of chromosomal abnormalities seen in a range of pre-malignant gastric tissue were 
investigated.
The hypothesis is that the progressive stages of gastric carcinogenesis are the 
consequence of genomic instability leading to aneuploidy.
Correlation with patient characteristics and Helicobacter pylori infection was 
also possible during this study.
4.2 Materials and methods
4.2.1 Patients enrolled into study.
Patients were enrolled at the Endoscopy Unit in Neath Port Talbot Hospital as 
outlined in Chapter 2. Samples were also received from Dr AP Griffiths, Consultant 
Pathologist at Morriston Hospital Swansea, from patients having undergone upper GI 
surgery for gastric malignancy.
4.2.2 Histological diagnoses.
Gastric biopsies (one or two) were taken at the site of the brush sample and 
sent for histological analysis (Pathology Department Morriston Hospital) including 
the determination of Helicobacter pylori by the designated Consultant Pathologist, Dr 
AP Griffiths.
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Gastric biopsies were also taken during the upper GI endoscopy, stored at 
-70°C, and used later to determine Helicobacter pylori and subtype status by PCR 
(see Chapter 6).
4.2.3 Gastric cell collection, preparation of slides, interphase FISH, scoring
The methods of gastric cell collection using cytology brushes, the preparation 
of slides for FISH and the details of the FISH methodology used have been described 
in Chapter 2.
4.2.4 Reproducibility of FISH technique.
Duplicate gastric slides from the same patients were exposed to the same FISH 
probes and scored to ensure the reproducibility of the technique. Any significant 
statistical differences in the results were calculated using the Fisher exact test, p<0.05.
4.2.5 Statistical analysis.
Fisher’s exact analysis was used to compare the chromosomal changes 
between the differing histological stages.
Standard error bars were also calculated for each histological group
4.3 Results
4.3.1 Patients enrolled in the study.
Twenty seven patients were enrolled at the Endoscopy department at Neath 
Port Talbot Hospital. Cytology brushes from four of these patients did not yield 
adequate cell numbers to perform FISH. As the study proceeded improvements in the
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method of collection of cells with the cytology brushes and transport medium 
modification resulted in fewer samples being lost. Three additional pre-malignant 
patient samples were obtained from brushes taken at the Pathology Department in 
Morriston Hospital from surgical resections. Hence the total number of patients 
samples considered in this part of the study was thirty.
Table 4.2 illustrates the information collected on the case record forms of 
patients enrolled in the study, and shows the histological diagnoses for each patient 
together with Helicobacter pylori status. The information available was provided by 
the patients and not corroborated by other sources, therefore underreporting of risk 
factors may be present. Seventy-seven percent were female, all were white and the 
age range was 23 to 79 years. Alcohol excess was noted when above national 
recommended limits (21 units a week), and three people admitted to such an intake. 
Eight people admitted to a smoking history whether current or within the last 5 years. 
Seven people described a family history of GI cancer; medical notes were not sought 
to confirm this. Dietary history was determined by using patients’ response to two 
simple questions (1) how many portions of fruit and vegetables do you eat per day? 
(2) Do you add salt to your food? Patients diet was regarded as poor if they had < 3 
portions of fruit or vegetables daily, or added salt to their food, and 7 patients fitted 
these criteria.
The reason for referral was also noted for each patient involved in the study, 
and more than one symptom was often cited. 30% complained of dyspepsia, 26% of 
reflux, 26% of epigastric pain, 9% of GI bleeding (melana/haematemesis), 4% of 
anaemia, 4% of dysphagia, and 22% were re-referred for endoscopic follow up 
(ulcer/polyps/dysplasia).
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4.3.2 Histological diagnosis.
Figure 4.1 illustrates the distribution of histological diagnoses amongst the 
patients. Gastric samples from patients were divided into three broad groups - normal 
gastric mucosa, gastritis and intestinal metaplasia. Patients were not subdivided into 
active, chronic or atrophic gastritis as numbers were too small. Where more than one 
diagnosis was present the patient was assigned to the more advanced pathology in the 
Correa pathway. All of these histological diagnoses can be found in the pathway 
outlined by Correa depicting a stepwise change from normal gastric mucosa to 
adenocarcinoma (Correa 1988), and they represent the pre-malignant changes in the 
mucosa. Although, it should be remembered that the changes in the mucosa can be 
arrested at any point and do not always result in cancer.
One patient could not be diagnosed histologically because of inadequate 
biopsy size, therefore FISH results on this patient were excluded.
As has been explained in Chapter 2.2 patients with no macroscopic 
abnormality at endoscopy had brushes/biopsies taken from the gastric antrum. It was 
interesting to note that of the patients analysed in this part of the study, one patient 
who had macroscopically normal gastric mucosa had evidence of antral gastritis on 
biopsy. All of the patients with abnormal endoscopies had abnormalities limited to the 
gastric antrum, and therefore brushes/biopsies were taken from this area. Five people 
were noted to have mild antral gastritis endoscopically but histological analysis was 
normal.
Eighteen patients of twenty seven had their oesophageal brushes analysed in 
this study, and this group acted as an internal control.
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4.3.3 Risk factors associated with gastric cancer.
Family history, male sex and increasing age have all been implicated as risk 
factors for gastric cancer. Smoking, alcohol, and dietary habits have also been linked 
to the aetiology of gastric cancer. Figure 4.2 shows the frequency of these risk factors 
according to histological diagnosis. As can be seen the numbers were small in each 
group therefore no statistical significance was calculated, but it appeared that apart 
from male sex, there was no obvious trend to suggest that any of the risk factors were 
associated with the pre-malignant progression to gastric cancer. The fact that male 
gender showed a stepwise increase with increasing grade of histology was interesting 
when it was considered that in this study over three quarters of the patients were 
female, and gastric cancer is considered predominantly a disease of men.
Helicobacter pylori infection has been strongly implicated as a risk factor for 
gastric cancer. The determination of the bacteria in the gastric mucosa of these 
patients was made by a Consultant Pathologist using standard haematoxylin and eosin 
histological preparations produced from the biopsy samples, and included searching 
for organisms with oil immersion lens when gastritis was present. Chapter 6 compares 
these findings with a more sensitive method of H. pylori infection, PCR analysis, 
using a second gastric biopsy taken alongside that used for histological purposes 
(Ismail 2004). However, based upon the histological diagnosis of infection given here, 
no normal gastric mucosa was infected, but 50% of patients in the gastritis group had 
H. pylori. This percentage falls in the intestinal metaplasia group, as one might expect 
to occur when the gastric environment changes and the pH alters, making the 
environment less optimal for H. pylori to adhere to the tissue and survive (Graham 
2000, 5, You et al., 2000). This is illustrated in Figure 4.3.
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When the data was analysed to look for a link between H. pylori infection and 
the other risk factors for gastric cancer, none was seen.
4.3.4 Reproducibility of FISH technique.
Two slides from the gastric brushing of patient 26 were used to perform FISH 
using probes LSI p53 and CEN 8. The Fisher’s exact test was employed using the 
results for both probes, in order to assess the reproducibility of the FISH technique.
No statistical difference was found. The result was the same for individual probe loss 
or gain, as well as when any abnormality in chromosome complement was present. A 
further two slides from the gastric brushing of patient 15 were used with probe CEN 
20, and again no statistical difference was found for altered chromosome complement, 
amplification or deletion. Furthermore, a brushing from a surgical resection, T7 (see 
Chapter 5), produced two slides and FISH was performed with CEN 4, and again the 
Fisher’s exact test was used to show no statistical difference. Again the result 
indicated the same levels of abnormality and amplification /deletion. Table 4.3 shows 
the raw data.
This highlights the robust nature of the technique and validates the 
reproducibility of the scoring performed.
4.3.5 Chromosomal abnormalities between oesophageal and normal gastric tissue.
Cytology brushes were taken from the gastric mucosa, and also from 
macroscopically normal oesophagus in each patient to act as internal controls, 
ensuring any gastric abnormality seen was not widespread in the patient i.e. a germ 
cell abnormality. Eighteen of the twenty seven oesophageal brushings taken produced 
adequate cell numbers for FISH.
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Figure 4.4 graphically represents the chromosomal abnormalities seen in the 
oesophageal cells and in the normal gastric cells. CEN probes highlight the 
centromere of the chromosome and were used to determine whole chromosome 
changes i.e. aneuploidy, whereas the LSI probe was a marker of the p53 locus. As is 
demonstrated in Figure 4.4, oesophageal cells had fewer chromosomal abnormalities 
detected using these probes than normal gastric cells. Oesophageal cells had generally 
less than 1% of cells bearing either amplifications or deletions of chromosome 20, 8,
4 and the p53 gene, therefore oesophageal cells in this study were seen to be 
genetically stable. When comparing chromosomal changes in oesophageal cells to 
gastric cells, and it should be stressed that these gastric cells were histologically 
normal, more chromosomal instability was seen in the gastric cells. For each type of 
probe abnormality, whether deletion or amplification was sought, abnormalities were 
higher in the gastric cells. Statistical significance was reached when loss of p53 was 
compared between the two groups. As p53 is a tumour suppressor gene, a loss would 
be expected to provide a selective growth advantage to cells, favouring 
tumourigenesis. Statistical significance was also reached for a deletion of 
chromosome 20, and a deletion and amplification of chromosome 8. This may suggest 
genetic instability has been induced by the stomach contents (acid, pepsin bile) in 
constant contact with gastric cells, unlike the transient contact that is seen for 
oesophageal cells.
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4.3.6 Chromosomal abnormalities in gastric tissue at different stages of disease 
severity.
Cells from gastric tissue with different histological diagnoses were examined 
for abnormalities of chromosomes 20, 4 and 8 using FISH. The p53 LSI probe also 
allowed examination of the p53 locus in the different tissues.
Figure 4.5 shows the percentage of cells with abnormalities of each probe as a 
function of the histological diagnosis. For CEN probes 20, 8 and 4, the percentage of 
abnormalities (loss or gain) were higher in abnormal gastric tissue i.e. gastritis and 
intestinal metaplasia, as compared to normal gastric tissue, and this was observed 
despite the fact that normal gastric tissue has already been found to be genetically 
unstable. In fact, there was a clear trend for the instability to increase with histological 
progression, from normal gastric tissue through to gastritis and then to intestinal 
metaplasia. Therefore, an increase in chromosomal instability was shown through the 
early pre-malignant stages of gastric cancer. A similar trend was seen for the LSI p53 
probe, suggesting increasing instability at the site of the p53 tumour suppressor gene 
through the early stages of the gastric carcinogenesis pathway.
Figure 4.6 illustrates the gains of each individual probe and thus the 
amplification of chromosomes 20, 8 and 4, and the p53 locus. Error bars demonstrate 
the standard error, showing the variation in the data. For each chromosome 
investigated, the percentage of amplification increased with each successive step in 
the Correa progression, with highest amplifications being seen in the intestinal 
metaplasia group. Amplifications were more frequent in the centromeric chromosome 
probes than in the gene specific p53 probe. The difference in the levels of 
chromosome amplification between normal gastric mucosa and abnormal gastric 
tissue (gastritis and intestinal metaplasia) was most striking in chromosome 4.
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Chromosome 20 amplification showed a clear stepwise increase in the progression to 
metaplasia. This trend was also present for chromosome 8, yet less obvious with error 
bars overlapping between each group. p53 was also amplified with increasing 
frequency along the pathway but percentages of abnormalities were small, <2%.
Figure 4.7 represents the loss of chromosomal probes, therefore the 
chromosomal deletions. As seen above with the amplifications, deletions of each 
probe were more frequently found in abnormal gastric tissue as compared to normal 
gastric tissue. A clear and significant increase in probe deletions with worsening 
histological progression was only seen with the p53 locus specific probe. This was not 
unexpected, as loss of this tumour suppressor gene would herald genetic instability 
and be selected for in tumour evolution. Chromosome 20, 8 and 4 deletions showed a 
trend to increase with histological progression but to a lesser degree, with overlapping 
error bars.
Figures 4.8, 4.9,4.10 and 4.11 again illustrate the individual deletions and 
amplifications of each chromosomal and locus specific probe, as a function of the 
histology, with p values being shown calculated with Fisher’s exact test. Chromosome 
20 amplifications were statistically significant in the gastritis and intestinal metaplasia 
group, when compared to the normal gastric mucosa (p<0.005). Chromosome 20 
deletions were only significant when comparing the most severe pathological group, 
intestinal metaplasia to normal gastric mucosa (p<0.05). Chromosome 8 amplification 
and deletion was significant in the intestinal metaplasia group (p<0.005), but deletion 
was also significant in the gastritis group when compared to normal gastric mucosa 
(p<0.05). Amplification of chromosome 4 was a highly significant event seen in both 
gastritis and intestinal metaplasia in relation to normal gastric cells (p<0.005). 
Deletion of chromosome 4 was also significant in the intestinal metaplasia group
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(p<0.005). The loss of p53 was highly significant in both gastritis and intestinal 
metaplasia (p<0.005). In the intestinal metaplasia group the amplification of the p53 
probe was also significant (p<0.005).
In an attempt to determine the rank order of importance of the chromosomal 
abnormalities detected in the pre-malignant tissues studied here, Table 4.4 
demonstrates the fold differences in chromosomal amplification and deletion in 
gastritis and intestinal metaplasia compared to normal gastric tissue. As can be seen 
amplification of chromosome 20, amplification of chromosome 4 and deletion of p53 
rank highly in both pre-malignant groups, suggesting their importance in the early 
stages of gastric carcinogenesis.
4.3.7 Correlation of Helicobacter pylori infection and chromosomal abnormalities.
H. pylori infection in these gastric tissues has been determined histologically 
in this chapter. Figure 4.3 has already illustrated the different frequencies of H. pylori 
infection seen in normal gastric tissue and in different disease states, gastritis and 
intestinal metaplasia. I have also already discussed the fact that chromosomal 
abnormalities differ depending upon histological diagnosis. In an attempt to determine 
whether H. pylori presence in the tissue had an influence on the chromosomal 
abnormalities seen, Figure 4.12 shows the different chromosomal abnormalities seen 
in patients with the same diagnosis, gastritis, but with and without H. pylori infection. 
Only gastritis patients were analysed, as this is the stage most closely linked to H. 
pylori. Surprisingly perhaps, only chromosome 4 showed more chromosomal 
instability in H  pylori infected tissue compared to non-infected tissue, and this was 
statistically significant (p<0.005). In fact, chromosome 4 amplification accounted for 
81% of the abnormalities seen in chromosome 4 of the H. pylori positive patients.
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When the levels of amplification of chromosome 4 were compared between H. pylori 
positive and negative patients, a statistical significance was still seen (p<0.05). Figure 
4.13.
Obviously numbers were small in the groups compared (5 in each group), and 
infection was only diagnosed with one technique, histology. Therefore a comparison 
of the H. pylori positive and negative patients in Chapter 6, with the additional benefit 
of H. pylori diagnosis using the more sensitive PCR techniques, may provide further 
interesting information.
4.4 Discussion
The experiments described in this chapter have attempted to study the 
chromosomal abnormalities present in gastric tissue in vivo, using interphase FISH, 
and as such investigate the hypothesis that as gastric carcinogenesis progresses, so 
genomic instability leading to aneuploidy increases. Interphase FISH was successfully 
performed on gastric cell preparations to determine chromosomal abnormalities. The 
level of aneuploidy found in chromosomes 4, 8, 20 and 17(p53) of gastric cells 
increased as disease severity increased. Amplifications of chromosomes 4 and 20, 
together with deletions of chromosome 17(p53), were the most significant findings.
As explained in Chapter 2, the patients were enrolled from my routine open 
access endoscopy lists at Neath Port Talbot Hospital, and as no selection policy for 
appointing them to my list was in place they represent the population referred with 
upper GI symptoms by general practitioners in that area. A maximum of two patients 
per list were enrolled due to time constraints on a busy open access endoscopy list. It 
may have been possible to screen patients for suitability to the study by interview
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prior to their arrival at endoscopy, and thereby improve efficiency of enrolment. 
However, this would have required an additional hospital visit by the patient and 
therefore it was not done. Information was collected from each patient on known 
gastric cancer risk factors to determine if any one factor stood out. The information 
collected was provided by patients’ alone, and as such underreporting of risk factors 
may be present, in particular alcohol and smoking history. The accuracy of 
information collected on risk factors such as family history has to be questioned as no 
other source (GP/medical case notes) was used to confirm the information given. 
Interviewing the patients prior to their endoscopy date and allowing more time to 
answer the questions may have improved accuracy. Also it was evident that when the 
data was analysed the numbers in each group were too small to show significant 
differences, and a larger data collection was needed. Again, with improved efficiency 
of enrolment and the optimisation of transport methods to the laboratory, this would 
be possible.
Solid tissue has often proven difficult to manipulate into a form such that 
FISH techniques can be employed. A monolayer of cells needs to be generated onto a 
glass slide such that FISH probes can be added, and then detected in the nuclei of 
these cells using microscopy. Therefore, initially in this study the development of a 
successful methodology to deliver cells suitable for FISH analysis was paramount. 
The modification of a technique described by Doak et al. 2003 has shown that 
endoscopic cytology brushing is a reliable and safe method of cell collection from the 
gastric mucosa. Furthermore, it allows the preparation of cytodots with adequate cell 
numbers for analysis using interphase FISH. Interphase FISH is an observer 
dependent technique and in order to check the validity of the results from this study, a 
reproducibility exercise was performed, 4.3.4. The histological diagnosis of the tissue
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studied was determined from biopsies taken at the same site as the brushings to allow 
I direct comparison (Doak et al., 2003). In order not to prolong the endoscopic
procedure, whereby increased risk to patients could result, only one site was analysed. 
Hence sampling error in this study, particularly in the determination of H. pylori 
infection, may be a problem. However, in Chapter 6 H. pylori identification was 
determined from a second biopsy and using a second method of detection.
Using these cell preparations, the purpose of the study was to determine the 
level of chromosomal abnormality present in pre-malignant gastric tissue samples 
from patients. The chromosomes targeted have all been implicated as being important 
in gastric or oesophageal adenocarcinoma, as outlined in the introduction. A variety of 
histological stages were obtained for investigation. All fitted into the early stages of 
the multi-step model for gastric carcinogenesis, as described by Correa i.e normal 
gastric mucosa, gastritis and intestinal metaplasia (Correa 1988).
Initially, a comparison was made of normal oesophageal tissue and normal 
gastric tissue from the same patients. The oesophageal squamous tissue, which was 
macroscopically normal, had little evidence of aneuploidy in chromosomes 20, 4 and 
8 and also little instability of the p53 locus, broadly speaking <1%. A small 
percentage of probe abnormalities could be expected due to the experimental 
processes, in particular losses of probe can occur due to poor probe penetration and 
labelling inside the cell nuclei, and also because of shielding of signals. This low 
incidence of chromosomal abnormality in the oesophageal tissue suggests a very 
stable tissue, and is comparable with the results shown by Doak et al. 2003.
Histologically normal gastric tissue however showed significantly more 
chromosomal instability. This may be explained by considering the different 
environments in which the two tissues exist. Gastric cells live in an acidic medium
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and are bathed in gastric secretions often containing a combination of acid, bile, food, 
mucus, enzymes and bacteria (H. pylori), whereas the contact of these agents with the 
oesophageal tissue is transient only during reflux episodes. In this study oesophageal 
brushings were from the mid oesophagus where contact with gastric secretions would 
be minimal. Hence, the suggestion is that acid or bile, key agents in gastric secretions, 
may play a role in inducing aneuploidy in gastric tissue. Bile and acid have been 
implicated as having a role in the mechanism of upper GI cancer (Triadafilopououlos
2001). Bile acids in particular have been shown to cause DNA damage (Scates et al., 
1995, Scates et al., 1996) and chromosomal aberrations (D’Souza et al., 2003).
Against the unstable background found in gastric tissue, specific chromosomal 
abnormalities and possible correlations with histological diagnosis were sought. 
Chapter 1 has already discussed p53 abnormalities as being implicated in not only 
cancer, but specifically in gastric cancer. In this study, deletions of p53 were detected 
using a FISH probe for the p53 locus in pre-malignant gastric tissue. Deletions of p53 
were found more commonly than amplifications. p53 function involves control of cell 
cycle progression and apoptosis in response to DNA damage, therefore loss of the 
function would lead to cell instability (Grady 2001). Deletions of p53 were found in 
all types of gastric tissue, with a significant stepwise trend to increase with 
histological progression along the pathway to cancer. Thus higher numbers of p53 
abnormalities were seen in the intestinal metaplasia group. Previous studies have 
shown p53 abnormalities in the various stages of pre-malignant disease, commonly 
dysplasia and intestinal metaplasia (Tamura et al, 1991, Uchino et al., 1993). Becker 
et al. demonstrated levels of p53 mutation/LOH to be 30% in cancers, 30% in 
adenomas and 10% in intestinal metaplasias (Becker et al., 2000). Other studies 
support the findings of p53 abnormalities in pre-malignant conditions (Dixon et al.,
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2001, Nardone et al., 1999, Brito et al., 1994, Ochiaia et al., 1996, Shiao et al., 1994). 
This study however, has also shown p53 losses to be significantly increased in 
gastritis when compared to normal tissue, suggesting important abnormalities of this 
tumour suppressor gene are present very early in the progression to carcinoma. In 
fact, p53 losses were present to a lesser degree in normal gastric tissue.
Alterations in chromosome 8 copy number were also found in pre-malignant 
gastric tissue as early as gastritis. The trend involving chromosomal 8 abnormalities 
increased with histological progression. Chromosome 8 copy number is very often 
abnormal, usually amplified, in all types of gastric cancer (see Table 4.1). Some 
authors suggest that its amplification is more frequent in advanced cancers and 
therefore may be a late event (Wu et al., 2001). This is in contrast to the data shown 
here in pre-malignant tissue, where chromosome 8 abnormalities appeared early. Both 
deletions and amplifications were seen in this study in all tissue types investigated. 
Chromosome 8 houses an important oncogene, c-myc, which acts as a proliferative 
transcription factor. Its amplification and rearrangement has been observed in many 
tumour types (Grady 2001). C-myc over-expression has been reported in gastric 
cancers with varying frequencies, 16-67% (Grady 2001). There are some reports in 
the literature of abnormalities of c-myc being present in some pre-malignant stages of 
gastric cancer. Panani et al. have shown gains of chromosome 8 in gastric adenomas 
(Panani et al., 1995). One study reports frequencies of c-myc over-expression in 36% 
of cancers, and 15% of chronic gastritis. All these abnormalities were also associated 
with abnormal p53 expression (Nardone et al., 1999). Further work will need to be 
performed on the pre-malignant histological types in this study to see if the 
amplification of chromosome 8 is associated with an upregulation of c-myc, and 
therefore implicating a role in early gastric carcinogenesis. Also it was not possible to
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determine from the data shown here how frequently chromosome 8 amplification co­
existed with p53 deletion, as suggested by Nardone et al (Nardone et al., 1999). This 
may prove a worthwhile follow up.
Abnormalities of chromosome 20 were found to be present in pre-malignant 
tissue, with both amplifications and deletions existing, although amplification showed 
more statistically significant differences between the tissue types as pathology 
progressed. Chromosome 20 is implicated in a number of CGH and FISH studies of 
all types of gastric cancer (Table 4.1 in the introduction), and again amplification is 
more usual. Chromosome 20 does not have any of the classic cancer related genes, but 
the Cancer Genetics Web (www.cancer-genetics.ore) does give information on certain 
genes located on chromosome 20 being over-expressed in gastric cancers - 
TNFRSF6B -  20ql3.3, PYGB -  20pl 1.2-11.1. Panani has shown with CGH that 
amplification of chromosome 20 can occur in adenomas as well as carcinoma (Panani 
et al., 1995), a stage further along the carcinogenesis pathway than gastritis or 
intestinal metaplasia. In this study, abnormalities of chromosome 20, both losses and 
gains, were usually found to be more frequent than other chromosomal abnormalities, 
also having a higher prevalence in normal gastric tissue. This could therefore be 
representative of general instability of the tissue, and be a marker of aneuploidy, i.e. 
chromosome non-disjunction, due to increased cell proliferation. It is interesting to 
note that Aurora kinase A has been located on chromosome 20ql3.2. Aurora kinases 
have been discussed in the general introduction as having a possible role in causing 
cells to develop aneuploidy, and Aurora kinase A has a function associated with 
centrosomes during chromosome separation (Carmena and Eamshaw 2003). In fact, 
this protein kinase has been amplified and overexpressed in cancers and cell lines 
(Zhou et al., 1998, Giet et al., 1999). It may be that abnormality of this protein has a
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role in the further development of aneuploidy, and hence cell instability, in gastric 
carcinogenesis.
Chromosome 4 aneuploidy was highlighted in this study. As with the other 
chromosomal abnormalities, the frequency of chromosome 4 aneuploidy increased as 
histology progressed, and there were significant changes of chromosome 4 in even the 
earliest step along the pathway to gastric cancer. Amplifications of chromosome 4 
were the most striking abnormalities to exist in gastritis and intestinal metaplasia, 
when compared to normal gastric mucosa. This may suggest an important role for 
chromosome 4 amplification in the initiation of gastric carcinogenesis. Chromosome 
4 amplification has been recently shown to be a significant event in the progression of 
disease from Barretts oesophagus to adenocarcinoma, especially in the early 
histological changes of this pathway (Croft et al., 2002, Doak et al., 2003). The level 
of chromosome 4 amplification in the intestinal metaplasia samples studied here, 7%, 
was less than, but nonetheless comparable with, that seen in the metaplasia patients 
with Barretts disease i.e. 12% (Doak et al., 2003). Further work by the same group 
has linked the amplification of chromosome 4 to the protein Nuclear Factor kB 
(NFkB) (Jenkins et al., 2003). NFkB resides on chromosome 4 and acts as an anti- 
apoptotic factor, as well as influencing the pro-inflammatory action of interleukin-8 
(IL-8) (Rayet and Gelinas 1999). The increased copy number of NFkB allows 
continued cell survival with avoidance of the usual cell regulators. Could a similar 
situation be present in gastric pre-malignant tissue? NFkB has already been linked to 
many cancers including gastric cancer (Rayet and Gelinas 1999).
Figure 4.14 shows a modified Correa model of gastric carcinogenesis (Correa 
1988). An attempt has been made to fit the chromosomal abnormalities identified in
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this study into the pathway, implicating their possible role in early gastric 
carcinogenesis. As is shown, amplification of chromosome 4 and 20, together with 
deletion of p53, are significant events in the sequential change from normal gastric 
mucosa through gastritis to intestinal metaplasia.
Chapter 3 has shown the types of chromosomal abnormalities induced by 
Reactive Oxygen Species (ROS). To recapitulate, out of the chromosomes studied, 
amplification of chromosome 4 and deletion of p53 were the most prominent 
abnormalities induced by ROS, together with instability of chromosome 20. These 
ROS induced changes in chromosomal copy number are in concordance with the 
types of aneuploidy that I have demonstrated in pre-malignant gastric tissue, 
suggesting maybe that ROS could be a causative agent of the aneuploidy shown in 
pre-malignant gastric tissue. Helicobacter pylori infection has been well documented 
as causing oxidative DNA damage through activation of ROS released by the immune 
system, some of the evidence to support this statement has been summarised in 
chapter 1. The final experiments in this chapter have attempted to determine if a 
correlation exists between chromosomal abnormalities and H. pylori infection. As the 
histological stage of gastric tissue itself affects the level of aneuploidy present, and 
also as H. pylori infection can be lost in gastric tissue with changed phenotype 
(Graham 2000, Grady 2001), the comparison of aneuploidy in tissue with and without 
H. pylori infection was restricted to gastritis tissue samples only. Also, Morgan et al. 
2002 noted that in tissue with gastritis, higher levels of ROS, and therefore oxidative 
DNA damage, were present. As such, any chromosomal damage present due to ROS 
would be enhanced in this group. Again it should be noted that diagnosis of H. pylori 
was on histological grounds only, although this is discussed further in Chapter 6 when 
more sensitive PCR techniques are used to detect H. pylori in the same tissue samples.
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However in the results illustrated here, the frequency of abnormalities in chromosome 
4 was found to be significantly higher in the H. pylori positive patients, and 
specifically amplification of chromosome 4. Therefore, it could follow that 
amplification of chromosome 4 is associated with ROS, but a causative role is still 
only suggestive. Also it should be reiterated that numbers in this study group are now 
small, only 10.
Gastric cells exposed to H. pylori have been shown to have an upregulated 
expression of IL-8, and it is known that IL-8 is a transcription factor of NFkB 
(Jenkins et al., 2003, Maeda et al., 2001). It is therefore possible to hypothesise that 
H. pylori infection acts as a trigger to activate NFkB, and that cells with amplification 
of chromosome 4 and NFkB possess a distinct survival advantage, hence favouring 
tumourigenesis. This would support a role for H. pylori in gastric carcinogenesis.
Other reports in the literature discuss increased specific genetic abnormalities 
associated with pre-malignant gastric disease and H. pylori infection. Nardone et al. 
found that in atrophic gastritis, aneuploidy and c-myc and p53 expression were only 
found if H. pylori infection was also present (Nardone et al., 1999).
Chapter 5 will look at the level of aneuploidy in gastric tumours from a patient 
cohort within the same geographic location as those patients studied in this chapter, as 
we know external factors influence gastric cancer incidence. This can allow a 
comparison of the chromosomal abnormalities present in tumours with those 
chromosomal abnormalities identified in this chapter in pre-malignant tissues. In other 
words, to establish whether the levels of aneuploidy continue to increase in a stepwise 
manner as pathology progresses as would be expected in the Correa model of gastric 
carcinogenesis, and also to identify any specific chromosomal abnormalities that are
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strongly associated with progression to cancer, and therefore are suggestive of a 
driving force in cancer.
Chapter 5
Detection of chromosomal abnormalities in gastric cancer, using Interphase 
Fluorescence in Situ Hybridisation
In this chapter tissue samples of gastric cancer were obtained from surgical 
resections of 10 patients undergoing gastrectomy for gastric cancer. Cytology 
brushings were used to collect cells, and interphase FISH was performed with CEN 
probes 20, 4 and 8 and LSI 17(p53). All the chromosomes studied showed 
aneulpoidy, and in greater frequencies than that already found to exist in pre- 
malignant tissue (Chapter 4). Intra-tumoural heterogeneity was also found in some of 
the tumours studied, and the effects of chemotherapy discussed.
5.1 Introduction.
Gastric cancer is a common cancer worldwide and a significant cause of death 
in the UK (Parkin et al., 1995, Cancer Research Campaign 1995). The general 
introduction outlines what is known of the evidence available on the incidence and 
aetiology of gastric cancer.
Ninety percent of all gastric cancers are adenocarcinomas (Luk 1998). Gastric 
carcinoma can be divided into 2 types histologically, using the Lauren classification, 
intestinal and diffuse (Lauren 1965, Grady 2002). The intestinal type is composed of 
gland-like tubular structures that often form a mass or an ulcer (Faraji and Frank
2002). Correa hypothesised that intestinal type gastric cancer was preceded by 
atrophic gastritis and intestinal metaplasia (Correa 1988). These pre-malignant stages 
are described in detail in Chapter 1 and Chapter 4. Diffuse type gastric cancer is a 
poorly differentiated cancer that infiltrates and thickens the gastric wall, and tends to
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arise without a precursor lesion (Faraji and Frank 2002). These two types occur with 
differing frequencies worldwide, and also differ in their patient profile. The intestinal 
type of gastric cancer is more prevalent in the 7th decade in men, and diffuse cancer is 
seen predominantly in a younger population with no sex difference. Also importantly, 
the diffuse type of gastric cancer has a poorer survival rate than the intestinal type of 
cancer (Faraji and Frank 2002, Sipponen et al., 1998, Grady 2002). Genetic studies on 
both types of cancers have been reported but whether intestinal and diffuse gastric 
cancers have different chromosomal abnormalities and therefore different genetic 
pathways remains controversial (Kokkola et al., 1998, Pathak 1992, Nowinski et al., 
1990, Hoshi et al, 1999, Yasui et al., 2000). As different phenotypic pathways are 
said to exist for each cancer, and as patient characteristics differ, then it would be 
plausible that there are two distinct genetic pathways.
The wide range of cytogenetic abnormalities found in gastric cancer has been 
reviewed in the Table 1.1 in chapter 1 which summarises a number of studies. The 
majority of the studies investigated advanced cancers, and there is general agreement 
that advanced cancers have more genetic change than early cancers (Kityama et al., 
2000, Koo et al., 2000, Kim et al., 2000, Lee et al., 1999, Igasharo et al., 2000, Brito 
et al., 1994, Uchino et al., 1992). Advanced cancers contain genetic changes that are a 
result of the inherent instability of the tumour i.e. ‘passenger’ alterations. These de- 
novo abnormalities arising within the tumour can cause intra-tumoural heterogeneity. 
Obviously, the most important genetic abnormalities exist early in a cancer, and hence 
drive the carcinogenic process. These abnormalities would also be present in the pre- 
malignant stages before cancer is fully established. Cytogenetic abnormalities have 
already been identified in pre-malignant gastric tissue using patients from the 
Neath/Swansea locality (Chapter 4). As has been stated in Chapter 1 and Chapter 4,
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there is significant variation in the incidence of gastric cancer worldwide. Ideally a 
comparison should be made between pre-malignant stages and tumour samples from 
patients in the same area, therefore the gastric cancer resections studied in this chapter 
were also from patients in the Neath/Swansea area. In fact, the better way to assess 
whether genetic changes present in pre-malignant tissue have a role in the 
development of cancer is to examine different tissue stages from the same patient. A 
longitudinal study like this would probably take several years to accumulate the 
tissue. Also, because the pre-malignant conditions of atrophic gastritis are so 
common, a huge population would need to be followed up in the hope of catching 
some developing cancers. However in this study, different tissue types within the 
same surgical resection were found and analysed using FISH, which may represent a 
convenient way to mimic a longitudinal study in individual patients.
Gastric cancers can also be subdivided on the basis of their site into distal and 
proximal tumours. The more proximal tumours, found at the gastric cardia and gastro- 
oesophageal junction, are often indistinguishable from tumours of oesophageal origin 
and in fact may be Barretts associated cancers (Clark et al., 1994). As such they are 
often managed as oesophageal tumours, where pre-operative chemotherapy now plays 
an important role (Clark 2001, Walsh et al., 1996). Unlike distal gastric cancers the 
incidence of proximal tumours is increasing suggesting a different aetiology or 
pathogenesis from antral tumours (Faraji and Frank 2002, Blot et al., 1991). In Wales, 
a 3.6% increase in male oesophageal cancer rates per annum has been noted since 
1992 (www.wcisu.nhs.ukf  The types of genetic changes in proximal and distal 
cancers have been shown to differ (El Rafai et al., 2002, Beuzen et al., 2000, 
Nowinski et al., 1990).
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Chemotherapy is effective in some human cancers. It can play a role in upper 
GI cancer as a palliative or curative tool, with or without radiotherapy/surgery (Yosef 
and Nicolson 2001). Pre-operatively, it can shrink a tumour making successful 
surgical resection more likely. Agents found to be of use include, 5-fluorouracil, 
cisplatinum, mitomycin C, doxarubicin, epirubicin and, more recently, etoposide and 
taxane (Yosef and Nicolson 2001). As chemotherapeutic agents are delivered 
systemically they have an effect on all cells, although they have a prediliction for 
those cells that are most actively dividing, and hence cancer cells are selectively 
targeted. Chemotherapeutic agents have been shown to cause DNA damage, including 
chromosomal abnormalities, and more specifically aneuploidy (Acar et al., 2001,
Silva et al., 2002, Kamguchi and Tateno 2002, Frias et al., 2003). This factor can 
often make it difficult to assess the genetic abnormalities in tumour tissue after 
treatment with chemotherapeutic agents.
5.2 Aims
The experiments described in this chapter have looked for specific 
chromosomal aberrations in ten gastric cancers in the patients from the 
Neath/Swansea locality using the methodology described in Chapter 4, Interphase 
Fluorescence In Situ Hybridisation. Hence, it was possible to compare any 
abnormalities in chromosomes 20, 8, 4 and 17 (p53) found in gastric cancer, with 
those chromosomal abnormalities already identified in the pre-malignant gastric tissue 
studied in Chapter 4. In addition, a pseudo-longitudinal study of three patients looked 
at chromosomal abnormalities in pre-malignant and malignant gastric tissue within 
three gastric resection specimens. Intra-tumoural heterogeneity was also assessed in
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three patients. Finally, the influence of chemotherapy on the chromosomal 
abnormalities in the gastric tissue of one patient was investigated.
5.3 Materials and Methods
5.3.1. Patients’ samples and histological diagnosis.
Surgical resections for gastric cancer were performed at Monriston Hospital 
Swansea, and samples analysed histologically at the Pathology Department 
Morrriston Hospital, by a Consultant-Pathologist, Dr AP Griffiths. Mucosal brushings 
were taken from the cancer and surrounding mucosa, as well as from normal gastric 
or duodenal tissue to act as an internal control. Brushings were taken from freshly 
opened gastrectomy specimens. After fixation, sections were taken from the brushing 
sites so that the cytological findings could be correlated with mucosal histology.
Ten patients were included in this study.
5.3.2. Cytology brushings. Interphase cell preparation and FISH analysis.
Within 30 minutes of surgical resection, brushes were taken from the tissue 
and stored in 90% methanol for transportation and further analysis in the laboratory. 
The same protocols for Interphase cell preparation, FISH analysis and signal 
visualisation and scoring, were used as has been described in chapter 2.
The reproducibility of the technique has been described in Chapter 4. 
Statistical analysis was determined using the Fisher’s exact test.
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5.4 Results.
5.4.1 Patient characteristics and histological diagnoses.
Ten patients’ surgical resection specimens were analysed. Table 5.1 gives the 
sex and age of patients, and the histological diagnosis of the tumours surgically 
resected. Fifty percent of patients were male and the average age was 63.7 years.
Male sex is considered a risk factor for gastric cancer and as such it is interesting that 
50% of cases in this study were female. Female preponderance was a notable feature 
in the pre-malignant study described in Chapter 4, with only 33% of the patients 
studied being male. Therefore, the relative increased representation of men in this 
gastric cancer cohort as compared to the pre-malignant patient cohort studied earlier, 
may be important, consistent with the fact that male sex is a risk factor for gastric 
cancer. Figure 5.1 illustrates the demographics of the patients studied in this chapter.
Nine of the ten gastric tumours were from the distal stomach and one from the 
proximal stomach. Of the distal cancers, eight were diagnosed histologically as 
adenocarcinoma, with a variation in the level of cell differentiation found, and only 
one was noted to be an early gastric cancer i.e. not invading the muscularis propria, 
patient T7. The other distal lesion consisted of high grade dysplasia / intramucosal 
carcinoma.
As can be seen from Table 5.1 in three of the distal cancers, Tl, T2 and T3, 
sections were taken at different sites for histological analysis, and correlation made 
with the brushings taken for chromosomal analysis by FISH. Tissue from all stages of 
Correa’s multi-step pathway of gastric carcinogenesis could be identified in the 
gastric resection specimens (Correa 1988). Figures 5.2, 5.3 and 5.4 illustrate the
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Table 5.1: Patient characteristics and histological diagnoses.
Patient Age Sex Histology and site
T1 45 M -Adenocarcinoma (poorly differentiated) 
-Intestinal metaplasia 
-Normal gastric
DISTAL
T2 46 F -High grade dysplasia
-intestinal metaplasia / chronic gastritis
DISTAL
T3 72 M -Intestinal adenocarcinoma (poorly differentiated) 
-Moderately dysplastic adenoma 
-Intestinal metaplasia / chronic gastritis
DISTAL
T4 83 M Adenocarcinoma (poorly differentiated) 
DISTAL
T5 61 F Adenocarcinoma (poorly differentiated) 
DISTAL
T6 52 M Adenocarcinoma (poorly differentiated) 
DISTAL
T7 70 F Early intestinal adenocarcinoma 
DISTAL
T8 74 F Intestinal adenocarcinoma (poorly differentiated) 
DISTAL
T9 70 F Intestinal adenocarcinoma (moderately/poorly differentiated) 
DISTAL
T10 64 M Adenocarcinoma post chemotherapy, metastatic adenocarcinoma in 
nodes
PROXIMAL (gastro-oesophageal junction)
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different types of tissue found in each resection analysed, and their location with 
respect to the actual tumour present.
Out of the ten tumour resections examined, one was noted to be at the gastro- 
oesophageal junction (GOJ), extending proximally into the stomach. This patient, 
T10, had been managed differently to the other patients, with pre-operative 
chemotherapy (see appendix 1.5) before resection, and as such the biopsies of the 
tumour site showed little residual cancer. The surrounding nodes, however, contained 
metastatic adenocarcinoma. This tumour has therefore been analysed separately.
It is worth commenting that no mucosal site showed the presence of 
Helicobacter pylori infection. H. pylori infection is commonly lost in tissues with 
advanced disease (Graham 2000, You et al., 2000). H. pylori may be lost due to 
intestinal metaplasia, to which it cannot adhere, previous antibiotic therapy or 
possibly adoption of cocciod morphology.
5.4.2 Chromosomal aberrations in distal gastric cancer.
Abnormalities of chromosomes 20, 8, 4 and 17(p53) were identified in the 
cells from the gastric tumours studied. Figure 5.5 show the types of specific 
chromosomal abnormalities present in the cancer and dysplastic cells. Gains of CEN 
probes 20, 8 and 4 occurred more frequently than losses, showing that amplification 
of chromosomes, and increase in DNA content was more prevalent in gastric cancer 
cells and gastric dysplasia. Deletion of the tumour suppressor gene p53 was also 
common in the cancer cells, which was not surprising, as inactivation of this gene 
provides a growth advantage in the cell, hence favouring tumourigenesis. Aneuploidy 
was seen in up to 25% of cancer cells. Compared to the pre-malignant cells with
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aneuploidy, the copy number of chromosomes was greater in cancer cells i.e. cancer 
cells often had greater than 3 copies of chromosomes, see figure 5.6.
There was only one early gastric cancer found, patient T7. The level of 
aneuploidy was less in the early cancer as compared to the other more advanced 
cancers. Amplification of chromosome 4 was seen in 15% of cells in the early cancer 
compared to 20% in later cancers, and aneuploidy of chromosome 8 also was present 
in 11.5% of cells in the early cancer compared to 24.7% in the more advanced. No 
statistical differences have been calculated as numbers in each group were small.
5.4.3 A comparison of the chromosomal abnormalities found in distal gastric cancer 
cells to those found in pre-malignant gastric cells.
The incidence of gastric cancer, as mentioned earlier, varies depending upon 
geographical location, and the level of aneuploidy should ideally be compared in 
cohorts from the same locality, as it was in this study. Figure 5.7 demonstrates the 
level of aneuploidy found in gastric cancers as compared to that already found in pre- 
malignant gastric tissue analysed in Chapter 4. There was an obvious increase in the 
degree of chromosomal instability in the cancer group as compared to the pre- 
malignant groups. This was visible for each chromosome studied. The trend was 
stepwise, increasing from normal gastric mucosa, through gastritis, intestinal 
metaplasia to dysplasia and then to cancer i.e. through the stages of Correa’s pathway 
of gastric carcinogenesis (Correa 1988). The most significant chromosomal 
abnormalities identified in the pre-malignant tissue studied, were amplification of 
chromosome 4 and 20, plus deletion of p53. Figures 5.8, 5.9 and 5.10 illustrate the 
frequency of these chromosomal aberrations in all the tissue types studied in chapters 
4 and 5 - normal gastric, gastritis, intestinal metaplasia, dysplasia and cancer. As can
85
Figure 5.6 Examples of FISH photographs from gastric cancer cells
Amplification of chromosome 4
- 4 copies in one cell
- 3 copies in two cells
with 1 copy o f chromosome 20
Amplification of chromosome 4
- 5 copies in one cell, with 2 copies 
o f chromosome 20
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be seen in each graph, there was a stepwise increase in each chromosomal 
abnormality with histological progression, with up to 20% of cells bearing the 
abnormality at the malignant stage.
The comparisons of aneuploidy between gastric cancer tissue and pre- 
malignant tissue described have been made using the pooled data from patient groups. 
In this chapter, three of the gastric cancer resection specimens contain both pre- 
malignant and malignant tissue therefore I was able to offer a better comparison of 
these tissues within an individual. Figure 5.11 depicts the specific chromosomal 
abnormalities in Tl. The most common chromosomal abnormalities in the cancer 
cells were again the amplifications of chromosomes, and the deletion of p53. 
Chromosome 4 amplification, which was found to be significantly elevated in the pre- 
malignant tissue studied in Chapter 4, continued to increase in frequency in this 
patient with histological progression to cancer, as did chromosomes 8 and 20 
amplification. Figure 5.12 looks at the specific chromosomal abnormalities in T2, and 
again a similar picture existed of increasing abnormalities with histological 
progression, with chromosomal amplifications and p53 loss predominating. Figure 
5.13 illustrates the chromosomal abnormalities in patient T3 and again a similar trend 
was seen. It was interesting to note that chromosome 4 amplification was often the 
most frequent chromosomal abnormality seen in the pre-malignant stages in all 3 
patients. The frequency of chromosomal 4 amplification continued to increase along 
the pathway to cancer hence strengthening the hypothesis already suggested that it 
may have a significant role in gastric carcinogenesis.
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5.4.3 Intra-tumoural heterogeneity in distal gastric cancer.
Two of the distal gastric cancer surgical resections analysed had more than 
one brushing taken from the tumour mass, T1 and T3. Figures 5.14 and 5.15, illustrate 
the variation of chromosomal aberrations within each tumour. Amplifications and 
deletions of chromosomes 20, 8, 4 and 17 (p53) are shown. As can be seen T1 had 
very little diversity within the tumour. A significant difference in the 2 samples was 
only seen with p53 gain, p<0.005. However, T3 showed a greater variation between 
sites within the tumour, with obvious significant differences occurring in the 
amplification of chromosomes 20, 8 and 4, p<0.005.
5.4.4 Chromosomal aberrations in a gastro-oesophageal cancer, post-chemotherapy.
The resection sample from patient T10 was of a gastro-oesophageal tumour
extending into the stomach. Prior to surgery the patient had received chemotherapy 
(Appendix 1.5) as is the local practice with oesophageal tumours. The tumour mass 
present at resection was analysed histologically showing little evidence of residual 
cancer, however metastatic adenocarcinoma was found in associated nodes, 
suggesting the disease process had not been eradicated fully. Cytology brushes were 
taken from 4 quadrants of the tumour mass, and from normal gastric mucosa away 
from the tumour.
When the tumour cells were compared to normal gastric mucosa in patient T10, 
significant chromosomal abnormalities were seen in chromosome 20 (p<0.05), 
chromosome 8 (p<0.005) and chromosome 4 (p<0.005), and in 17(p53) (p<0.005), 
see Figure 5.16. The most frequent abnormalities were as expected chromosome 4 
amplification (17%), chromosome 8 amplification (11.6%), p53 deletion (9.4%) and 
chromosome 20 amplification (7.8%). As few residual cancer cells were found in the
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tumour mass, it was interesting to find such increased levels of chromosomal 
instability present in the tumour compared to the normal gastric cells. This may 
possibly reflect the pre-operative chemotherapy the patient had received, and its 
increased uptake into cancer cells compared to non-malignant cells.
Figure 5.16 also shows a comparison between the chromosomal data from the 
pooled normal gastric tissue to the normal gastric tissue of T10, away from the 
tumour. A higher level of chromosomal abnormality was seen in the patient treated 
with pro-operative chemotherapy, statistical significance was only reached for 
chromosome 20 abnormalities (p<0.05). Again this may well reflect the effects on 
normal gastric cells of the chemotherapy. The last comparison made was with the data 
from the pooled distal gastric cancers to the tumour mass at the gastro-oesophageal in 
T10. As you would expect the distal gastric cancers had more chromosomal 
abnormalities present, but the order of chromosomal abnormalities was the same, with 
the most prominent abnormality being amplification of chromosome 4 and deletion of 
p53.
The level of intra-tumoural heterogeneity was also looked for in this gastro- 
oesophageal tumour mass. Four quadrantic biopsies were taken and Figure 5.17 
shows the results. As can be seen there was a degree of genetic heterogeneity in the 
tumour mass. A similar trend was observed to that seen for the distal gastric cancer 
samples already analysed (Figures 5.14 and 5.15) with genetic heterogeneity primarily 
in chromosomal amplification, p<0.05, but also p53 deletion, p<0.05.
5.5 Discussion
The aim of the studies described in this chapter was to identify chromosomal 
abnormalities in gastric cancer resections using Interphase FISH, targeting the
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chromosomes found to be abnormal in the pre-malignant tissue studied in Chapter 5 
i.e. chromosome 20, 8, 4 and 17 (p53). Aneuploidy of chromosomes 4, 8, 20 and 
17(p53) was detected in the gastric cancers studied. Compiling the data from this 
chapter and Chapter 4, a stepwise elevation of aneuploidy was seen as disease severity 
progressed from normal gastric mucosa through gastritis and intestinal metaplasia to 
dysplasia and cancer. Amplification of chromosome 4 and 20, together with deletion 
of 17(p53) were the most prominent chromosomal abnormalities detected.
This chapter validates the choice of chromosomal probes studied in this thesis, 
as these chromosomes (20, 8, 4 and 17p53) are indeed progressively involved in 
gastric cancer. Surprisingly, chromosome 4, which was chosen because of its 
involvment in the progression of Barretts oesophageal cancer and not gastric cancer, 
has been shown to be a common event in gastric carcinogenesis
Ten surgical resection samples were studied, and using the brush cytology 
technique described in chapter 2, FISH was successfully performed. As there are 
inherent differences between gastro-oesophageal cancers and distal cancers, (as 
outlined in the introduction), only the nine distal cancers were analysed together. All 
the cancers were adenocarcinomas as would be expected (Luc 1998). Only one was 
termed an early cancer, another expected finding, bearing in mind that the bulk of 
gastric cancers present with symptoms only when the disease is advanced and hence 
the usual poor prognosis for patients. The majority of cancers in this group were 
classified as intestinal type gastric cancer. As intestinal type cancers are said to be the 
endpoint of the Correa pathway of environmental gastric carcinogenesis (Correa 
1998, Faraji and Frank 2002), the comparison of the genetic abnormalities found in 
these tumours to those found in the pre-malignant tissue in chapter 4 was more 
relevant.
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As the chromosomal abnormalities in this patient cohort were compared to the 
patient group studied in Chapter 4, then ideally a comparison of the patient 
characteristics should have been made to assess the effect of confounding variables. 
Unfortunately, in this series of patients only information relating to age and sex was 
available and not other lifestyle factors, as the patients were not interviewed. The age 
of the study population was in the 6th decade, generally a decade younger than what 
would be expected. The mean age for male presentation in Wales is 70.7 years, and
75.2 years in females (www.wcisu.nhs.ukf  However it was comparable with the age 
of patients studied in Chapter 4. The mean age of patients assigned to each 
histological group i.e. normal gastric tissue, gastritis and intestinal metaplasia, all fell 
within the 6th decade. Regarding sex, the proportion of women in the study described 
in this chapter was 50%. Gastric cancer is said to be a predominantly male disease 
(Faraji and Frank 2002, Sipponen et al, 1998, Grady 2002), and as such this is 
relatively high percentage. However, the pre-malignant study of patients in the same 
locality (Chapter 4) only had a male incidence of 33%, therefore the fact the male 
percentage does increase in the gastric cancer cohort is important. All Wales data 
shows that Swansea/Neath/Port Talbot area has the highest incidence rate of gastric 
cancer in women in the principality (www.wcisu.nhs.ukV
Aneuploidy is a common finding in cancer (Lengauer et al., Nardone et al., 
1999), and in particular gastric cancer (Beuzen et al., 2000). Specific abnormalities of 
chromosomes 20, 8 and 4 have been demonstrated using CGH and FISH (see Table
4.1 in Chapter 4). In this study of distal gastric adenocarcinomas in Swansea/Neath, 
altered copy number of all these chromosomes was found (Figure 5.5). Increased copy 
number i.e. amplifications, were most often seen, with amplification of chromosome 8 
occurring in 20% of the cells studied. As has been discussed in Chapter 4, this
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chromosome houses the oncogene c-myc, which is a proliferative transcription factor, 
c-myc over-expression has been reported in gastric cancers with a varying frequency, 
16-67% (Grady 2001), which is comparable to the amplification levels of 
chromosome 8 in this study. Chromosome 4 amplification was also a significant 
finding in gastric tumour cells. Again the importance of chromosome 4 amplification 
has been discussed in Chapter 4, outlining the favourable characteristics this genetic 
abnormality offers cancer cells with up-regulation of the protein NFkB. The 
amplification of chromosome 20, which was a prominent abnormality in this study of 
gastric tumours, has also been documented frequently in a number of cytogenetic 
studies of gastric cancers (see Table 4.1 in Chapter 4), and the significance of its 
effect on further aneuploidy development discussed again in Chapter 4. p53 deletion 
was also noted to be common in the gastric cancers studied here. The action of p53 
and its role as an important tumour suppressor gene has also been discussed in 
Chapter 1 and Chapter 4. The literature reports it be abnormal in 30-58% of intestinal 
and diffuse gastric tumours (Grady 2001). Therefore, it would be fair to say that the 
tumours investigated in this study were typical of those seen elsewhere. In addition, as 
would be expected on the basis of the previous cytogenetic studies discussed in the 
introduction, the early gastric cancer in this study demonstrated less genetic instability 
than the more advanced cancers.
A comparison was made of the chromosomal abnormalities found in the pre- 
malignant tissues in Chapter 4, to the chromosomal abnormalities found in the gastric 
cancer samples. Figure 5.7 shows that chromosomal abnormalities are more common 
in cancer cells compared to that seen in its pre-malignant stages. As the multi-step 
pathway of carcinogenesis has documented the series of phenotypic changes normal 
gastric cells undergo before becoming cancer cells (Correa 1988), it is important to
91
investigate and determine the series of genetic changes that occur at each stage. 
Hopefully, by identifying the genetic changes that occur early in the pathway and 
persist throughout the process, more information will be available on what drives the 
carcinogenic process, and hence eventually determine molecular markers of important 
diagnostic and prognostic value, as well as determine strategies to halt the disease 
process and prevent cancer. Chapter 4 identified amplification of chromosome 4 and 
20, and deletion of p53, as being significantly elevated in pre-malignant gastric tissue. 
This study (Figures 5.8, 5.9 and 5.10) confirms that these chromosomal abnormalities 
not only persist but become more common in both dysplastic and cancer cells. This 
helps to confirm a role for these abnormalities as a driving force in gastric 
carcinogenesis. When individual patients were assessed for accumulation of genetic 
abnormalities in their gastric cells as these cells changed from normal to cancer cells, 
the same result of a stepwise elevation in aneuploidy was seen (Figures 5.11, 5.12 and 
5.13).
Intra-tumoural heterogeneity has been a recognised feature of established 
gastrointestinal cancers, reflecting the general instability of the tumour, and the 
development of de-novo genetic abnormalities in individual cells. Owonikoko et al. 
2002, has demonstrated this phenomenon in Barretts associated cancers, using a 
number of genetic markers, whereas Lindforss et al. 2000, has looked at the lower GI 
tract. In this study separate areas within two distal gastric tumours were analysed. The 
genetic heterogeneity described in these other studies was seen, with statistically 
significant differences being identified, particularly the levels of chromosomal 
amplifications (p<0.005). The patient with a gastro-oesophageal tumour and treated 
with chemotherapy also showed genetic heterogeneity and again, chromosomal 
amplifications varied most, but p53 deletion was also noted to be heterogeneous
92
within the tumour. If a tumour shows significant intra-tumoural heterogeneity then the 
likelihood is that at least one of the various clones of cells present will not be as 
sensitive to chemotherapy as the other clones. Hence these ‘chemoresistant’ cells will 
survive, and the cancer will continue to grow.
The gastro-oesophageal tumour mass analysed showed significant 
abnormalities in the chromosomes studied, in particular the amplification of 
chromosomes 4 and 8, and deletion of p53. This is interesting as the histology of this 
tissue showed little residual cancer. However as has been already established, the 
patient did receive chemotherapy prior to surgery, possibly suggesting this has a 
causative role for the genetic instability seen. Both clastogenic and aneugenic 
chromosomal damage has been reported as occurring post chemotherapy (Acar et al., 
2001, Silva et al., 2002, Kamguchi and Tateno 2002, Frias et al., 2003). This idea is 
supported by the fact the normal gastric cells in this patient had a higher level of 
genetic abnormality as compared to the levels of chromosomal abnormalities already 
shown in normal gastric mucosa (Chapter 4). Chemotherapeutic agents are taken up 
by all cells, but cell death is greater in those cells dividing more actively i.e. cancer 
cells, hence a greater degree of genetic disruption is seen in the tumour. Also, as 
metastatic adenocarcinoma was found in adjacent nodal tissue, the original disease 
process was not fully eradicated with the chemotherapeutic treatment prior to surgery, 
and this may also help to explain the genetic instability seen.
In summary, the prominent chromosomal abnormalities demonstrated in 
gastric pre-malignant tissue, amplification of chromosomes 4 and 20, plus the deletion 
of p53, continued to be a feature of dysplasia and cancer. These abnormalities 
persisted and increased in frequency as the multi-step pathway to gastric 
carcinogenesis (Correa 1988) progressed. The early appearance of these abnormalities
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and their persistence in cancer cells, strengthens the hypothesis that they have an 
important role in driving gastric cancer, as discussed in Chapter 4. In the future this 
may help to target patients who are likely to develop cancer, using molecular markers. 
Identifying the actual mutations that lead to the aneuploidy demonstrated in early 
gastric carcinogenesis may even help to create potential therapeutic agents capable of 
halting the carcinogenic process at its earliest stages.
It would also be important to correlate the genetic abnormalities with 
potential causative agents for this disease, and this has been done to some extent in 
Chapter 4, and will be developed further in Chapter 6 and correlated with 
Helicobacter pylori subtype.
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Chapter 6
The determination of Helicobacter vvlori infection in gastric biopsies using 
Polymerase Chain Reaction technology and correlation with histological 
diagnosis and chromosomal abnormalities.
In this series of experiments H. pylori infection in the gastric biopsies 
collected at endoscopy was determined using PCR technology. All the patients found 
to be H. pylori positive on histological assessment were also detected using PCR. 
43% of H. pylori infection diagnosed was found to be Cag A positive. Chromosomal 
abnormalities were greater in those patients with Cag A positive H. pylori infection. 
Amplification of chromosome 4 may be important in H. pylori infection.
6.1 Introduction
The bacterium Helicobacter pylori has already been introduced in the opening 
chapters of this thesis, with details of its incidence, association with gastric cancer, its 
proposed mechanism of action and its effect on aneuploidy in cells discussed.
6.1.1. Detection of H. pylori infection.
H. pylori is a known human pathogen capable of causing many diseases, with 
its most serious association being that with gastric cancer (Blaser 1998). As such the 
importance of its diagnosis and hence eradication, whereby a stimulus capable of 
causing serious disease is removed, is obvious. There are a number of methods 
available to detect H. pylori infection and all have differing sensitivities.
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Non-invasive methods include the Urea Breath test. This is based upon the 
fact that the bacterium produces a urease enzyme. An ingested solution of urea, 
labelled with carbon 13, is rapidly hydrolysed by the H. pylori urease enzyme, and the 
resulting carbon dioxide is absorbed across the gastric mucosa and via the systemic 
circulation eventually excreted as expired gas. It detects current infection and 
therefore is a useful follow up investigation to assess eradication. False negatives can 
occur with antibiotic and proton pump inhibitor therapy. In children a faecal antigen 
test is also available as an alternative (O’Connor and Sebastian 2003, Dunn et al, 
1997, Logan and Walker 2001).
Serological testing relying upon elevated IgG and IgA antibodies is also 
possible. ELISA (enzyme linked immunosorbent assay) technology is used to detect 
those antibodies. Different antigen preparations are available in the commercially 
available kits, giving reasonable sensitivity. Following the successful treatment of H. 
pylori antibody levels can be slow to fall, and hence the test is not a reliable indicator 
of eradication or re-infection. This method of H. pylori detection identifies ‘global’ 
infection i.e. is not reliant on detection of the bacteria at the site of infection, and as 
such it may be a useful screening test, whereby a negative result would confer a low 
probability of infection, however a positive test would need further evaluation (Dunn 
et al., 1997). Further technology to develop a ‘fingerprick’ method would enhance the 
benefits of this test clinically, although results are not yet reliable (Logan and Walker 
2001).
Invasive detection of H. pylori infection by the analysis of a gastric biopsy 
histologically is probably regarded as the gold standard from a clinical perspective, 
yet newer technology can now questions this. There are several ways to determine 
infection from a gastric biopsy. The major downside of all these detection methods is
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obviously the need to undergo an upper GI endoscopy to obtain the biopsy, a 
procedure not without risk or discomfort. Sampling error is a major consideration. Up 
to 14% of infected patients do not have H. pylori evident on the biopsy analysed, 
especially in the case of gastric atrophy, intestinal metaplasia and bile reflux (Logan 
and Walker 2001). Also after eradication treatment the bacteria levels can be very low 
making it difficult to diagnose. Proton pump inhibitors also interfere with the gastric 
pH and as such modify the H. pylori habitat again making detection of bacteria 
harder. Multiple biopsies from multiple sites should minimize sampling error, 
however laboratory workload is increased. Histological assessment of the gastric 
biopsies using modified Giemsa staining and immunohistochemistry can give good 
pick-up rates for H pylori infection, but is heavily reliant upon histopathologist 
expertise (Dunn et al., 1997). A method of H. pylori detection bypassing the need for 
laboratory analysis would be a CLO test (Delta West LTD., Bentley, Australia), 
whereby the urease activity of the bacteria causes a colour change detectable in pre­
packaged agar gel of phenol red and urea. The test is readable for up to 24 hours in 
the Endoscopy Unit and as such is now becoming more popular than the histological 
analysis of biopsies (Dunn et al., 1997, O’Connor and Sebastian 2003). Detection 
rates however fall in cases of GI bleeding. Culturing the bacterium has always proved 
to be time consuming, with problems of contamination and overgrowth. This method 
does however allow determination of the antibiotic sensitivities, and this would help 
decrease the numbers of resistant infections which is an emerging problem (Logan 
and Walker, 2001, Owen 2001). Table 6.1 summarises the sensitivity and specificity 
of the more popular clinical methods of H. pylori detection, giving an indication of 
the cost and availability.
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Table 6.1. H  pylori detection methods. (Logan and Walker 2001)
Test Sensitivity Specificity Available Cost
Histology 88-95 90-95 ++++ ++-H
Culture 80-90 95-100 ++ +++
Clo 90-95 90-95 +-i i I +
13 Carbon 90-95 90-95 ++++ +++
Serology 80-95 80-95 +++ +
Stool antigen 90-95 90-95 ++ ++
The method used to determine H. pylori infection in a gastric biopsy studied in 
this chapter, is the Polymerase Chain Reaction (PCR). This methodology has the 
advantage of an amplification step enabling a target gene to be amplified more than 
106 fold (Saiki et al., 1988), and as such even a single bacterium present in the biopsy 
could be identified making it up to 100% sensitive, excluding sampling error (Clayton 
et al., 1992, Dunn et al., 1997, Lage et al., 1995). Choosing the appropriate primer to 
drive the reaction is obviously important, and a number of genes in the H  pylori 
species have been targeted. In this study flagellin primers have been used which target 
genes involved in the flagella development, and therefore are specific to bacterium 
such as H. pylori that have flagella. The protocol used in this study was initially 
optimised in a previous study using patients from the same region (Ishmail 2004). The 
sensitivity was 100% as compared to histological analysis. In fact, H  pylori DNA was 
found in gastric biopsies where H. pylori organisms had failed to be identified 
histologically. This technique also allows the subtyping of the bacterium (Balaratnum 
et al, 2001, Ismail et al., 2001, Lage et al., 1995), and in this study, the Cag A status 
of the bacterium was determined by PCR. The major drawback to this technique has 
to be the technical expertise needed and therefore the cost. Further work by Ishmail 
and other authors have shown that the technique can be modified and employed 
successfully on dental plaque, thereby reducing the need for an invasive endoscopy 
and possibly representing a screening test that could be used nationwide (Banatvala et 
al., 1994, Dunn et al., 1997, Ishmail 2004).
6.1.2. The Cag A subtype of H. pylori infection.
H  pylori has evolved throughout time leading to the emergence of different 
strains, capable of occurring in a single host; Cag A is one such subtype. Cag A is a
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marker for the cag pathogenicity island (35kb), encoding a high molecular weight 
protein (128 kDa) (Censini et al., 1996). The actual function of the gene is unclear but 
its effect on intracellular phosphorylation may be the key to its wide range of effects 
on gastric cells (Catherton 2000). Cag A positive strains are highly immunogenic 
strains of H. pylori and are associated with increased cytokine expression (interleukin- 
8) (Crabtree et al., 1995), inflammatory cell infiltrate and release of reactive oxygen 
species in the gastric tissue (Sipponen et al., 1997, Fiocca et al., 1994). Clinical 
studies have shown significant association between Cag A positive H. pylori infection 
and the activity of gastritis and the presence of gastric atrophy and intestinal 
metaplasia (Blaser et al., 1995, Fiocca et al., 1994, Kuipers et al., 1995, Sipponen et 
al., 1998, Yamaoka et al., 1999). Cag A positive H. pylori infection is also associated 
with increased rates of gastric cancer (Basso et al., 1998, Miehlke et al., 2000, 
Parsonnet et al., 1997, Rugge et al., 1999). Environmental factors and host factors 
determine how strong the association is between H. pylori and gastric disease 
(Graham 2000). Thus, these factors contribute to the association between Cag A 
positivity and gastric carcinoma. A Portuguese group showed that polymorphisms of 
the human interleukin 1 (3 gene also affect the virulence of Cag A infection 
(Figueiredo et al., 2002).
The prevalence of H. pylori infection varies geographically and so does that of 
the Cag A subtype. 60% of all H. pylori strains in Europe and the USA are said to be 
Cag A positive (Dunn et al., 1997). A community based Scandinavian study estimated 
infection rates of Cag A positive H. pylori, from antibody levels in the serum, as 
20.4% in 1994 which was significantly lower than 20 years before (Perez-Perez et al., 
2002). Cag A infection rates also vary between age groups, and again the
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Scandinavian study suggested a relatively higher infection rate in the older population 
studied (Perez-Perez et al., 2002).
6.1.3 Aims
The aims of the studies described in this chapter were two fold.
Firstly, the study compared the sensitivity of PCR technology with 
histological analysis in diagnosing Helicobacter pylori infection in gastric biopsies.
At the same time, the frequency of Cag A positive H. pylori infection was also 
determined, using PCR technology again.
Secondly, a correlation was made between H. pylori infection, and subtype, in 
gastric biopsies with the histological diagnosis and the levels of aneuploidy, which 
have already been determined for each patient in Chapter 4.
Therefore in this chapter I tested the hypothesis that H. pylori infection, 
particularly with the more virulent Cag A strain, would be associated with greater 
disease severity and greater chromosomal damage.
6.2 Material and Methods
6.2.1 DNA extraction
Gastric biopsies were taken from the antrum of consenting patients enrolled in 
the study as outlined in Chapter 2. The biopsies were stored at -70°C until analysis, 
which was between 1 and 12 months. A high salt DNA extraction kit (Stratagene) was 
used to extract the DNA. The biopsies were sliced using a scalpel onto glass slides, 
and the diced tissue then added to 700pl of lysis solution in an eppendorf, on ice.
2.5jli1 of pronase was added to each eppendorf and the solution inverted. They were
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placed on a shaking incubator at 37°C for 16 hours. The samples were then chilled on
ice for 10 minutes. 250pl of NaCl was added at room temperature and the tubes 
inverted x3. They were returned to the ice and a white precipitate of protein was 
formed in each tube. The tubes were centrifuged at -4° C for 15 minutes at 34000rpm 
to pellet the protein and cell debris. The clear supernatant containing the DNA was 
extracted into new tubes and 12pl of RNAase added to each tube. They were then left 
to incubate at 37°C for 15-30 minutes. Two volumes of iced isopropanol were added 
to precipitate the DNA. The tubes were gently inverted until a ‘hairbalT appeared in 
each tube. The tubes were left at -20°C for 1 hour, and then centrifuged at -4°C for 10 
minutes at 13000rpm. The supernatant was removed and 2 washes were performed 
using 70% iced ethanol with centrifugation for 10 minutes at 13000rpm. The pellets 
were dried at 37°C for 12 hours. lOOpl of water was added to each pellet and the 
DNA was stored at -4° C until further analysis.
6.2.2 DNA quantitation
A mass spectrophotometer (Beckman DU 530) was used to quantitate the 
DNA extracted from each biopsy. 4jnl of the DNA solution was added to 96pl of 
water to perform x25 dilution. Absorbance at 260nm was measured, and used to 
calculate the DNA concentration, given that 10D unit equated to a DNA 
concentration of 50 pg/ml. To visualise the extracted DNA and check its integrity, 
agarose gel electrophoresis was performed.
A 1% agarose solution was made using 100ml of lxTAE buffer and lg of 
agarose (Fluorgen). The solution was heated in a microwave until dissolved. After 
cooling, the solution was poured into a casting stand and allowed to set for 30 
minutes. 15 pi of the DNA solution was added to 5 pi of DNA loading buffer
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containing Syber gold (Molecular probes) and the combined solution added to the gel 
wells. A marker solution of lOpl water, 5 pi Syber gold and 2pl of lkb DNA ladder 
(Promega) was also run. 900pl of the lx TAE buffer was used in the electrophoresis 
tank. The electrophoresis was run at 110V/70 mA for I hour and the DNA visualised 
under UV light.
6.2.3 PCR to determine H. vvlori infection and Cag A status
To avoid contamination in PCR reactions, the experiments were performed in 
designated laminar flow hoods (GRI). Prior to useage the hoods were treated with UV 
light for 5 minutes, and ethanol wipes were used to reduce contamination with any 
residual DNA present. Designated PCR eppendorff tubes, pipettes and filtered tips 
were also used, to again reduce contamination.
The agents needed for PCR were defrosted at room temperature ten minutes 
before use. A range of PCR primers have been used to detect H. pylori in gastric 
biopsies successfully (Clayton et al., 1992, Lage et al., 1995). In this series H. pylori 
flagellin primers were used to generate a 94 base pair fragment of the flagellin gene 
(Chaleshtori 1999, Ishmail 2004), designated Fla Reverse (primer sequences 
ACGGAAGGCTTTCTCTCACA) and Fla forward (primer sequences 
AAACCAATCGCTGTGAAACC). The CagA primers were synthesised according to 
Lage et al., 1995. A ‘master mix’ solution was made allowing 50pl for each sample 
tested - 5pl Taq polymerase buffer xlO (Promega), 4pi dNTP’s (ATP, GTP, CTP, 
TTP giving a final concentration lOOpM), 1.5mM Mg CI2 , 0.5pl Taq polymerase, 
20pM Fla F and Fla R, 3pi DNA, 32pl water. An additional sample was made up to 
allow a simultaneous ‘negative’ sample to be analysed, containing no DNA. The 
master mix solution was centrifuged for 10 seconds to ensure thorough mixing. The
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PCR machine (MJ research) was set at 94°C for 2 minutes and then 94°C for 30 
seconds, 60°C for 20 seconds and 72°C for 20 seconds, to allow amplification of the 
DNA sequence recognised by the chosen primers, 30 cycles were performed (Ishmail 
2004).
A 6% acrylamide gel was run to visualise the PCR product for each sample. A 
marker tube was run with each gel. The marker tube contained 5 pi of a 100 base pair 
DNA ladder (Promega), with equal volumes of water and dye. Positive controls for H  
pylori and Cag A positive Hpylori were obtained from the previous study by Ishmail 
2004.
The gels were stained with silver to allow visualisation of the PCR products 
produced. Each plate was incubated for 5 minutes in silver solution (0.1% AgNC>3), 
and then washed with water, before being incubated for 5 minutes in developing 
solution (13.5g NaOH, 5ml formaldehyde, 11 water) to develop the colour reaction. 
Photographs of the gels were then taken using a gel doc 2000 instrument (BioRad). 
The presence of the H. pylori PCR product was visualised as a discrete dark band of 
94base pairs and the CagA product of 400 base pairs.
6.2.4 Statistical analysis of chromosomal damage in patients with and without H. 
vvlori infection.
The Fisher’s exact test was used to assess statistical significance between the 
degree of chromosomal abnormalities in patients with and without H. pylori infection.
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6.3 Results
6.3.1 DNA extraction from gastric biopsies and its quantitation.
Gastric biopsies were taken from 19 patients who attended Neath Port Talbot 
General Hospital for an upper GI endoscopy and were enrolled in the study as 
outlined in Chapter 2. One biopsy was taken for histological assessment and a second 
biopsy was taken in close proximity for PCR analysis of H. pylori infection. Both 
biopsies were taken from the gastric antrum. The results of one patient, patient 8, 
were not included in the analysis as no corresponding histological sample was 
available.
The amount of DNA extracted from each sample was determined and 
tabulated in Table 6.2. Agarose gels were run to visualise the DNA product.
6.3.2 PCR to determine H. pylori infection and Cag A status in each patients’ gastric 
biopsy.
Duplicate PCRs were performed for each sample, according to the protocol 
described by Ishmail 2004 using the flagellin primers to determine H. pylori infection. 
Examples of the PCR gels are shown in Figure 6.1, with the discrete dark band 
representing H. pylori DNA.
Table 6.3 illustrates those patients with H. pylori infection diagnosed using 
PCR, those with Cag A positive H. pylori strains, along with a correlation to 
histological diagnosis, and H. pylori presence on histological slides. All patients with 
H. pylori infection determined using the histological techniques were also identified 
using the PCR technique. An additional patient, patient 26, had a positive H. pylori 
PCR test. This biopsy contained intestinal metaplasia to which H. pylori do not adhere
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Table 6.2: DNA values of patient gastric biopsies
Patient DNA value 
(Pg /ml)
4 25
5 87.5
7 30
9 117.5
10 127.5
11 15
12 22.5
13 67.5
14 35
Patient DNA value 
(Pg /ml)
15 57.5
16 72.5
17 25
18 30
20 110
22 22.5
23 50
26 50
27 92.5
Figure 6.1: gel photographs to illustrate the H  pylori infection in gastric biopsies, 
as determined by PCR (flagellin primers)
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Order: marker, 13, 4, 8, 9, patient x, 10, 12, 27, 26, 23, 18, 14 
Hpylori positive -  8, 9, patient x, 26, 18, 14
(patient x = clinical sample, outside study)
Table 6.3: Correlation of histological diagnosis with Hpylori status, as 
determined using PCR with flagellin primers and Cag A nrimers.
Patient Histology Hpylori 
histology +
H pylori 
PCR fla +
PCR Cag A +
4 normal - -
5 gastritis + + -
7 gastritis - -
8 no histology no histology + -
9 intestinal
metaplasia
+ + +
10 gastritis - -
11 atrophic gastritis - -
12 normal - -
13 normal - -
14 gastritis + + -
15 normal - -
16 gastritis + + +
17 normal - -
18 gastritis + + -
20 normal - -
22 gastritis + + -
23 gastritis - -
26 intestinal
metaplasia
+ +
27 intestinal
metaplasia
(Graham 2000, You et al., 2000). This may well explain why the more sensitive PCR 
technique demonstrated the H  pylori organisms in this biopsy whereas they were not 
identified on histological assessment. Also H. pylori may have been patchily 
distributed or occur in a coccoid form only recognisable with imunohistochemistry. 
Seven of the 18 patients who had their gastric biopsies analysed had H. pylori 
infection, 39%. All patients with H  pylori infection had abnormal gastric mucosa; 
gastritis with or without intestinal metaplasia. There was exact correlation between 
duplicate PCR reactions.
H  pylori organisms with the Cag A pathogenicity island are known to be more 
virulent, producing more severe pathological infection in humans (Blaser 1998).
Again following the protocol described by Ishmail 2004, the Cag A status was 
determined for each patient with H. pylori infection by PCR. Figure 6.2 shows a 
photograph of a gel identifying those biopsies with Cag A positive H. pylori infection. 
Table 6.3 correlates this result with the histological diagnosis. Three patients were 
infected with the Cag A strain of H. pylori, therefore 43% of the H. pylori infections 
were Cag A positive. Of the three patients found to be Cag A positive two had 
evidence of the more severe pathological diagnosis associated with H  pylori, 
intestinal metaplasia, with the remaining patient having gastritis. In fact, one of the 
patients determined Cag A positive, patient 26, was the patient whose H. pylori 
infection was not recognised with histological diagnosis alone, highlighting the 
importance of using the more sensitive diagnostic tool for H. pylori infection.
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Figure 6.2: gel photographs to illustrate Cag A positive Hpylori infections by
PCR.
Order: 5, 9, 14, 16, 18, 22, 26 
H pylori Cag A positive -  9, 16, 26
6.3.3 Correlation of chromosomal abnormalities with H. pylori infection and Cag A
status diagnosed using PCR technology.
Figure 6.3 illustrates the differences in the levels of chromosomal damage, as 
previously determined in Chapter 4 using FISH probes (CEN 20, 8 and 4, and LSI 
probe p53), between H  pylori PCR positive and negative patients. Amplifications of 
chromosomes 20, 8 and 4 were found more frequently in those infected with H. 
pylori. Amplification of chromosome 4 was found to be significant, p<0.005. 
Deletions of the tumour suppressor locus p53 were also commoner in H. pylori 
infected cells, p<0.005, together with deletion of chromosome 20. All of these 
chromosomal abnormalities have already been suggested to be important in the gastric 
carcinogenic process, therefore their association with H. pylori infection may be 
important. Chromosome 4 amplification was of particular note.
Figure 6.4 attempts to determine any differences in the levels of aneuploidy 
for each chromosome studied in those patients infected with the more virulent H. 
pylori infection, Cag A, and those infected with organisms lacking this pathogenicity 
island. It should be noted that even though numbers were small when the original 
patient cohort was subdivided this way, three patients versus four patients, a trend 
could be seen for chromosomal abnormalities to be greater in those infected with the 
more virulent Cag A strain of H. pylori infection. Aneuploidy of chromosomes 8 and 
4 were particularly noted, p<0.005, with up to 10% of cells infected with CagA 
positive H. pylori being affected. Amplification of chromosome 4, which has already 
been shown to be prominent in H. pylori infected tissue, was again the most 
frequently observed abnormality in the Cag A patients, affecting 7% of the cells with 
Cag A infection as compared to 5.9% of Cag A negative H. pylori infection (statistical 
significance was not achieved, p=0.132).
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6.4 Discussion
The experiments in this chapter have shown that PCR detection of H. pylori in 
gastric biopsies is a sensitive method of H  pylori detection when compared to the 
histological analysis of the gastric biopsies. Previous work by a number of groups has 
supported the accuracy of this method of determination of H. pylori infection 
(Ashton-Key et al., 1996, Clayton et al. 1992, Lage et al. 1995). Results of this study 
using gastric biopsies confirms the findings of Ishmail 2004, who previously 
investigated a different patient cohort in the same locality. In fact, both studies 
identified patients who had evidence of H. pylori DNA in their gastric biopsies hence 
evidence of bacterial infection, but where the histological analysis had failed to 
identify the organisms. As already discussed, PCR has the advantage of an 
amplification step thereby making the detection of very small DNA content possible 
i.e. a low bacterial load is identifiable.
The clinical relevance of the increased sensitivity of these PCR techniques can 
be discussed using the information available in this study. The additional patient 
identified as having H. pylori infection in this study was diagnosed as having 
intestinal metaplasia, a condition known to be a precursor to gastric cancer (Correa 
1998). Firstly, H. pylori is known to be capable of inducing phenotypic changes in 
gastric tissue such as intestinal metaplasia (Graham 2000, Kuniyasu et al., 2000, 
Sipponen et al, 1997), and secondly, it causes genotypic abnormalities (Morgan et 
al., 2003, Mamett 2004). The mechanism of action of H. pylori in inducing cell 
damage has been discussed in Chapter 1. In this particular patient it would be 
important to eradicate the bacteria, thereby removing a stimulus for continued DNA 
damage in a tissue already known to be abnormal and already partway along the 
multistep path towards gastric cancer (Correa 1998). Previous work has shown that
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the successful eradication of H. pylori in abnormal gastric tissue can cause a 
resolution of abnormal phenotypic and genetic changes (Blaser 1998, Nardonne et al., 
1999, Walker 2002). Hence, the identification of H. pylori in this patient would be 
clinically important, and may have significant influence on clinical outcome.
As to whether PCR detection of H. pylori using gastric biopsies has a practical 
clinical use would involve a cost analysis and evaluation of the availability of the 
appropriate expertise. The sensitivity of PCR has been well reported and its reliability 
in the locality has now been demonstrated in studies performed at different times and 
with different personnel. A technique worthy of assessment on a larger scale would be 
H. pylori detection using dental plaque. 100% sensitivity has been reported when 
compared with histological analysis of gastric biopsies (Ismail 2004). As the 
examination of dental plaque by PCR would be non-invasive, without the need for an 
upper GI endoscopy, it certainly warrants consideration.
Sampling error has been highlighted in the introduction as a pitfall when 
relying upon gastric biopsy based techniques to determine H. pylori infection. In this 
study, factors known to be affect sampling error, such as proton pump inhibitor use, 
were addressed and form part of the exclusion criteria outlined in Chapter 2.2.
Patients enrolled in the endoscopic study required 2 sets of cytology brushings and 2 
gastric biopsies, as well as whatever was determined appropriate on clinical need. 
Therefore in an effort not to prolong the endoscopy and put the patients at increased 
risk of complications I did not take additional biopsies to determine H  pylori 
infection. However, the prevalence of H. pylori infection in this cohort of patients 
undergoing upper GI endoscopy was 39%, and this is comparable to the findings of a 
similar endoscopy based study from the same locality in which multiple gastric 
biopsies were analysed for H. pylori using PCR. Their prevalence rate of H  pylori
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infection was 35% (Balaratnam et al., 2001). This infection rate is also comparable to 
another European study looking at infection rates in patients undergoing endoscopy 
that found 39% of gastric biopsies had PCR evidence of H. pylori infection (Lage et 
al., 1995). Other studies quote higher rates in patients attending for an endoscopy of 
65% (Nardonne et a\., 1999) and 72% (Banatvala et al., 1994). Incidence rates vary 
not only with geography and time difference, as discussed in the introduction, but also 
with the method used to determine H. pylori infection. The incidence rates quoted in 
the introduction from larger studies tend to be population based and use the non- 
invasive serological tests.
The utilisation of the PCR technique to detect H. pylori organisms in gastric 
biopsies has also allowed the determination of the H. pylori subtype. The 
identification of the Cag A strain was chosen as it is known to be associated with 
greater disease severity. The prevalence of the Cag A strain of H. pylori in this study 
was 43%, which is lower than some of the other studies reported but comparable to a 
local study in which only gastritis patients were analysed, 44% of H. pylori infections 
being Cag A positive (Morgan et al., 2003). Lage et al. 1995 documented 80% of the 
H. pylori infections detected in patients undergoing endoscopy were Cag A positive.
A Swedish study showed a Cag A positivity rate in their endoscopy patients with H. 
pylori infection of 71% (Maaroos et al., 1999). In 2001 a similar endoscopy study in 
the Neath Port Talbot area showed that 77% of the H. pylori infections were CagA 
positive (Balaratnum et al., 2001). A significant fall of 25% in the H. pylori infection 
rates in Scandinavia has been reported in the last 20 years (Kosunen et al., 1997), and 
a similar decline in the frequency of Cag A infection, 26%, has also been reported in 
larger population based studies, particularly in the younger cohort (Perez-Perez et al., 
2002). This could help to explain the 34% difference in prevalence of Cag A infection
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seen in the 2 similar studies in Neath Hospital which are separated by 3-4 years. Falls 
of infection rates in developed countries have been attributed to improved socio­
economic conditions and increased antibiotic useage in childhood (Blaser 1999). 
Reports suggest that the Cag A variant of H. pylori is more susceptible to antibiotic 
treatment than other subtypes (Marais et al., 1998, Van Dooman et al, 1999). This 
phenomenon, whereby the more virulent bacterial strain is lost first as infection rates 
decline, has also been observed over time with the Shigella infection in developed 
countries (Kostrzewski et al., 1968).
In this study all the patients identified with H. pylori infection had diseased 
gastric mucosa, (gastritis or intestinal metaplasia). Three patients had Cag A H. pylori 
infection, two of which had intestinal metaplasia on the gastric biopsy, a more 
advanced stages of pre-malignant phenotype. As discussed in the introduction Cag A 
infection is associated with greater inflammation and disease severity. Nardonne et 
al. 1999, found that in their patient group high levels of gastric atrophy and intestinal 
metaplasia were associated with a high prevalence of Cag A H. pylori infection. 
Yamaoka et al., also found an association between the Cag A strain and gastric 
atrophy and intestinal metaplasia, however they also further subtyped the bacteria and 
found that different Cag A genotypes conferred different disease severities. Cag A 
positivity has also been associated with increased rates of gastritis as well as atrophy 
(Maaroos et al., 1999). Peek et al. 1999 found that Cag A positive strains of H. pylori 
have a greater effect on the gastric epithelial cell cycle and apoptosis than Cag A 
negative strains. The effect of the Cag A strain was found to be dependent upon other 
bacterial characteristics, such as Vac A status, therefore further complicating the 
association between Cag A infection and disease severity.
110
Aneuploidy has been shown to exist in gastric tissue, both normal and 
diseased. Chapters 4 and 5 have shown that levels of chromosomal damage increase 
with histological progression, peaking as the gastric tissue becomes malignant. 
Amplifications of chromosomes 4 and 20, together with deletion of p53, have been 
common abnormalities throughout the gastric carcinogenesis pathway. The frequency 
of these chromosomal abnormalities has increased stepwise as the phenotype changes 
from normal gastric mucosa to gastric adencocarcinoma, thereby implicating their 
importance in driving carcinogenesis. The importance of H. pylori as a causative 
agent for gastric cancer has already been discussed, and in this chapter H. pylori 
infection has been determined using PCR, a more sensitive method of diagnosing H. 
pylori infection, to investigate further the link between H. pylori infection and 
chromosomal abnormalities. For chromosomes 4, 20 and 17(p53) levels of 
abnormalities were greater in H. pylori positive tissue. Abnormalities of p53 have 
already been identified in H. pylori positive infections. Murakami et al. 1999, has 
shown that p53 mutations are associated with H. pylori infected gastritis tissue. In 
particular in this study, chromosome 4 amplification was notably increased in infected 
tissue. The importance of this abnormality has already been discussed in Chapters 4 
and 5.
Chapter 4 has already determined that levels of aneuploidy differ between 
disease severity therefore histology may be a confounding factor in the comparison of 
aneuploidy in H. pylori positive and negative patients. Of the patients found in this 
chapter to be H. pylori positive tissue diagnoses were either gastritis or intestinal 
metaplasia, whereas half of the patients in the H. pylori negative group had normal 
gastric tissue. Chapter 4 has already established that aneuploidy was a less common 
finding in normal gastric cells as compared to gastritis/intestinal metaplasia. Chapter 4
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analysed gastritis patients only, finding that only abnormalities of chromosome 4 were 
higher in H. pylori infected patients, and that amplification of chromosome 4 in 
particular was associated with H. pylori infection. The link between H. pylori 
infection, an agent known to be causally linked to gastric cancer, and the 
amplification of chromosome 4 suggests the importance of H. pylori as an initiating 
agent in gastric carcinogenesis, and the amplification of 4 as an early genetic event.
An attempt has been made in this chapter to determine if greater chromosomal 
damage is seen with infection by the more virulent Cag A positive strain of H. pylori 
infections as compared to Cag A negative infections. Although numbers were small 
when the data was further subdivided in this way, aneuploidy of chromosomes 4, 8 
and 17 (p53) was seen at a higher frequency in those gastric biopsies infected with 
Cag A positive H. pylori infection. Nardonne et al., looked at genetic instability and 
found that Cag A infection was associated with greater levels of DNA aneuploidy, 
and p53 and c-myc expression. In this chapter it was possible to highlight 
amplification of chromosome 4 as a common abnormality associated with Cag A H. 
pylori infection. Chapter 4 has discussed in some detail the potential link between 
chromosome 4 amplification, NF kB activity, interleukin 8 overexpression and H. 
pylori infection. Cag A infection has already been associated with greater interleukin 
8 levels as compared to Cag A negative infection (Crabtree et al., 1995), and therefore 
the association of chromosomal 4 amplification and Cag A positivity may strengthen 
the hypothesis that amplification of chromosome 4 is particularly important in gastric 
carcinogenesis.
In summary, this series of experiments has confirmed that PCR detection of H. 
pylori infection in gastric biopsies is a sensitive and reliable method of H. pylori 
diagnosis, giving the added benefit of enabling the more virulent strain of H. pylori to
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be identified. The prevalence of Cag A H. pylori infection in this patient cohort is in 
keeping with that recorded in developed countries. The association of increased 
disease severity and DNA damage with Cag A infection has been shown. The 
importance of chromosome 4 amplification, which has previously been linked to early 
gastric carcinogenesis, has also been implicated in H. pylori infection especially of the 
Cag A type.
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Chapter 7 
General discussion
7.1 A summary of the findings
Helicobacter pylori has been causally linked to gastric cancer (IARC 1994), 
and much of the evidence to support this statement has been outlined at the start of 
this thesis. This study has attempted to investigate the hypothesis that H. pylori 
induces oxidative damage, which in turn induces aneuploidy, and that this is 
important in the initiation and progression of gastric cancer. Initial experiments have 
shown that Reactive Oxygen Species caused aneuploidy in human cells. The same 
type of aneuploidy has been demonstrated in pre-malignant gastric tissue and 
malignant gastric tissue. The level of aneuploidy increased in a stepwise manner as 
disease severity progressed to gastric cancer. Certain chromosomal abnormalities 
were notable by their presence in the early stages of carcinogenesis, and continued 
through to full blown gastric cancer, hence they may play a specific role in the 
initiation and progression to cancer. Finally, Chapter 6 has confirmed that H. pylori 
can be successfully detected in gastric tissue using PCR technology. This technique 
has also been employed to distinguish Cag A positive H. pylori infection from Cag A 
negative infection. The detection of this strain is clinically relevant as Cag A H. pylori 
infection is associated with more gastric severe disease (Yamaoka et al., 1999, 
Sipponen et al., 1998, Fiocca et al., 1994, Blaser et al., 1995, Kuipers et al., 1995), 
and importantly is also associated with an increased risk of gastric cancer (Parsonnet 
et al 1998, Miehlke et al., 2000, Rugge et al., 1999, Basso et al., 1998). In this study I 
wanted to see if patients with Cag A positive H. pylori infection had more aneuploidy 
than Cag A negative infection, but even though the trend was for increased
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abnormalities in the Cag A positive group, the numbers analysed were too small to be 
conclusive.
7.2 Advances in cytogenetic and molecular methodologies
The recent strides in cytogenetic methodologies have meant that chromosomal 
abnormalities in interphase cells can be investigated in greater detail (Sen 2000), and 
Fluorescence in Situ Hybridisation (FISH) has been used to detect aneuploidy of 
specific chromosomes. Table 4.1 in Chapter 4, illustrates a number of studies that 
have identified a wide range of chromosome abnormalities present in gastric cancers. 
The determination of chromosomal abnormalities has often proved difficult in solid 
tumours, but in this study the modification of the technique described by Doak et al. 
2003 has proved successful at producing a monolayer of interphase gastric cells, 
which are suitable for FISH analysis. The collection of cells using cytology brushes 
from both endoscopic tissue and surgical resection tissue, and their preparation with 
centrifugation/washes and pepsin digestion (as described in Chapter 2), has proved a 
reliable method of slide preparation. Using this technique it was possible to determine 
the levels of aneuploidy in gastric, oesophageal and duodenal tissue, and hence this is 
a useful technique to aid cancer risk assessment.
A number of methods are currently available to diagnose H. pylori infection, 
as outlined in chapter 6, and the use of PCR to detect H. pylori has been demonstrated 
in a number of studies (Lage et al., Cayton et al., 1992). Experiments in this study 
have shown that PCR detection of H. pylori infection was at least as sensitive at 
diagnosing the bacteria as histological assessment. PCR actually detected H. pylori 
DNA in a tissue sample in which was not seen to contain H. pylori on histological 
analysis. This phenomenon has been found in a previous study (Ismail 2004), and
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may be due to a low bacterial load, which would not readily be seen on histology but 
is detectable using PCR due to the amplification step involved (Saiki et al., 1999). 
Low bacterial load would not be an unexpected finding in the patient in this study 
who was found to be H. pylori positive by PCR alone, as the phenotypic diagnosis 
was intestinal metaplasia. It is well recognised that H  pylori infection is often lost as 
phenotypic changes occur due to a loss of the optimal habitat for H. pylori (Graham 
2000, You et al., 2000). The determination of Cag A H. pylori infection has been 
described in previous studies (Lage et al., 1995, Ismail et al, 2001, Balaratnum et al., 
2001), and was again successfully performed using the protocol described in Chapter 
6. As H. pylori is a human carcinogen reliable detection is important, and as more is 
being learnt about the different strains and their relationship to disease the need to 
reliably determine bacterial subtype will become more clinically important.
7.3 The importance of ROS and H. pylori in gastric disease
H. pylori is known to cause inflammation and the release of ROS in gastric 
tissue (Farinatti et al., 1998, Bagchi et al., 1996, Obst et al., 2000). Studies have 
shown that ROS and oxidative damage are also important factors in gastric cancer 
development (Correa and Shiao, 1994, Stadtlander et al., 1999). Chapter 3 has 
described the type of aneuploidy induced by a model ROS, hydrogen peroxide, in a 
cell line. Hydrogen peroxide was chosen as it has been found in vivo, and therefore 
mimics the actual type of ROS released during tissue inflammation (Fenech et 
al., 1999, Mamett 2000). By comparing the types of chromosomal abnormalities 
induced by hydrogen peroxide with those found in gastric tissue at different stages of 
gastric carcinogenesis it was possible to determine any similarities. Figure 7.1 
illustrates the type of aneuploidy found in the in vitro and in vivo studies. As can be
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seen, chromosomal abnormalities were seen in both groups. The levels of aneuploidy 
in the model ROS study compared favourably to that seen in gastritis. The actual dose 
of ROS in vivo is unknown, but the dose chosen in this study may represent a chronic 
inflammatory state as cytotoxicity experiments have shown the dose to be sub-toxic 
(Jenkins et al., 2001). Gastritis is a highly inflammatory condition possessing high 
levels of ROS (Morgan 2000, Mamett 2000). Similarities in the levels of aneuploidy 
of chromosomes 4 and 20 were noted between the model ROS study and the gastritis 
cells. Interestingly, p53 abnormalities were more predominant in the model ROS. The 
next step was to compare the chromosomal damage in the model ROS study with that 
in H. pylori positive patients. H. pylori infection results in inflammation with a dense 
infiltrate of neutrophil polymorphs and also high levels of ROS. Figure 7.2 compares 
the levels of aneuploidy in H. pylori gastritis tissue with the model ROS. Generally, 
the same degree of aneuploidy could be seen in both, however differences were 
evident. Again, p53 abnormalities were higher in the model ROS study. This 
difference in levels of p53 abnormality may reflect differences of growth rate in the 
cell line compared to actual gastric tissue, i.e. cultured cells may select for the p53 
abnormality with increased growth rates. The levels of chromosome 4 aneuploidy was 
similar in both groups but at a higher frequency was seen in gastritis, especially H. 
pylori positive gastritis. Aneuploidy of 20 was also similar between the model ROS 
study and the in vivo study, but this time the similarity was greater between the H. 
pylori negative gastritis cells and the model ROS study. In conclusion, aneuploidy 
induced by a model ROS is similar to that seen in vivo in gastric disease, though not 
identical. Therefore, the results are inconclusive, and have not proven that H. pylori 
induces oxidative damage through ROS release in gastric disease. This is not 
surprising when one considers that the ROS released in gastric tissue inflammation
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comprises of a number of different ROS and not merely hydrogen peroxide. Also 
other toxins, such as pepsin, food and non-H. pylori bacteria are in contact with the 
gastric cells, and hence may also influence chromosome damage.
7.4 Specific cytogenetic abnormalities in gastric carcinogenesis
Certain chromosomal abnormalities have been identified in the experiments 
with pre-malignant and malignant gastric issue, in particular chromosomes 4 and 20. 
Figure 4.14 is a modified version of Correa’s multistep pathway to gastric cancer, 
with the addition of chromosomal abnormalities at each stage.
7.4.1 Amplification of chromosome 4
Chromosome 4 was studied in this thesis because of the increasing evidence 
that has been published demonstrating the importance of chromosome 4 amplification 
in the progression of another upper GI cancer, Barretts adenocarcinoma (Croft et al., 
2002, Doak et al., 2003). The amplification of chromosome 4 was, in this study, the 
most prevalent abnormality in gastritis and intestinal metaplasia, with significant 
differences found when compared to normal gastric tissue (Figure 4.6). The 
amplification persisted with increasing frequency to gastric adenocarcinoma, 
suggesting it may have an important link with the initiation and development of 
gastric cancer. Chromosome 4 abnormalities were also highlighted in H. pylori 
patients (Figure 6.4) In Chapter 4, when H. pylori positive and negative gastritis 
patients were compared, chromosome 4 aneuploidy was the only abnormality to be 
significantly increased in H. pylori positive patients. In fact, Figure 4.13 shows that 
the predominant abnormality was again amplification of chromosome 4. Chapter 4 
has discussed in some detail the potential effects amplification of chromosome 4
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could have on a cell. Jenkins et al. 2003, have linked the amplification of 
chromosome 4 to the protein Nuclear Factor kB (NFkB). NFkB, present on 
chromosome 4, has also been linked to gastric cancer (Rayet and Gelinas 1999).
NFkB acts as an anti-apoptotic factor and influences the pro-inflammatory action of 
interleukin-8 (IL-8) (Rayet and Gelinas 1999). The increased copy number of NFkB 
in a cell could allow continued cell survival with the avoidance of the usual cell 
regulators, hence favouring tumourigenesis. Selection for the abnormality that causes 
the increased level of this protein could result in the continued presence of these 
abnormal cells throughout the disease process. The selection of chromosome 4 
amplification in cells has been found in the analysis of aneuploidy in pre-malignant 
and malignant tissue (Chapter 4), with the increasing presence of chromosome 4 
amplification occurring as carcinogenesis progresses. H. pylori infection has also been 
linked to NFkB, in that infected gastric cells have been shown to have an upregulated 
expression of IL-8, and we know that IL-8 is a transcription factor of NFkB (Jenkins 
et al., 2003). Hence, H. pylori infection may act as a trigger to activate NFkB (Maeda 
et al., 2001). This would support a mechanistic role for H. pylori in gastric 
carcinogenesis.
7.4.2 Aneuploidy of chromosome 20
Chromosome 20 aneuploidy has been a frequent finding at all stages of gastric 
carcinogenesis, with amplification of the chromosome being the predominant finding. 
As both amplification and deletion are common this could therefore be representative 
of general instability of the tissue, and be a marker of aneuploidy, due to increased 
cell proliferation. As discussed earlier, Aurora kinase A has been mapped to 
chromosome 20, and this has been found to be amplified in cancer and cancer cell
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lines (Carmen and Eamshaw 2003, Zhou et al., 1988). This protein is one of a family 
of serine/threonine kinases that have important roles in the regulation of cell division. 
Aurora A is associated with centrosomes and nearby microtubules, exerting an effect 
on the separation of centrosomes and microtubules as well as on spindle assembly 
(Carmena and Eamshaw 2003). Hence, the abnormalities of chromosome 20 may 
reflect abnormalities of this protein kinase, whose altered function may then affect the 
development of further aneuploidy.
7.4.3 Deletion of chromosome 17(p53)
p53 deletion was the other significant abnormality that emerged during this 
thesis. p53 is involved in the control of cell cycle progression and apoptosis in 
response to DNA damage, and hence loss of its function would lead to cell instability 
(Grady 2001).This tumour suppressor gene is the most frequently involved gene in 
human cancers (Levine et al., 1991) and loss of p53 is a frequent finding in gastric 
cancer (Grady 2001). In this study, loss of p53 was shown to be a frequent 
abnormality in pre-malignant tissue. Many studies have demonstrated abnormalities 
of p53 in gastritis (Morgan et al., 2003, Stemmerman et al., 1994), and intestinal 
metaplasia (Uchino et al., 1993, Shaio et al., 1994) as well as gastric cancer. p53 
abnormalities have also been linked to H. pylori infection (Murakami et al., 1999). In 
this study p53 was abnormal slightly more often in H. pylori positive patients than in 
patients without the infection, Figure 4.13 and Figure 6.4.
7.5 Expanding this work -  future studies
It would be possible to build on the work described in this study in a number 
of ways. Firstly, it would be extremely interesting to perform a follow up study in 5
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years time and review individual patients found to have high levels of aneuploidy, and 
assess any phenotypic deterioration or progression of aneuploidy. This would allow 
assessment of aneuploidy as a predictor of gastric cancer, Also, the patients with Cag 
A H. pylori infection could be assessed to determine if successful eradication of H. 
pylori has occurred, and whether there was a regression of the degree of aneuploidy. 
Resolution of some genotypic abnormalities has been reported when eradication of H. 
pylori has been successful (Blaser 1998, Nardonne et al., 1999, Walker 2002). 
Another idea would be to use the remaining gastric DNA from the patients enrolled at 
endoscopy, after receiving ethical approval of course, and consider investigation into 
the potential causes for the aneuploidy demonstrated in these patients. Mutations of 
the mad and bub genes, introduced in Chapter 1 as a potential reason for aneuploidy, 
may be worthy of investigation. Also further investigation into Aurora A kinase, 
which has already been discussed in relation to chromosome 20 amplification and 
aneuploidy development, would be worthwhile. As chromosome 4 amplification was 
consistently found to be a significant event in gastric carcinogenesis and H. pylori 
infection, the further analysis of the protein NFkB may prove fruitful.
It would also be interesting to expand the in vitro study, and attempt to assess 
the level of aneuploidy induced by exposure to activated neutrophils, hence improve 
the in vitro modelling of carcinogenesis. It may be possible to identify the types of 
ROS present.
In the in vivo pre-malignant study described in Chapter 4, chromosomal 
abnormalities were found in normal gastric tissue. If the study was expanded to 
include a larger patient cohort an age related effect may be seen. Other risk factors 
were considered in this study but no significant association found, hence for example 
a more detailed dietary history may be useful. A high female prevalence in gastric
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cancer patients has been reported in the Neath/Swansea/Port Talbot area 
(www.wcisu.nhs.ukT This study has also demonstrated a high percentage of women 
in the gastric cancers studied which is unexpected as male sex is a known risk factor 
to gastric cancer, and interestingly female sex was also common in the pre-malignant 
patients examined in Chapter 4. It would be possible to arrange a data collection 
study, GP/Endoscopy Units, to determine the numbers of women with H. pylori 
infection, and those who have pre-malignant gastric disease.
The intra-tumoural heterogeneity of some cancers was revealed in this study. 
As the success of chemotherapy may be reliant on tumours having little clonal 
variation with fewer surviving resistant clones, a study to assess the effect 
chemotherapy has on tumours with different levels of heterogeneity may be 
interesting. Also, the effect specific chromosomal abnormalities have on success of 
chemotherapy may prove interesting. The techniques in this study to assess 
aneuploidy could be used for this investigation.
Background levels of aneuploidy have been demonstrated in stomach, and 
these were not apparent in squamous oesophageal mucosa. It could be that these are 
related to the microenvironment of the stomach. It would be interesting to analyse 
tissue from other GI sites, such as duodenal, jejunal, ileal, colonic and rectal to see 
whether a similar phenomenon exists or if it is peculiar to the stomach. This could be 
achieved if brushings were taken of fresh surgical resections.
Finally, as the detection of H. pylori infection using PCR has again been 
proved effective, it may be possible to assess the cost effectiveness of undertaking a 
change in clinical practice in this area. Initially, a study would be required, and 
possibly it would be more sensible to use a less invasive technique which would not 
require endoscopy such as PCR of dental plaque, as described by Ishmail 2004.
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7.6 Concluding remarks
In conclusion, aneuploidy is important in gastric carcinogenesis. The 
identification of chromosome 4 amplification and chromosome 20 amplification, in 
pre-malignant and malignant gastric tissue, may have highlighted specific 
mechanisms in gastric cancer progression. The development of these findings into 
clinically useful molecular markers of gastric cancer may come with future studies.
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Appendix 1.1
Research Project looking at the cause of gastric disease.
[Fluorescence in situ (FISH) analysis of Helicobacter pylori induced chromosomal 
aberrations in gastric tissue.]
Lisa Williams, Research Registrar Gastroenterology 
Day Ward, Neath General Hospital, Neath 
01639 762304
Patient information leaflet 
24th October 2001
When you come to the Day Ward for the endoscopy that has been 
arranged for you, you will be invited to take part in a research study. 
Before you agree to this, please read this information leaflet and discuss it 
with friends or family. If anything is unclear and you need to ask any 
questions please contact us before, or when you attend for the 
appointment. Please take time to decide if you wish to participate.
Why are we doing this research?
A bacterium is often found in the stomach, that can cause different 
diseases in the stomach. In our study, we want to look for this bacterium 
and then, very closely at the cells lining the stomach. Hopefully this will 
help explain what triggers disease, and improve our ability to diagnose 
and treat gastric diseases.
All patients attending the Day Ward for this test are being asked to read 
this leaflet.
It is up to you to decide whether or not you wish to take part in the study. 
If you do agree then you will be asked questions, by a doctor when you 
arrive in the hospital, and then asked to sign a consent form and 
participate. If you are taking certain tablets or have had surgery on your 
stomach, then we may not ask you to participate. If you do not wish to 
take part, the endoscopy that has been arranged for you will take place as 
planned, and your future care will not be affected. If you agree to take 
part you may change your mind at any time.
If you agree to take part, then it will not involve any additional hospital 
visits.
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When you come to the Day Ward we will need to collect certain details 
from you. Your age, gender, family history, eating and drinking habits, 
smoking habits and medication history. All the information we collect 
will remain confidential. This will take no longer than ten minutes.
During the endoscopy we often need to take small samples of tissue to 
help us make a diagnosis. This we do with a biopsy, whereby we take 
very small bites of tissue, and a small brush, which allows us to trap the 
cells in the bristles. Both procedures take a minute or two and you will be 
unable to feel them. Taking biopsies carries a very small risk. For this 
study we will need extra biopsies and brushings, which we can look at 
closely in the laboratory in University of Wales Swansea. We may also 
need to gently scrape the inside of your mouth and collect some cells. 
This again takes only a minute and is not painful. Any samples we take 
out of the hospital will have had your name removed and you will not be 
recognised from them.
If you agree to participate then we hope that the information we get will 
help us understand better the reason why people suffer with stomach 
diseases, and may help in the treatment of future patients.
There are no special compensation arrangements to anyone taking part in 
this research project. You are a patient of Bro Morgannwg NHS Trust 
and as such the NHS complaints mechanisms are available to you if 
needed.
When the research study stops all the information will be analysed and 
the results used to improve our knowledge of gastric disease. They may 
be published in the scientific literature, but you will not be identified.
After the tissue samples have been analysed for this research project they 
will be incinerated, following the guidelines at the University.
The research study is under the supervision of Professor J Williams and 
Professor J Parry. Professor Williams is a consultant in Gastroenterology 
at Neath General hospital and supervises endoscopy lists at the hospital. I 
am employed as a research registrar by Bro Morgannwg NHS Trust to 
perform these tests, and to undertake this research project. Professor J 
Parry is a molecular biologist in University of Wales Swansea and is 
responsible for the supervision of my work in the laboratory, in 
accordance with the University guidelines.
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This research project has been approved by the Local Research Ethics 
Committee.
If you need any further information please contact me at the Day Ward, 
Neath General Hospital, 01639 762304.
Thank you for taking the time to read this leaflet and I look forward to 
meeting you on the Day Ward when you attend for the test.
Lisa Williams
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Appendix 1.2
Fluorescence in situ hybridisation (FISH ) analysis of Helicobacter 
pylori induced chromosomal aberrations in gastric tissue
Lisa Williams, Specialist Registrar Gastroenterology 
Patient consent form
I have read the patient information leaflet and received a verbal explanation of the proposed research 
project.
I consent to a buccal scrape and the taking of additional biopsies and brushings during the endoscopic 
procedure for research purposes.
I agree for information about me to be held but I understand that the information I give will not be 
communicated to anyone outside the research team.
Patient name:
Patient Signature: Date:
I have supplied the written information on this research project, given a verbal explanation and 
answered any questions posed.
Investigator name:
Investigator signature: Date:
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Appendix 1.3
Fluorescence in situ hybridisation (FISH ) analysis of Helicobacter 
pylori induced chromosomal aberrations in gastric tissue
Lisa Williams, Specialist Registrar Gastroenterology 
Patient profile
Name:
Date of birth: Sex: Race:
Family history of GI cancer:
Family history peptic ulcer disease:
Smoking history:
Alcohol history:
Dietary habits (salt, fruit, vegetables, meat):
Drug history:
Employment history:
Endoscopic diagnosis (+ location):
Histological diagnosis:
Helicobacter pylori status: [ 1 ] histological [2] PCR
Helicobacter pylori strain:
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Appendix 1.4
FISH raw data from gastric and oesophageal brushings, chapters S and 6.
Brushings from patients enrolled at endoscopy 
Patient 1 -  very few cells therefore not suitable for FISH
Patient 2
-gastric
Probe 2 signal 1 signal 3
20 123 20 1
8 112 9 5
-oesophageal
Probe 2 signal 1 signal 3
20 127 7 6
8 118 4 2
Patient 3
-gastric
Probe 2 signal 1 signal 3
20 51 7 3
8 55 4 3
-oesophageal
Probe 2 signal 1 signal 3
20 123 13 1
8 123 1 3
Patient 4
-gastric
Probe 2 signal 1 signal 3
20 203 7 0
8 195 3 2
-oesophageal
Probe 2 signal 1 signal 3
20 115 5 0
8 117 1 0
166
Patient 5
■gastric
Probe 2 signal 1 signal 3 signal
20 212 21 3
8 401 10 18
4 200 1 6
p53 213 7 1
■oesophageal
Probe 2 signal 1 signal 3 signal
20 400 12 0
8 400 5 3
4 280 2 5
p53 220 2 1
Patient 6
-gastric
Probe 2 signal 1 signal 3 signal
20 115 1 0
8 115 2 0
-oesophageal
Probe 2 signal 1 signal 3 signal
20 400 4 1
8 400 1 3
Patient 7
-gastric
Probe 2 signal 1 signal 3 signal
20 330 6 1
8 337 6 2
-oesophageal
Probe 2 signal 1 signal 3 signal
20 336 7 0
8 327 2 1
4 393 2 1
p53 399 4 1
Patient 8
-gastric
Probe 2 signal 1 signal 3 signal
20 291 6 3
8 341 11 8
4 400 6 10
p53 400
-oesophageal
7 1
Probe 2 signal 1 signal 3 signal
20 280 4 1
8 283 2 4
4 306 2 3
p53 306 2 0
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Patient 9
-gastric 
Probe 2 signal
20 293
8 270
4 290
p53 320
■oesophageal
Probe 2 signal
20 198
8 203
4 429
p53 429
Patient 10
■gastric
Probe 2 signal
20 294
8 290
■oesophageal
Probe 2 signal
20 100
8 100
Patient 11
-gastric
Probe 2 signal
20 246
8 323
4 403
p53 236
-oesophageal
Probe 2 signal
20 76
8 131
4 260
p53 260
Patient 12
-gastric
Probe 2 signal
20 239
8 248
-oesophageal
Probe 2 signal
20 239
8 248
4 251
p53 251
1 signal 3 signal 4 signal
18 0
2 4
6 8 2
5 1
1 signal 3 signal
6 0
0 1
0 5
2 4
1 signal 3 signal 4 signal
4 13 1
3 21 1
1 signal 3 signal
4 1
0 4
I signal 3 signal 4 signal
16 6
II 16
4 6 1
10 0
1 signal 3 signal
4 0
2 2
2 0
0 1
1 signal 3 signal
10 2
3 6
1 signal 3 signal
5 2
1 4
2 1
1 1
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Patient 13
-gastric 
Probe 2 signal
20 330
8 392
■oesophageal
Probe 2 signal
20 50
8 50
Patient 14
-gastric
Probe 2 signal
20 267
8 356
4 408
p53 410
-oesophageal
Probe 2 signal
20 196
8 215
4 200
p53 210
Patient 15
-gastric
Probe 2 signal
20 354
8 358
4 380
p53 387
-oesophageal
Probe 2 signal
20 320
8 318
4 300
p53 300
Patient 16
-gastric
Probe 2 signal
20 403
8 396
4 400
p53 400
-oesophageal
Probe 2 signal
20 271
8 271
4 100
1 signal 3 signal
19 0
0 19
1 signal 3 signal
0 0
0 0
1 signal 3 signal
9 12
0 21
3 18
10 3
1 signal 3 signal
4 0
1 4
1 1
1 1
1 signal 3 signal
6 7
4 19
1 4
2 2
1 signal 3 signal
0 1
0 6
1 0
2 2
1 signal 3 signal
5 1
3 11
0 39
19 1
1 signal 3 signal
4 1
2 2
1 0
3 signal
7
2
4 signal 
6
4+ signal
13
2
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Patient 17
-gastric
Probe 2 signal 1 signal 3 signal
20 281 10 0
8 385 8 10
4 413 4 6
p53 290
-oesophageal
3 1
Probe 2 signal 1 signal 3 signal
20 366 19 2
8 366 5 3
4 216 4 4
p53 200 2 0
Patient 18
-gastric
Probe 2 signal 1 signal 3 signal
20 437 13 2
8 443 2 3
4 385 0 26
p53 411
-oesophageal
18 0
Probe 2 signal 1 signal 3 signal
20 400 3 10
8 400 1 4
4 405 0 9
p53 375 6 0
Patient 19
-gastric
Probe 2 signal 1 signal 3 signal
20 96 10 1
8 101 2 0
-oesophageal
Probe 2 signal 1 signal 3 signal
20 400 10 0
8 400 3 1
4 signal
2
4 signal 
2
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Patient 20
-gastric
Probe 2 signal
20 407
8 407
4 345
p53 345
-oesophageal
Probe 2 signal
20 75
8 73
4 200
p53 200
Patient 21
Patient 22
-gastric
Probe 2 signal
20 185
8 231
4 180
p53 194
-oesophageal
Probe 2 signal
20 196
8 208
4 400
p53 210
Patient 23
-gastric
Probe 2 signal
20 203
8 271
4 202
p53 262
-oesophageal
Probe 2 signal
20 190
8 202
4 215
p53 197
1 signal 3 signal
7 3
5 8
2 1
4 0
1 signal 3 signal
1 0
0 0
1 1
2 0
1 signal 3 signal
11 9
6 4
3 17
7 3
1 signal 3 signal
0 0
1 3
1 2
3 0
1 signal 3 signal
15 5
5 6
0 17
8 3
1 signal 3 signal
3 0
1 2
1 1
3 0
4 signal 
3
4 signal
3
3
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Patient 24
-gastric
Probe 2 signal 1 signal 3 signal
20 195 1 3
8 174 13 11
4 218 8 14
p53 189 22 5
Patient 25
Patient 26
-gastric (repeat)
4 signal
1
Probe 2 signal 1 signal 3 signal 4 signal
20 297 34 11
8 214(218) 5(5) 16(19) 1
4 300 8 20 4
p53 216(202) 16(16) 3(6) 2
-oesophageal
Probe 2 signal 1 signal 3 signal 4 signal
20 251 4 0
8 345 3 1
4 251 1 1 1
p53 215 3 1 0
Patient 27
-gastric
Probe 2 signal 1 signal 3 signal 4 signal
20 265 20 44 2
8 336 18 8 7
4 297 9 22 3
p53 338 16 8
- oesophageal
Probe 2 signal 1 signal 3 signal
20 255 5 2
8 300 0 5
4 255 4 7
p53 300 2 5
Surgically resected patients
Patient T1
(See pictures 6.3)
-gastric al - cancer
Probe 2 signal 1 signal(O) 3 signal 4 signal
20 193 12 11 3
8 215 11 48 13
4 192 3 21 10
p53 230 33 16 3
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-gastric a2 - cancer
Probe 2 signal 1 signal 3 signal 4
20 183 12 10 6
8 239 11 73 2
4 183 8 31 5
p53 276 42 7
-gastric a4 -  intestinal metaplasia
Probe 2 signal 1 signal 3 signal 4
20 191 4 2
8 239 5 10 4
4 186 2 15 3
p53 191 16 2
-gastric a6 -  intestinal metaplasia
Probe 2 signal 1 signal 3 signal 4
20 213 17 2
8 307 7 9 2
4 218 2 10 4
p53 213 6 1
-gastric a9 =- intestinal metaplasia
Probe 2 signal 1 signal 3 signal 4
20 238 14 3
8 310 6 7
4 243 5 6 1
p53 300 12 2
Patient T2
(See pictures -  6.1)
-gastric b2 - dysplasia
Probe 2 signal 1 signal 3 signal 4
20 188 4 17 3
8 214 7 16 3
4 228 3 25 3
p53 195 10 3 7
-gastric b3 -  intestinal metaplasia
Probe 2 signal 1 signal 3 signal 4
20 195 7 5
8 200 8 5
4 191 1 11
p53 198 5 4
-gastric b4 -  intestinal metaplasia
Probe 2 signal 1 signal 3 signal 4
20 208 5 6 1
8 128 2 3
4 208 7 13 2
p53 200 9 2
 signal
 signal
 signal
 signal
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Patient T3
(See pictures 6.4)
-gastric cl - cancer 
Probe 2 signal 1 signal 3 signal 4 signal
20 195 18 13 3
8 203 11 43 16
4 182 1 33 8
p53 213 26 18 6
Probe
-gastric c2 -  intestinal 
2 signal
metaplasia 
1 signal 3 signal 4 signal
20 203 9 13
8 199 4 20 5
4 185 2 39
p53 227 13 8 2
Probe
-gastric c3 - cancer 
2 signal 1 signal 3 signal 4 signal
20 149 18 21 8
8 175 12 4 19
4 127 2 53 14
p53 170 15 14 3
Probe
-gastric c4 -  intestinal 
2 signal
metaplasia 
1 signal 3 signal 4 signal
20 176 2 24 1
8 197 8 17 2
4 179 4 17 J)
p53 197 14 8 2
Probe
-c5 - duodenum 
2 signal 1 signal 3 signal 4 signal
20 263 16 1
8 208 11 0
4 235 3 12
p53 206 13 3
Probe
-gastric c6 -  intestinal metaplasia 
2 signal 1 signal 3 signal 4 signal
20 188 9 18
8 218 5 1
4 202 1 12
p53 215 17 7
Probe
-gastric c7 -  intestinal metaplasia 
2 signal 1 signal 3 signal 4 signal
20 186 7 28 2
8 189 5 19 1
4 207 4 10 1
p53 201 13 6
5 signal
9
5 signal
3
5 signal 
2
4
5 signal 
3
3
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-gastric c8 -  mod dysplastic adenoma
Probe 2 signal 1 signal 3 signal 4 signal
20 186 7 28 2
8 215 9 15
4 207 4 10 1
p53 186 20 2
Patient T4
-tumour
Probe 2 signal 1 signal 3 signal 4 signal 5 signal
20 169 8 50 3 1
8 137 4 54 54 5 1
4 172 0 39 14 2
p53 185 26 4
-duodenum
Probe 2 signal 1 signal 3 signal
20 230 2 5
8 241 11 3
4 227 3 5
p53 268 3 1
Patient T5
-tumour
Probe 2 signal 1 signal 3 signal 4 signal 5 signal
20 170 11 30 8
8 248 11 23 4 1
4 199 4 26 10
p53 192 21 4 1
-gastric
Probe 2 signal 1 signal 3 signal 4 signal
20 214 14 6
8 170 10 10 1
4 205 1 21 5
p53 172 7 4 1
Patient T6
-tumour
Probe 2 signal 1 signal 3 signal 4 signal 5 signal
20 187 10 34 6
8 162 13 30 16 10
4 169 9 45 18 2
p53 173 24 7 1
-duodenum
Probe 2 signal 1 signal 3 signal 4 signal
20 114 9 10 2
8 194 9 5 1
4 103 1 23 4
p53 191 8 5
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Patient T7
-tumour (repeat)
Probe 2 signal 1 signal 3 signal 4 signal
20 169 12 20 1
8 185 2 17 4
4 108(101) 2(4) 28(16) 2
p53
-duodenum
Probe 2 signal 1 signal 3 signal
20 200 3 2
8 196 3 3
4 200 3 5
p53 196 3 5
Patient T8
-tumour
Probe 2 signal 1 signal 3 signal 4 signal
20 212 27 29 13
8 208 4 25 6
4 200 7 20 13
p53 203 16 6 1
-duodenum
probe 2 signal 1 signal 3 signal
20 222 11 5
8 212 5 3
4 284 8 4
p53 222 11 5
Patient T9
-tumour
Probe 2 signal 1 signal 3 signal 4 signal
20 159 16 16 14
8 184 5 20 11
4 162 7 28 5
p53 191 13 17 3
-duodenum
Probe 2 signal 1 signal 3 signal 4 signal
20 187 7 7 4
8 198 9 3 2
4 124 0 8 1
p53 200 3 6 2
Patient T10
-normal gastric
Probe 2 signal 1 signal 3 signal
20 194 11 7
8 255 5 9
4 205 3 5
p53 214 3 2
5 signal 
1 
1
5 signal 
4 
2 
4
5 signal 
7 
2 
3
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Probe
-tumour(2)
2 signal 1 signal
20 200 14
8 227 6
4 169 6
Probe
-tumour (3)
2 signal 1 signal
20 182 15
8 175 5
4 191 4
p53 88 15
Probe
-tumour (4)
2 signal 1 signal
20 198 12
8 212 6
4 158 1
p53 216 15
Probe
-tumour (5)
2 signal 1 signal
20 133 5
8 181 5
4 102 2
p53 181 24
3 signal 4 signal 5 signal
12 6
14 4
16 9 1
3 signal 4 signal 5 signal
12
20 12 1
18 5 1
3
3 signal 4 signal 5 signal
9 6
17 6 1
23 15 1
14 1
3 signal 4 signal 5 signal
19
23 6 3
25 14 2
12 3
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Appendix 1.5
Welsh Cancer Trial for operable carcinoma of oesophagus -  chemotherapeutic regime 
(abbreviated version)
Induction chemotherapy (weeks 0-6)
Paclitaxel 125mg/m23 hours day 1 
Cisplatin 60mg/m2 days 1 
5FU 200mg/m2/day 1-21
(pre-medication -  dexamethasone, chlorpheniramine)
(Antiemetics)
(Hydration)
repeated every 3 weeks for 2 cycles
Concurrent chemotherapy (weeks 7-11)
Paclitaxel 40mg/m2 dayl 
Cisplatin 30mg/m2 day 1 
5FU 200mg/m/day/m days 1-35
(pre-medication / antiemetics / hydration)
repeated every lweek for 5 cycles
Radiotherapy -  45Gy/25F/5 weeks
Radical oesophagectomy (weeks 16-18)
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Appendix 1.6
Publications/abstracts from this work to date
Fluoresence in situ hybridisation (FISH) of Helicobacter pylori induced 
chromosomal abnormalities in gastric tissue.
L Williams, JG Williams, E Parry, JM Parry. Mutagenesis 2002; 17(6): 565.
Interphase Fluoresence in situ hybridisation (FISH) to detect chromosomal 
abnormalities in gastric cancer progression.
L Williams, JG Williams, AP Griffiths, T Brown, S Doak, GSJ Jenkins, E 
Parry, JM Parry. Gut 2003; 52: A 50.
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